
<html lang="en"     class="pb-page"  data-request-id="2ce259b0-ddbb-45bf-a79f-15eb1413fae7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-15;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c00346"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors" /></meta><meta name="dc.Creator" content="Wuhong  Chen" /></meta><meta name="dc.Creator" content="Feifei  Liu" /></meta><meta name="dc.Creator" content="Qiliang  Zhao" /></meta><meta name="dc.Creator" content="Xinna  Ma" /></meta><meta name="dc.Creator" content="Dong  Lu" /></meta><meta name="dc.Creator" content="Heng  Li" /></meta><meta name="dc.Creator" content="Yanping  Zeng" /></meta><meta name="dc.Creator" content="Xiankun  Tong" /></meta><meta name="dc.Creator" content="Limin  Zeng" /></meta><meta name="dc.Creator" content="Jia  Liu" /></meta><meta name="dc.Creator" content="Li  Yang" /></meta><meta name="dc.Creator" content="Jianping  Zuo" /></meta><meta name="dc.Creator" content="Youhong  Hu" /></meta><meta name="dc.Description" content="HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active..." /></meta><meta name="Description" content="HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 21, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00346" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00346" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00346" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00346" /></link>
        
    
    

<title>Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00346" /></meta><meta property="og:title" content="Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0012.jpeg" /></meta><meta property="og:description" content="HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure–activity relationship studies based on metabolic pathways of 4r led to the identification of a phthalazinone derivative 19f with appropriate anti-HBV potencies (IC50 = 0.014 ± 0.004 μM in vitro), which demonstrated high oral bioavailability and liver exposure. In the AAV-HBV/mouse model, administration of 19f resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment with 150 mg/kg dosing twice daily." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00346"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00346">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00346&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00346&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00346&amp;href=/doi/10.1021/acs.jmedchem.0c00346" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 8134-8145</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00298" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00377" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Wuhong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wuhong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wuhong++Chen">Wuhong Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Feifei Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feifei Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feifei++Liu">Feifei Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qiliang Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qiliang Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qiliang++Zhao">Qiliang Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xinna Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xinna Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div><div class="loa-info-affiliations-info">Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xinna++Ma">Xinna Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dong Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dong Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dong++Lu">Dong Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Heng Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Heng Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Heng++Li">Heng Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanping Zeng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanping Zeng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanping++Zeng">Yanping Zeng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiankun Tong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiankun Tong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiankun++Tong">Xiankun Tong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Limin Zeng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Limin Zeng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Limin++Zeng">Limin Zeng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jia Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jia Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jia++Liu">Jia Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Li Yang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div></div><span class="conrtib-corresp"><strong>*</strong>L.Y.: fax, +86-2150806701; email, <a href="/cdn-cgi/l/email-protection#8ef7efe0e9e2e7cefde7e3e3a0efeda0ede0"><span class="__cf_email__" data-cfemail="1b627a757c77725b68727676357a78357875">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Yang">Li Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianping Zuo</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianping Zuo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div><div class="loa-info-affiliations-info">Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China</div></div><span class="conrtib-corresp"><strong>*</strong>J.Z.: fax, +86-2150806701; email, <a href="/cdn-cgi/l/email-protection#d6bca6aca3b996a5bfbbbbf8b7b5f8b5b8"><span class="__cf_email__" data-cfemail="fa908a808f95ba89939797d49b99d49994">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianping++Zuo">Jianping Zuo</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Youhong Hu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Youhong Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</div><div class="loa-info-affiliations-info">School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, Hangzhou 310024, China</div></div><span class="conrtib-corresp"><strong>*</strong>Y.H.: fax, +86-2150805896; email, <a href="/cdn-cgi/l/email-protection#493021213c093a20242467282a672a27"><span class="__cf_email__" data-cfemail="572e3f3f2217243e3a3a793634793439">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Youhong++Hu">Youhong Hu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1770-6272" title="Orcid link">http://orcid.org/0000-0003-1770-6272</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00346&amp;href=/doi/10.1021%2Facs.jmedchem.0c00346" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 8134–8145</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 21, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 February 2020</li><li><span class="item_label"><b>Published</b> online</span>21 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 August 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00346</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8134%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWuhong%2BChen%252C%2BFeifei%2BLiu%252C%2BQiliang%2BZhao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D15%26contentID%3Dacs.jmedchem.0c00346%26title%3DDiscovery%2Bof%2BPhthalazinone%2BDerivatives%2Bas%2BNovel%2BHepatitis%2BB%2BVirus%2BCapsid%2BInhibitors%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8145%26publicationDate%3DAugust%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00346"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1598</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00346" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wuhong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Feifei&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Qiliang&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Xinna&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Dong&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Heng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yanping&quot;,&quot;last_name&quot;:&quot;Zeng&quot;},{&quot;first_name&quot;:&quot;Xiankun&quot;,&quot;last_name&quot;:&quot;Tong&quot;},{&quot;first_name&quot;:&quot;Limin&quot;,&quot;last_name&quot;:&quot;Zeng&quot;},{&quot;first_name&quot;:&quot;Jia&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Jianping&quot;,&quot;last_name&quot;:&quot;Zuo&quot;},{&quot;first_name&quot;:&quot;Youhong&quot;,&quot;last_name&quot;:&quot;Hu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;8134-8145&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00346&quot;},&quot;abstract&quot;:&quot;HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure–activity relationship studies based on metabolic pathways of 4r led to the identification of a phthalazinone derivative 19f with appropriate anti-HBV potencies (IC50 = 0.014 ± 0.004 μM in vitro), which demonstrated high oral bioavailability and liver exposure. In the AAV-HBV/mouse model, administration of 19f resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment with 150 mg/kg dosing twice daily.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00346&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00346" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00346&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00346" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00346&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00346" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00346&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00346&amp;href=/doi/10.1021/acs.jmedchem.0c00346" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00346" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00346" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00346%26sid%3Dliteratum%253Aachs%26pmid%3D32692159%26genre%3Darticle%26aulast%3DChen%26date%3D2020%26atitle%3DDiscovery%2Bof%2BPhthalazinone%2BDerivatives%2Bas%2BNovel%2BHepatitis%2BB%2BVirus%2BCapsid%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D15%26spage%3D8134%26epage%3D8145%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/jmcmar.2020.63.issue-15/20200813/jmcmar.2020.63.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound <b>4r</b>, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure–activity relationship studies based on metabolic pathways of <b>4r</b> led to the identification of a phthalazinone derivative <b>19f</b> with appropriate anti-HBV potencies (IC<sub>50</sub> = 0.014 ± 0.004 μM <i>in vitro</i>), which demonstrated high oral bioavailability and liver exposure. In the AAV-HBV/mouse model, administration of <b>19f</b> resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment with 150 mg/kg dosing twice daily.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12665" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12665" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatitis B virus (HBV) infection is a global public health issue with an estimated 250 million people chronically infected worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Among those, one-quarter of the patients are likely to develop serious liver diseases such as cirrhosis and hepatocellular carcinoma.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The current therapies for HBV infection are limited to nucleos(t)ide analogues (lamivudine, tenofovir, or entecavir (ETV), etc.) and interferons (IFNs).<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> These two types of therapies can effectively suppress HBV replication, successfully delay liver disease progression, greatly reduce liver cancer incidence, and significantly improve long-term survival. However, both present major challenges: nucleos(t)ide therapies typically require lifetime treatment to prevent viral rebound, while IFNs-based therapies are associated with poor tolerance, limited responsiveness, and frequent adverse effects.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Current HBV treatments do not offer a satisfactory clinical cure rate for chronic HBV infection.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">HBV capsid assembly is an essential step in the HBV life cycle, which can be interrupted to block HBV core protein aggregation and efficiently inhibit the synthesis of HBV DNA production.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Therefore, it is considered an attractive target for new antiviral therapies against HBV. During the past decade, several chemotypes of capsid assembly modulators (or effectors) were reported (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> The heteroaryldihydropyrimidine (HAP) compounds represented by compound <b>1</b> (Bay 41-4109),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> prevented the normal assembly of core proteins leading to aberrant capsid formation. <b>2</b> (GLS-4) and <b>3</b> (HAP-R10) are new generations of HAP analogues featuring 6-morpholine substituents and 2-thioazolyl groups attached to the core scaffold.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref15">(11−15)</a> By contrast, the phenylpropenamide (PPA) derivative <b>4</b> and the sulfamoylbenzamide (SBA) <b>5</b> act as HBV pgRNA encapsidation blockers, which accelerate the assembly of normal empty capsids.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20 ref21">(16−21)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative HBV capsid assembly modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The capsid assembly modulators were found to be able to disrupt capsid formation and subsequently inhibit HBV pgRNA encapsidation, reverse transcription, and DNA synthesis.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Previously, we found a novel class of pyridazinone derivative <b>6</b> (<b>4r</b>) through HBV DNA-free capsid formation that showed potent antiviral activity (IC<sub>50</sub> = 0.087 ± 0.002 μM) with low cytotoxicity (CC<sub>50</sub> = 90.6 ± 2.06 μM), sensitivity to nucleoside analogue-resistant HBV mutants, and synergistic effects with nucleoside analogues in HepG2.2.15 cells.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> These results confirmed <b>4r</b> as an attractive lead compound for further investigation in the treatment of HBV infection. Although the rat single dose pharmacokinetics (SDPK) profile (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) of <b>4r</b> showed moderate plasma clearance (Cl) (77.6 mL min<sup>–1</sup> kg<sup>–1</sup>) and acceptable oral bioavailability (<i>F</i>) (25%), the exposure of compound <b>4r</b> in liver could not be detected (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Supporting Information, Figure S1</a>). We also tested the single-dose pharmacokinetics (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Table S1</a>) and liver distribution of <b>4r</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Figure S1</a>) in mice, which showed the low oral bioavailability and no exposure of <b>4r</b> in liver. The metabolic stability of <b>4r</b> in liver microsomes of humans, monkeys, dogs, rats, and mice was examined to identify any significant difference in the metabolic rate of <b>4r</b>. After incubation for 60 min with human, monkey, dog, rat, and mouse liver microsomes, 34%, 73%, 79%, 64%, and more than 95% of the prototype drugs were metabolized from the relative UV area of <b>4r</b>, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Most of compound <b>4r</b> in mice was metabolized after the incubation with mouse liver microsomes for 60 min. Although compound <b>4r</b> was more stable in human liver microsomes than in mouse, <i>in vivo</i> drug efficacy has to be evaluated in HDI mouse models. From the analysis of the metabolites for <b>4r</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), the major metabolite is oxide <b>M1</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Comparing with the metabolic pathway of its analogue <b>S4a</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (with <i>p</i>-F phenyl substitution at 6-position of pyridazinone) in human liver microsomes with GSH (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Table S2</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Figure S2</a>), we hypothesized that the methyl substituent on the pyridazinone moiety could be easily oxidized. In this paper, we focus on the replacement of pyridazinone moiety to find the new phthalazinone scaffold and further SAR study to afford this novel anti-HBV lead compound with the improved PK profiles.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Single-Dose Pharmacokinetics of <b>4r</b> in SD Rats<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–<i>t</i></sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center">Cl_<sub>obs</sub> (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">Vss<sub>_obs</sub> (mL/kg)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po (20)</td><td class="colsep0 rowsep0" align="left">2.96 ± 0.15</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">352 ± 147</td><td class="colsep0 rowsep0" align="left">1095 ± 372</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">25.3 ± 8.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv (2)</td><td class="colsep0 rowsep0" align="left">2.03 ± 0.782</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">428 ± 47.6</td><td class="colsep0 rowsep0" align="left">77.6 ± 8.18</td><td class="colsep0 rowsep0" align="left">5.81 ± 2.53</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Single-dose pharmacokinetics (SDPK) studies of <b>4r</b> were carried out in SD rats according to standard procedures. The major parameters, including half-life (<i>T</i><sub>1/2</sub>), <i>T</i><sub>max</sub>, maximal concentration (<i>C</i><sub>max</sub>), the area under the curve (AUC<sub>0–<i>t</i></sub>), plasma clearance (Cl_<sub>obs</sub>), volume of distribution at steady state (Vss_<sub>obs</sub>), and oral bioavailability (<i>F</i>), were reported.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Information of Metabolites of <b>4r</b> in Liver Microsomes of Human, Monkey, Dog, Rat and Mouse</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">LC–MS area (×10<sup>3</sup>)</th><th class="rowsep1 colsep0" colspan="6" align="center">UV area (240 nm)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">metabolite name</th><th class="colsep0 rowsep0" align="center"><i>m</i>/<i>z</i></th><th class="colsep0 rowsep0" align="center">formula</th><th class="colsep0 rowsep0" align="center">error (ppm)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>R</sub> (min)</th><th class="colsep0 rowsep0" align="center">inactive microsomes</th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">monkey</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">inactive microsomes</th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">monkey</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">mouse</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M0</td><td class="colsep0 rowsep0" align="left">parent</td><td class="colsep0 rowsep0" align="left">348.0722</td><td class="colsep0 rowsep0" align="left">C<sub>17</sub>H<sub>12</sub>N<sub>3</sub>OF<sub>2</sub>Cl</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">7.3</td><td class="colsep0 rowsep0" align="left">27.6</td><td class="colsep0 rowsep0" align="left">13.5</td><td class="colsep0 rowsep0" align="left">5.42</td><td class="colsep0 rowsep0" align="left">3.09</td><td class="colsep0 rowsep0" align="left">7.40</td><td class="colsep0 rowsep0" align="left">1.00</td><td class="colsep0 rowsep0" align="left">125</td><td class="colsep0 rowsep0" align="left">82.0</td><td class="colsep0 rowsep0" align="left">34.1</td><td class="colsep0 rowsep0" align="left">26.3</td><td class="colsep0 rowsep0" align="left">44.8</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M1</td><td class="colsep0 rowsep0" align="left">parent + O</td><td class="colsep0 rowsep0" align="left">364.0672</td><td class="colsep0 rowsep0" align="left">C<sub>17</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub>F<sub>2</sub>Cl</td><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.64</td><td class="colsep0 rowsep0" align="left">8.30</td><td class="colsep0 rowsep0" align="left">5.97</td><td class="colsep0 rowsep0" align="left">3.05</td><td class="colsep0 rowsep0" align="left">10.3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">51.3</td><td class="colsep0 rowsep0" align="left">113</td><td class="colsep0 rowsep0" align="left">84.6</td><td class="colsep0 rowsep0" align="left">56.7</td><td class="colsep0 rowsep0" align="left">117</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M2</td><td class="colsep0 rowsep0" align="left">parent + O + O</td><td class="colsep0 rowsep0" align="left">380.0616</td><td class="colsep0 rowsep0" align="left">C<sub>17</sub>H<sub>12</sub>N<sub>3</sub>O<sub>3</sub>F<sub>2</sub>Cl</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.79</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">15.4</td></tr></tbody></table></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed metabolic pathway of <b>4r</b> in liver microsomes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Design and Structure–Activity Relationship (SAR)</h3><div class="NLM_p">First, 4-methylpyridazinone moiety replacements were designed, synthesized, and evaluated in HepG 2.2.15 cells (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The hydroxymethylated product <b>10a</b> maintained anti-HBV activity with an IC<sub>50</sub> of 0.17 μM. However, the carboxylic acid <b>10b</b>, which might be easily oxidized from <b>10a</b><i>in vivo</i>, lost the activity completely. The ester <b>10c</b> and methoxyl substitution <b>10d</b> at 4-position of pyridazinone also lost antiviral activity. The substitutions with cyclopropyl or isopropyl (<b>10e</b> and <b>10f</b>), which could be beneficial for the prevention of the oxidization <i>in vivo</i>, decreased the activity dramatically. 4,5-Disubstituted pyridazinone derivatives <b>10g</b> and <b>10f</b> also reduced the potency. When the replacements of pyridazinone with pyrazinone, pyridinone, phthalazinone gave <b>10i</b>, <b>10k</b>, <b>10j</b>, and <b>10l</b>, only compound <b>10l</b> with a phthalazinone scaffold retained the comparable anti-HBV activity with an IC<sub>50</sub> of 0.30 μM. On the basis of our previous SAR study (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Table S3</a>), 4-chlorobenzyl attached to the N atom of pyridazinone core can be changed by 4-cyanobenzyl group to keep the equitable activity. Compound <b>10m</b> was synthesized and showed moderate anti-HBV activity with low cytotoxicity compared to <b>4r</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR Study on the A-Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0008.gif" alt="" id="GRAPHIC-d7e1135-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0009.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">CC<sub>50</sub> is 50% cytotoxicity concentration in HepG2 2.2.15 cells.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> is 50% inhibitory concentration of cytoplasmic HBV-DNA replication. The CC<sub>50</sub> and IC<sub>50</sub> values are the averages and standard deviations (SD) derived from at least two independent determinations.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">NA, not active at concentration of CC<sub>50</sub>.</p></div></div><div></div></div><div class="NLM_p">Next, the distribution of <b>10m</b> by oral administration was evaluated in ICR (CD-1) mice. <b>10m</b> showed high exposure in the liver at 1, 3, 8 h and dismissed after 24 h by po 20 mg/kg administration (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Supporting Information, Figure S3</a>). The preferential liver distribution of <b>10m</b> could be beneficial to treat chronic HBV infections, which was targeted at the tissue.</div><div class="NLM_p">Our previous research indicated that the fluorine atom at the 2-position of pyridine ring could form two hydrogen bonds with the Trp102 and Ser106 residues of capsid protein, which may contribute to the improved antiviral activity.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Further optimization and SAR exploration based on phthalazinone scaffold were carried out to keep F substitution at the 2-position of the pyridine moiety in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR Study of Substituents on the Pyridine Moiety</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0010.gif" alt="" id="GRAPHIC-d7e1196-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0011.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">CC<sub>50</sub> is 50% cytotoxicity concentration in HepG2 2.2.15 cells.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> is 50% inhibitory concentration of cytoplasmic HBV-DNA replication.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">IC<sub>90</sub> is 90% inhibitory concentration of cytoplasmic HBV-DNA replication. The CC<sub>50</sub>, IC<sub>50</sub>, and IC<sub>90</sub> values are the averages and standard deviations (SDs) derived from at least two independent determinations.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">NA, not active at concentration of CC<sub>50</sub>.</p></div></div><div></div></div><div class="NLM_p">Introducing substitution at the 6-position of pyridine <b>18a</b>, <b>18b</b>, and <b>18d</b>–<b>18f</b> maintained activity except compound <b>18c</b>, which contained an amide group and is different from the SAR of pyridazinone derivatives.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> We speculated that the replacement of the core structure might change the electronic density and binding space slightly. Extending the group at the 6-position of pyridine (compound <b>18g</b>) yielded comparable inhibitory activity. Due to synthetic feasibility, 5-chloro substituted compound <b>19a</b> was obtained and significantly exhibited anti-HBV activity with low toxicity. The observed high activity may be a result of pyridine electronic density changes or increasing the hydrogen bond of Cl atom with the protein. Since the diverse side chain at the 6-postion of pyridine could adjust the physical property of the compound, we modified this area with an unchanged 5-chloro substitution. With a terminated <i>N</i>,<i>N</i>-dimethyl (<b>19b</b>) and carbonyl group (ester <b>19c</b> and acid <b>19d</b>), the compounds showed the moderate anti-HBV activities. With a hydroxyl group at the terminal end of the side chain, compound <b>19e</b> also exhibited reliable antiviral activity with acceptable toxicity. On the basis of <b>19e</b>’s activity, we extended the side chain’s hydroxy group to improve solubility (<b>19f</b>). <b>19f</b> showed excellent anti-HBV activity with an IC<sub>50</sub> value of 0.014 μM and CC<sub>50</sub> > 100 μM. These findings indicated that this diverse side chain could be tolerated with extended chemical space for further investigation. Since compound <b>19f</b> was a racemic mixture, the two enantiomers were synthesized. It was found that the <i>R</i>-configuration analogue <b>19h</b> showed better anti-HBV activity than the <i>S</i>-isomer <b>19g</b> with low toxicity. The activity of <b>19f</b> was consistent with the corresponding optical isomers <b>19g</b> and <b>19h</b>.</div><div class="NLM_p">Compounds <b>19a</b>, <b>19e</b>, and <b>19f</b> were selected to evaluate preliminary pharmacokinetic (PK) properties in mice following intravenous (iv) and oral (po) administration (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The AUC and oral bioavailability of <b>19a</b> and <b>19e</b> were low. The possible reason was that <b>19a</b> and <b>19e</b> were poorly absorbed in mice. <b>19f</b> exhibited favorable drug characteristics with low plasma clearance (CL = 4.1 mL min<sup>–1</sup> kg<sup>–1</sup>), excellent drug exposure (AUC<sub>0–<i>t</i></sub> = 49 744 h·ng/L), and oral bioavailability (<i>F</i> = 60.4%) using 20 mg/kg oral administration. In addition, compound <b>19f</b> also showed good distribution in liver exposure, which was 5950 ng/g after 8 h by oral administration (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Supporting Information, Figure S4</a>), being 4-fold higher than that in plasma. Higher liver concentrations of <b>19f</b> may be beneficial and reduce the side effects present in chronic HBV infections. As compared with <b>19a</b>, the introduction of the polar hydroxyl groups may increase solubility and absorption to improve the oral bioavailability.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Single-Dose Pharmacokinetics of Selected Compounds in Mice<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–<i>t</i></sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>INF_obs</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center">Cl_<sub>obs</sub> (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">Vss (mL/kg)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="left">20 (po)</td><td class="colsep0 rowsep0" align="left">3.83 ± 0.82</td><td class="colsep0 rowsep0" align="left">2.33 ± 1.53</td><td class="colsep0 rowsep0" align="left">94.8 ± 25.5</td><td class="colsep0 rowsep0" align="left">835 ± 208</td><td class="colsep0 rowsep0" align="left">850 ± 210</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2 (iv)</td><td class="colsep0 rowsep0" align="left">3.09 ± 0.88</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3047 ± 494</td><td class="colsep0 rowsep0" align="left">3073 ± 525</td><td class="colsep0 rowsep0" align="left">11.1 ± 1.96</td><td class="colsep0 rowsep0" align="left">3088 ± 356</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19e</b></td><td class="colsep0 rowsep0" align="left">20 (po)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1 ± 0.29</td><td class="colsep0 rowsep0" align="left">69.5 ± 36.4</td><td class="colsep0 rowsep0" align="left">115 ± 63</td><td class="colsep0 rowsep0" align="left">171 ± 102</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2 (iv)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">604 ± 108</td><td class="colsep0 rowsep0" align="left">735 ± 150</td><td class="colsep0 rowsep0" align="left">2720.2 ± 823.5</td><td class="colsep0 rowsep0" align="left">5444 ± 1250</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19f</b></td><td class="colsep0 rowsep0" align="left">20 (po)</td><td class="colsep0 rowsep0" align="left">2.15 ± 0.02</td><td class="colsep0 rowsep0" align="left">1.33 ± 0.58</td><td class="colsep0 rowsep0" align="left">9670 ± 3324</td><td class="colsep0 rowsep0" align="left">49744 ± 20791</td><td class="colsep0 rowsep0" align="left">49778 ± 20810</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">60.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2 (iv)</td><td class="colsep0 rowsep0" align="left">2.52 ± 0.14</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8241 ± 615</td><td class="colsep0 rowsep0" align="left">8251 ± 612</td><td class="colsep0 rowsep0" align="left">4.1 ± 0.3</td><td class="colsep0 rowsep0" align="left">766 ± 123</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Single-dose pharmacokinetics (SDPK) studies of selected compounds were carried out in mice according to standard procedures. The major parameters, including half-life (<i>T</i><sub>1/2</sub>), <i>T</i><sub>max</sub>, maximal concentration (<i>C</i><sub>max</sub>), the area under the curve (AUC<sub>0–<i>t</i></sub>, AUC<sub>INF_obs</sub>), plasma clearance (Cl<sub>_obs</sub>), volume of distribution at steady state (Vss), and oral bioavailability (<i>F</i>), were reported.</p></div></div></div><div class="NLM_p"><i>In vitro</i>, the anti-HBV activities of <b>10m</b>, <b>19a</b>, and <b>19f</b> were further examined using HepG2.2.15, which stably replicates HBV. HepG2.2.15 cells were treated with <b>10m</b>, <b>19a</b>, or <b>19f</b> at different concentrations for 8 days, and various replication intermediates were extracted and analyzed by Southern blotting. Southern blotting analyses showed that all three compounds inhibited the various forms (relaxed circular [rc] and single-stranded [ss] HBV DNA) in a dose-dependent manner. When compared with compounds <b>10m</b> and <b>19a</b>, <b>19f</b> showed the most potent anti-HBV activity and inhibited the various forms (rcDNA and ssDNA) with lower concentrations (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Subsequently, the effect of <b>19f</b> on HBV capsid assembly was analyzed. We detected capsid electrophoresis mobility and capsid-associated HBV DNA levels in situ on a 1.8% native agarose gel. A type of faster-migrating capsids was detected in <b>19f</b> treated samples, which were judged by their mobility on agarose gel as compared to capsids formed in untreated cells (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, top panel). In situ detection of the capsid-associated DNAs was performed by the transfer of HBV capsids onto a nylon sheet, followed by the disruption of capsids and the hybridization with DIG-labeled HBV-specific DNA probe. The treatment of <b>19f</b> could reduce capsid-associated DNAs dose-dependently (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, bottom panel). Notably, no HBV DNA was detected in the faster-migrating capsids. These results revealed that compound <b>19f</b> could induce the formation of genome-free capsids, including a phenotype of faster-migrating ones. We also compared the activity of <b>19f</b> with other better-studied classes of capsid assembly modulators (CAMs), such as AT-130<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and Bay 41-4109.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Phenylpropenamide (PPA) derivative AT-130, blocking RNA packaging, showed activity similar to that seen with <b>19f</b> treatment on capsid assembly. Heteroaryldihydropyrimidines (HAP), Bay 41-4109, effectively reduced the amount of HBV capsids and core-associated genome by stabilizing noncapsid polymers. In contrast, ETV, a well-characterized nucleos(t)ide drug used to treat chronic HBV infections, did not affect HBV capsid formation but, as expected, efficiently inhibited the amount of capsid-associated DNA.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <b>10m</b>, <b>19a</b>, and <b>19f</b> inhibited HBV DNA replication <i>in vitro</i>. HepG2.2.15 cells were treated with <b>10m</b>, <b>19a</b>, or <b>19f</b> at the indicated concentrations for 8 days. HBV replication intermediates were detected by Southern blotting hybridization using a DIG-labeled HBV genomic fragment as a probe. All three compounds inhibited the various forms in a dose-dependent manner, and <b>19f</b> specifically decreased the amount of intracellular HBV DNA with lower concentrations. rcDNA is relaxed circular HBV DNA. ssDNA is single-stranded HBV DNA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <b>19f</b> induced the formation of HBV DNA-free capsids. HepG2.2.15 cells were treated with <b>19f</b> at the indicated concentrations for 8 days. Capsids were analyzed on 1.8% agarose gel (top panel). Capsid-associated HBV DNA was detected by the transfer of HBV capsids on a nylon sheet, followed by Southern blotting hybridization upon disruption of capsids in situ (bottom panel). Compound <b>19f</b> treatment led to an accumulation of faster-migrating capsid. The levels of HBV DNA packaged in capsid with the same electrophoresis mobility as the control were decreased by <b>19f</b> treatment in a dose-dependent manner.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>19f</b> with appropriate anti-HBV potency and improved pharmacokinetic (PK) properties was further assessed against HBV infection <i>in vivo</i>. An AAV8-HBV-transduced Balb/c mice model was used to determine whether <b>19f</b> was effectively delivered via oral administration to exert an antiviral effect on HBV-expressing hepatocytes. Eight-week-old Balb/c male mice received a single tail vein injection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome (1 × 10<sup>11</sup> viral genome equivalents). After 5 weeks postinjection, 4 groups of 5 mice with stable viremia each were treated with 50 mg/kg <b>19f</b> or 150 mg/kg <b>19f</b> twice a day (b.i.d.) and 0.5% CMC-Na (vehicle) or 0.1 mg/kg ETV (positive control) once daily (qd) for 4 weeks. Finally, a 4-week treatment regimen with <b>19f</b> in this model resulted in a dose-responsive reduction of the HBV DNA level in plasma at the dosages of 50 and 150 mg/kg b.i.d. tested. In comparison to the vehicle-treated control group (0.5% CMC-Na), treatment with 150 mg/kg of <b>19f</b> achieved 2.67 log viral load reduction on week 4. Entecavir (ETV), a polymerase inhibitor, was used as a positive control and potently decreased the amount of HBV DNA in a specific manner (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). We also evaluated the antiviral activity of <b>19f</b> at the dosage of 100 mg/kg b.i.d. in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Supporting Information (Figure S5)</a> and showed the significant activity <i>in vivo</i>.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Levels of HBV DNA in the plasma of AAV/HBV-infected mice by treatment of <b>19f</b> with 50 mg/kg and 150 mg/kg, b.i.d. After 4 weeks treatment, oral administration of <b>19f</b> (b.i.d.) demonstrates a statistically significant reduction of the HBV DNA level of up to 2.67 log at 150 mg/kg in mice transduced with a recombinant AAV-HBV virus compared to that in the vehicle-treated control mice (Dunnett’s multiple comparisons test, <i>P</i> < 0.0001). The treatment regimen with 50 mg/kg <b>19f</b> resulted in a 1.08 log reduction of the HBV DNA viral load (<i>P</i> < 0.01). Data were shown as the mean ± SD. The number of animals per group for data analysis was 5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Chemistry</h3><div class="NLM_p">To optimize <b>4r</b>, analogues described herein were mostly prepared according to the procedure shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. First, 4-chloropyridazinone/phthalazinone <b>8</b> was prepared by 3,6-dichloropyridazine derivatives <b>7</b> refluxing in glacial acetic acid or commercially available pyrazinones <b>11</b>, <b>16</b>, pyridinone <b>14</b>, followed by treatment with 1-chloro-4-(chloromethyl)benzene in the presence of cesium carbonate in DMF to produce the key intermediates <b>9</b>, <b>13</b>, <b>15</b>, <b>17</b>, respectively. Afterward, Suzuki cross-coupling with boronic acids yielded the final compounds (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Then, 2,6-difluoropyridine derivative <b>10m</b> underwent nucleophilic substitution with alcohol or the corresponding substituted amines to provide <b>18f</b>–<b>18n</b> in good yield. Finally, the target compounds <b>19a</b>–<b>19h</b> were obtained through introduction of chlorine at the <i>ortho</i>-position of aniline of pyridine moiety by <i>N</i>-chlorosuccinimide (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>10a</b>–<b>10m</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AcOH, reflux; (b) 1-chloro-4-(chloromethyl)benzene/4-(chloromethyl)benzonitrile, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C; (c) boronic acids, Pd(OAc)<sub>2</sub>, X-Phos, K<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, 60 °C; (d) DIBAL-H, toluene, −10 °C; (e) LiOH, THF/H<sub>2</sub>O, rt; (f) tetramethyltin, Pd(PdPh<sub>3</sub>)<sub>4</sub>, toluene, reflux; (g) 1-chloro-4-(chloromethyl)benzene, Bu<sub>3</sub>SnSnBu<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, microwave, 170 °C.</p></p></figure><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>18f</b>–<b>18n</b> and <b>19a</b>–<b>19h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (h) CH<sub>3</sub>CH<sub>2</sub>OH, NaH, THF, 0 °C or RNH<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMSO, 70 °C, 3 h; (i) NCS, CH<sub>3</sub>CN/THF, reflux 3 h.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, due to the poor pharmacokinetic (PK) properties present in compound <b>4r</b>, we described the further optimization based on metabolic pathways, resulting in the discovery of <b>19f</b>, a novel phthalazinone derivative with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. In <i>in vitro</i> studies, <b>19f</b> inhibited HBV DNA replication in HepG2.2.15 cells with an IC<sub>50</sub> of 0.014 ± 0.004 μM and induced the formation of genome-free capsids. In <i>in vivo</i> studies, oral administration of <b>19f</b> b.i.d. demonstrated a significant reduction of viral DNA at 50, 100, and 150 mg/kg in mice transduced with a recombinant AAV-HBV virus and showed a 2.67 log drop in viral load at 150 mg/kg. On the basis of these results, we identified the novel phthalazinone derivatives that can be effective in both <i>vitro</i> and <i>vivo</i> activities with suitable druggability. The further modification and evaluation of phthalazinone derivatives are ongoing for the development of drug candidate as an oral anti-HBV infection agent.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Synthetic Materials and Methods</h3><div class="NLM_p last">All commercially available starting materials and solvents were reagent grade and used without further purification unless otherwise noted. All of the intermediates and final compounds were purified by silica gel (200–300 mesh) chromatography using Biotage SP1 system. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectral data were recorded in CDCl<sub>3</sub>, D<sub>2</sub>O, methanol-<i>d</i><sub>4</sub> on a Bruker- 600, Bruker-500, Bruker-400, or Varian 300 spectrometer. Data for NMR spectra were reported as follows: chemical shift (δ ppm), multiplicity integration (s = singlet, brs = broad singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet), coupling constant (Hz). The purities of all the final derivatives for biological testing were confirmed to be >95%, as determined using an Agilent 1260 series HPLC instrument (Agilent Eclipse XBD-C18, 5 μm, 4.6 mm × 150 mm, 30 °C, UV 254 nm, injection volume = 3 μL, flow rate = 0.7 mL/min) with aqueous CH<sub>3</sub>OH for 25 min. HR-MS was measured on a Micromass Ultra Q-Tof, and ESI-MS was carried out on an Agilent 1260 mass spectrometer (Agilent Technologies, Santa Clara, CA). Optical rotation was measured using a Rudolph Autopol V automatic polarimeter at a wavelength of 589 nm. The preparations of compounds <b>10c</b>–<b>10h</b>, <b>10l</b>–<b>10m</b>, <b>18a</b>–<b>18g</b>, <b>19a</b>–<b>19h</b> were described below, while the experimental procedures of <b>10a</b>–<b>10b</b>, <b>10i</b>–<b>10k</b>, and key intermediates were provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 2-(4-Chlorobenzyl)-6-(2,6-difluoropyridin-3-yl)-4-(hydroxymethyl)pyridazin-3(2<i>H</i>)-one (<b>10a</b>)</h3><div class="NLM_p last">The synthetic procedure was described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Supporting Information</a>. White solid (77% yield); mp 114.4–115.1 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.37–8.29 (m, 1H), 7.76 (brs, 1H), 7.43 (d, <i>J</i> = 8.2 Hz, 2H), 7.34 (d, <i>J</i> = 8.2 Hz, 2H), 7.00 (dd, <i>J</i> = 8.2, 3.0 Hz, 1H), 5.39 (s, 2H), 4.73 (d, <i>J</i> = 4.7 Hz, 2H), 2.82 (s, 1H).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 2-(4-Chlorobenzyl)-6-(2,6-difluoropyridin-3-yl)-3-oxo-2,3-dihydropyridazine-4-carboxylic Acid <b>(10b)</b></h3><div class="NLM_p last">The synthetic procedure was described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Supporting Information</a>. White solid (67% yield); mp 216.2–216.8 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 13.63 (s, 1H), 8.67 (brs, 1H), 8.35–8.28 (m, 1H), 7.47 (d, <i>J</i> = 8.2 Hz, 2H), 7.38 (d, <i>J</i> = 8.2 Hz, 2H), 7.06 (dd, <i>J</i> = 8.2, 3.0 Hz, 1H), 5.51 (s, 2H).</div></div><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure A for the Synthesis of <b>10c</b>–<b>10h</b>, <b>10l</b>, <b>10m</b></h3><div class="NLM_p">3,6-Dichloropyridazine-4-carboxylic acid <b>7</b> (10.0 g, 51.8 mmol) was placed in AcOH (100 mL) and stirred for 4 h at refluxing. After cooling, the reaction mixture was poured into water and a white solid was precipitated, filtered, washed with water, and dried to afford 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylic acid (6.7 g, 75%).</div><div class="NLM_p">To a solution of 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylic acid (4.8 g, 27.5 mmol) in MeOH (100 mL) was added HCl (30 mL, 4 M in dioxane), and the mixture was stirred for 20 h at 50 °C. After the reaction was finished, the solvent was removed under reduced pressure. The residue was diluted with water (20 mL), extracted with ethyl acetate (15 mL × 3) and the combined organic layers were washed with brine (10 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product, which was purified by column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 20/1, v/v) to afford methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate (4.5 g, 86%).</div><div class="NLM_p">To a solution of methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate (4.0 g, 21.2 mmol) in DMF (100 mL) were added Cs<sub>2</sub>CO<sub>3</sub> (7.6 g, 23.3 mmol) and 1-chloro-4-(chloromethyl)benzene (3.8 g, 23.3 mmol). The resulting mixture was stirred at 50 °C for 7 h, then the solvent was removed under reduced pressure. The residue was diluted with water (100 mL), extracted with ethyl acetate (50 mL × 3) and the combined organic layers were washed with brine (100 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product, which was further purified by column chromatography on silica gel eluting with 25% ethyl acetate in hexane to give the desired product <b>9c</b> (5.05 g, 76%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.73 (s, 1H), 7.42 (d, <i>J</i> = 8.1 Hz, 3H), 7.30 (d, <i>J</i> = 8.4 Hz, 3H), 5.24 (s, 3H), 3.93 (s, 9H).</div><div class="NLM_p last">To a three-necked round-bottom flask was added <b>9c</b> (50 mg, 0.16 mmol), Pd(OAc)<sub>2</sub> (1.79 mg, 0.016 mmol, 0.05 equiv), X-Phos (7.61 mg, 0.032 mmol, 0.1equiv), potassium carbonate (44 mg, 0.32 mmol, 2.0 equiv) under the atmosphere of nitrogen, followed by adding the combined solution of tetrahydrofuran (4 mL) and water (1 mL). Then a solution of (2,6-difluoropyridin-3-yl)boronic acid (30 mg, 0.19 mmol, 1.2 equiv) in THF (1 mL) was added dropwise. The resulting mixture was stirred at 60 °C for 2 h. After cooling, the reaction mixture was filtered and the filtrate was extracted with ethyl acetate (15 mL × 3) and the combined organic layers were washed with brine (10 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product, which was further purified by column chromatography to afford methyl-2-(4-chlorobenzyl)-6-(2,6-difluoropyridin-3-yl)-3-oxo-2,3-dihydropyridazine-4-carboxylate (<b>10c</b><i>)</i>. White solid (47.5 mg, 76% yield); mp 148.2–148.7 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.37–8.31 (m, 1H), 8.27 (d, <i>J</i> = 1.7 Hz, 1H), 7.46 (d, <i>J</i> = 8.4 Hz, 2H), 7.33 (d, <i>J</i> = 8.4 Hz, 2H), 7.02 (dd, <i>J</i> = 8.2, 3.0 Hz, 1H), 5.41 (s, 2H), 3.98 (s, 3H)</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 2-(4-Chlorobenzyl)-6-(2,6-difluoropyridin-3-yl)-4-methoxypyridazin-3(2<i>H</i>)-one (<b>10d</b>)</h3><div class="NLM_p last">This compound was prepared by replacement of 3,6-dichloropyridazine-4-carboxylic acid with 3,6-dichloro-4-methoxy-1,2-dihydropyridazine using a similar synthetic procedure A. White solid (73% yield); mp 125.6–126.0 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.39–8.31 (m, 1H), 7.44 (d, <i>J</i> = 8.4 Hz, 2H), 7.31 (d, <i>J</i> = 8.4 Hz, 2H), 6.98 (dd, <i>J</i> = 8.2, 3.0 Hz, 1H), 6.92 (s, 1H), 5.39 (s, 2H), 3.96 (s, 3H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 2-(4-Chlorobenzyl)-4-cyclopropyl-6-(2,6-difluoropyridin-3-yl)pyridazin-3(2<i>H</i>)-one (<b>10e</b>)</h3><div class="NLM_p last">This compound was prepared by replacement of 3,6-dichloropyridazine-4-carboxylic acid with 3,6-dichloro-4-cyclopropyl-1,2-dihydropyridazine using a similar synthetic procedure A. White solid (64% yield); mp 57.5–58.3 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.36–8.26 (m, 1H), 7.45 (<i>J</i> = 8.3 Hz, 2H), 7.33 (d, <i>J</i> = 8.3 Hz, 2H), 7.09 (brs, 1H), 6.97 (dd, <i>J</i> = 8.2, 3.0 Hz, 1H), 5.38 (s, 2H), 2.39–2.31 (m, 1H), 1.22–1.15 (m, 2H), 0.91–0.84 (m, 2H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 2-(4-Chlorobenzyl)-6-(2,6-difluoropyridin-3-yl)-4-isopropylpyridazin-3(2<i>H</i>)-one (<b>10f</b>)</h3><div class="NLM_p last">This compound was prepared by replacement of 3,6-dichloropyridazine-4-carboxylic acid with 3,6-dichloro-4-isopropyl-1,2-dihydropyridazine using a similar synthetic procedure A. White solid (69% yield); mp 62.5–63.2 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.35–8.29 (m, 1H), 7.49–7.48 (m, 1H), 7.44 (<i>J</i> = 8.3 Hz, 2H), 7.33 (<i>J</i> = 8.3 Hz, 2H), 7.00–6.97 (m, 1H), 5.38 (s, 2H), 3.33–3.22 (m, 1H), 1.27 (s, 3H), 1.25 (s, 3H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 2-(4-Chlorobenzyl)-6-(2,6-difluoropyridin-3-yl)-4,5-dimethylpyridazin-3(2<i>H</i>)-one (<b>10g</b>)</h3><div class="NLM_p last">This compound was prepared by replacement of 3,6-dichloropyridazine-4-carboxylic acid with 3,6-dichloro-4,5-dimethyl-1,2-dihydropyridazine using a similar synthetic procedure A. White solid (71% yield); mp 87.2–87.8 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.94–7.81 (m, 1H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 7.31 (d, <i>J</i> = 8.4 Hz, 2H), 6.99 (dd, <i>J</i> = 8.0, 2.8 Hz, 1H), 5.31 (s, 2H), 2.24 (s, 3H), 2.06 (s, 3H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 2-(4-Chlorobenzyl)-4-(2,6-difluoropyridin-3-yl)-5,6,7,8-tetrahydrophthalazin-1(2<i>H</i>)-one (<b>10h</b>)</h3><div class="NLM_p last">This compound was prepared by replacement of 3,6-dichloropyridazine-4-carboxylic acid with 1,4-dichloro-2,3,5,6,7,8-hexahydrophthalazine using a similar synthetic procedure A. White solid (72% yield); mp 114.2–114.6 °C; <sup>1</sup>H NMR (300 MHz, deuterium oxide) δ 7.89–7.81 (m, 1H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.29 (d, <i>J</i> = 8.3 Hz, 2H), 6.96 (d, <i>J</i> = 8.0 Hz, 1H), 5.28 (s, 2H), 2.65–2.61 (m, 2H), 2.32–2.30 (m, 2H), 1.81–1.66 (m, 4H).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 1-(4-Chlorobenzyl)-5-(2,6-difluoropyridin-3-yl)-3-methylpyrazin-2(1<i>H</i>)-one (<b>10i</b>)</h3><div class="NLM_p last">The synthetic procedure was described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Supporting Information</a>. White solid (68% yield); mp 116.7–117.3 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.03–7.90 (m, 1H), 7.57 (d, <i>J</i> = 8.0 Hz, 2H), 7.46 (d, <i>J</i> = 8.0 Hz, 2H), 7.16 (s, 1H), 6.97 (dd, <i>J</i> = 8.0, 2.8 Hz, 1H), 5.12 (s, 2H), 2.53 (s, 3H).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 1-(4-Chlorobenzyl)-2′,6′-difluoro-5-methyl-[3,3′-bipyridin]-6(1<i>H</i>)-one (<b>10j</b>)</h3><div class="NLM_p last">The synthetic procedure was described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Supporting Information</a>. White solid (75% yield); mp 119.8–120.2 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.88–7.82 (m, 1H), 7.48–7.46 (m, 1H), 7.41–7.39 (m, 1H), 7.37–7.30 (m, 3H), 6.92 (dd, <i>J</i> = 8.1, 3.0 Hz, 1H), 5.19 (s, 2H), 2.26 (s, 3H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 3-(4-Chlorobenzyl)-5-(2,6-difluoropyridin-3-yl)-1-methylpyrazin-2(1<i>H</i>)-one (<b>10k</b>)</h3><div class="NLM_p last">The synthetic procedure was described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">Supporting Information</a>. White solid (66% yield); mp 190.7–191.2 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.60–8.51 (m, 1H), 7.82 (s, 1H), 7.63 (d, <i>J</i> = 8.0 Hz, 2H), 7.54 (d, <i>J</i> = 8.0 Hz, 2H), 6.98 (dd, <i>J</i> = 8.4, 3.0 Hz, 1H), 4.28 (s, 2H), 3.64 (s, 3H).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 2-(4-Chlorobenzyl)-4-(2,6-difluoropyridin-3-yl)phthalazin-1(2<i>H</i>)-one (<b>10l</b>)</h3><div class="NLM_p last">This compound was prepared by replacement of 3,6-dichloropyridazine-4-carboxylic acid with 1,4-dichloro-2,3-dihydrophthalazine using a similar synthetic procedure A. White solid (78% yield); mp 125.3–125.9 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.53–8.49 (m, 1H), 8.07–7.99 (m, 1H), 7.83–7.75 (m, 2H), 7.45–7.39 (m, 3H), 7.31–7.26 (m, 2H), 7.03 (dd, <i>J</i> = 8.0, 2.6 Hz, 1H), 5.40 (s, 2H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 162.53 (d, <i>J</i> = 14.8 Hz), 160.54 (d, <i>J</i> = 14.7 Hz), 159.37 (d, <i>J</i> = 15.1 Hz), 158.41, 157.39 (d, <i>J</i> = 15.1 Hz), 146.23 (dd, <i>J</i> = 7.9, 3.9 Hz), 139.55 (d, <i>J</i> = 4.1 Hz), 134.48, 133.34, 132.91, 131.57, 129.68, 128.30, 128.26, 127.48, 126.96, 125.06 (d, <i>J</i> = 2.5 Hz), 114.20 (dd, <i>J</i> = 28.0, 6.4 Hz), 106.38 (dd, <i>J</i> = 34.5, 5.9 Hz), 53.91. HRMS (ESI): exact mass calcd for C<sub>20</sub>H<sub>13</sub>ClF<sub>2</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 384.0715; found, 384.0710. HPLC purity 98.3% (<i>t</i><sub>R</sub> = 19.35 min).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4-((4-(2,6-Difluoropyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>10m</b>)</h3><div class="NLM_p last">This compound was prepared by replacement of 1-chloro-4-(chloromethyl)benzene with 4-(chloromethyl)benzonitrile in a similar manner to <b>10l</b>. White solid (73% yield); mp 181.5–182.3 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.57–8.52 (m, 1H), 8.08–8.02 (m, 1H), 7.89–7.81 (m, 2H), 7.68–7.63 (m, 2H), 7.62–7.57 (m, 2H), 7.48–7.43 (m, 1H), 7.07 (dd, <i>J</i> = 8.1, 2.8, 1H), 5.50 (s, 2H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 163.10 (d, <i>J</i> = 14.4 Hz), 161.10 (d, <i>J</i> = 14.6 Hz), 159.88 (d, <i>J</i> = 13.9 Hz), 158.99, 157.90 (d, <i>J</i> = 13.8 Hz), 146.62 (dd, <i>J</i> = 8.1, 3.8 Hz), 141.62, 140.48 (d, <i>J</i> = 4.2 Hz), 133.65, 132.46, 132.29, 129.27, 128.83, 127.87, 127.49, 125.70 (d, <i>J</i> = 2.3 Hz), 118.60, 114.49 (d, <i>J</i> = 22.1 Hz), 111.86, 106.92 (dd, <i>J</i> = 34.6, 5.7 Hz), 54.65. HRMS (ESI): exact mass calcd for C<sub>21</sub>H<sub>12</sub>F<sub>2</sub>N<sub>4</sub>ONa <sup>+</sup> [M + Na]<sup>+</sup>, 397.0877; found, 397.0875. HPLC purity 98.5% (<i>t</i><sub>R</sub> = 10.10 min).</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 4-((4-(2-Fluoro-6-methylpyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>18a</b>)</h3><div class="NLM_p last">This compound (a white solid) was prepared by replacement of (2,6-difluoropyridin-3-yl)boronic acid with (2-fluoro-6-methylpyridin-3-yl)boronic acid using a similar synthetic procedure A. White solid (78% yield); mp 180.8–181.2 °C; <sup>1</sup>H NMR (300 MHz, deuterium oxide) δ 8.52–8.48 (m, 1H), 7.85–7.76 (m, 3H), 7.63 (d, <i>J</i> = 8.5 Hz, 2H), 7.57 (d, <i>J</i> = 8.5 Hz, 2H), 7.49–7.44 (m, 1H), 7.24–7.21 (m, 1H), 5.48 (s, 2H), 2.63 (s, 3H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 160.48, 159.05, 158.94, 158.58, 141.95 (d, <i>J</i> = 3.7 Hz), 141.30, 141.25 (d, <i>J</i> = 4.6 Hz), 132.96, 131.92, 131.57, 128.74, 128.58, 127.33, 126.79, 125.58, 120.67 (d, <i>J</i> = 4.4 Hz), 118.16, 113.88, 113.63, 111.25, 54.11, 23.41. HRMS (ESI): exact mass calcd for C<sub>22</sub>H<sub>16</sub>FN<sub>4</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 371.1308; found, 371.1303. HPLC purity 99.6% (<i>t</i><sub>R</sub> = 13.76 min).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 4-((4-(6-Amino-2-fluoropyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>18b</b>)</h3><div class="NLM_p last">This compound (a white solid) was prepared by replacement of (2,6-difluoropyridin-3-yl)boronic acid with (6-amino-2-fluoropyridin-3-yl)boronic acid using a similar synthetic procedure A. White solid (71% yield); mp 243.2–243.7 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.54–8.49 (m, 1H), 7.85–7.78 (m, 2H), 7.69–7.55 (m, 6H), 6.52 (dd, <i>J</i> = 8.0, 1.8 Hz, 1H), 5.50 (s, 2H), 4.81 (s, 2H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 160.68, 158.78, 158.64, 158.00, 157.86, 143.00 (d, <i>J</i> = 4.4 Hz), 141.93, 141.50, 132.78, 131.89, 131.34, 128.99, 128.69, 127.37, 126.67, 125.94, 118.22, 111.14, 104.57 (d, <i>J</i> = 4.6 Hz), 104.37, 54.06. HRMS (ESI): exact mass calcd for C<sub>21</sub>H<sub>15</sub>FN<sub>5</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 372.1261; found, 372.1253. HPLC purity 96.3% (<i>t</i><sub>R</sub> = 11.48 min).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-(5-(3-(4-Cyanobenzyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-6-fluoropyridin-2-yl)acetamide (<b>18c</b>)</h3><div class="NLM_p last">To a solution of <b>18b</b> (185 mg, 0.50 mmol) in anhydrous pyridine (2.2 mL) cooled to 0 °C was slowly added acetic anhydride (0.50 mL, 5.5 mmol). After addition was complete, the reaction was allowed to warm to room temperature and stir overnight. After an aqueous sodium bicarbonate workup with ethyl acetate extraction, the organic layers were pooled and concentrated to give an oil which was purified by silica gel chromatography with 50% ethyl acetate in hexanes to give the desired product <b>18c</b> (177 mg, 86%). White solid (76% yield); mp 249.1–249.8 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.54–7.52 (m, 1H), 8.29–7.27 (m, 1H), 7.97–7.92 (m, 1H), 7.86–7.80 (m, 2H), 7.65 (d, <i>J</i> = 8.3 Hz, 2H), 7.60 (d, <i>J</i> = 8.3 Hz, 2H), 7.50–7.47 (m, 1H), 5.51 (s, 2H), 2.30 (s, 3H).</div></div><div id="sec4_1_15_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedure B for the Synthesis of <b>18d</b>, <b>18e</b>, <b>18g</b></h3><div class="NLM_p last">A mixture of halogenated pyridine <b>10m</b> (1.0 mmol), amine (1.0 equiv), and K<sub>2</sub>CO<sub>3</sub> (1.3 equiv) in DMSO (5 mL) was allowed to react under air atmosphere. The reaction mixture was heated to 70 °C for 2 h. After reaction, the reaction mixture was added to brine (15 mL) and extracted with ethyl acetate (15 mL × 3). The solvent was concentrated under vacuum, and the product was isolated by short chromatography on a silica gel (200–300 mesh) column.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 4-((4-(2-Fluoro-6-(methylamino)pyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>18d</b>)</h3><div class="NLM_p last">White solid (71% yield); mp 222.8–223.4 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.54–8.47 (m, 1H), 7.85–7.77 (m, 2H), 7.67–7.57 (m, 6H), 6.40 (dd, <i>J</i> = 8.2, 1.8 Hz, 1H), 5.50 (s, 2H), 4.96 (s, 1H), 3.03 (d, <i>J</i> = 5.1 Hz, 3H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 160.75, 158.99 (d, <i>J</i> = 17.1 Hz), 158.85, 158.66, 142.50 (d, <i>J</i> = 4.4 Hz), 142.31 (d, <i>J</i> = 4.5 Hz), 141.57, 132.71, 131.88, 131.26, 129.12, 128.70, 127.38, 126.60, 126.07 (d, <i>J</i> = 2.7 Hz), 123.08, 118.24, 111.09, 102.82 (d, <i>J</i> = 30.4 Hz), 102.47, 54.03, 28.52. HRMS (ESI): exact mass calcd for C<sub>22</sub>H<sub>17</sub>FN<sub>5</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 386.1417; found, 386.1409. HPLC purity 99.8% (<i>t</i><sub>R</sub> = 13.36 min).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 4-((4-(6-(Dimethylamino)-2-fluoropyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>18e</b>)</h3><div class="NLM_p last">White solid (73% yield); mp 182.7–183.2 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.56–8.45 (m, 1H), 7.83–7.74 (m, 2H), 7.67–7.56 (m, 6H), 6.48 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 5.50 (s, 2H), 3.19 (s, 6H). <sup>13</sup>C NMR (151 MHz, chloroform-<i>d</i>) δ 160.13, 158.74, 158.55, 158.44, 142.60, 142.30 (d, <i>J</i> = 4.4 Hz), 141.66, 132.74, 131.94, 131.28, 129.24, 128.78, 127.42, 126.62, 126.23, 118.35, 111.10, 102.02 (d, <i>J</i> = 3.8 Hz), 101.54, 101.33, 54.07, 37.68, 24.43. HRMS (ESI): exact mass calcd for C<sub>23</sub>H<sub>19</sub>FN<sub>5</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 400.1574; found, 400.1570. HPLC purity 98.8% (<i>t</i><sub>R</sub> = 15.72 min).</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 4-((4-(6-Ethoxy-2-fluoropyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>18f</b>)</h3><div class="NLM_p last">Ethanol (42 μL, 0.53 mmol) was added to a suspension of NaH (16 mg, 0.53 mmol, 60% in mineral oil) in anhydrous THF (5 mL). After 10 min, a solution of <b>10m</b> (100 mg, 0.27 mmol) in THF was added at 0 °C. The reaction was then warmed to room temperature and stirred at ambient temperature overnight, quenched with water, extracted with ethyl acetate (15 mL × 3). The solvent was concentrated under vacuum and the product was isolated by short chromatography on a silica gel (200–300 mesh) column eluting with 40% ethyl acetate in hexanes to give the desired product <b>18f</b>. White solid (78% yield); mp 195.1–195.4 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.54–8.50 (m, 1H), 7.86–7.80 (m, 2H), 7.80–7.75 (m, 1H), 7.65 (d, <i>J</i> = 8.3 Hz, 2H), 7.60 (d, <i>J</i> = 8.3 Hz, 2H), 7.56–7.51 (m, 1H), 6.80 (dd, <i>J</i> = 8.2, 1.2 Hz, 1H), 5.50 (s, 2H), 4.45 (q, <i>J</i> = 7.1 Hz, 2H), 1.47 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 4-((4-(2-Fluoro-6-((2-methoxyethyl)amino)pyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>18g</b>)</h3><div class="NLM_p last">White solid (81% yield); mp 140.0–140.7 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.52–8.47 (m, 1H), 7.83–7.76 (m, 2H), 7.67–7.52 (m, 7H), 6.43 (dd, <i>J</i> = 8.2, 1.8 Hz, 1H), 5.49 (s, 2H), 5.26 (t, <i>J</i> = 5.2 Hz, 1H), 3.72–3.53 (m, 4H), 3.43 (s, 3H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 161.30, 159.41, 159.16, 158.71, 158.57, 142.79 (d, <i>J</i> = 4.5 Hz), 142.06, 133.20, 132.38, 131.75, 129.60, 127.89, 127.11, 126.57, 118.74, 111.61, 104.37, 103.46, 103.21, 70.92, 58.87, 54.53, 41.57. HRMS (ESI): exact mass calcd for C<sub>24</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 430.1679; found, 430.1675. HPLC purity 97.7% (<i>t</i><sub>R</sub> = 14.19 min).</div></div><div id="sec4_1_19_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> General Procedure C for the Synthesis of <b>19a</b>–<b>19h</b></h3><div class="NLM_p last"><b>18g</b> (200 mg, 0.46 mmol) was mixed with <i>N</i>-chlorosuccinimide (62 mg, 0.46 mmol, 1.0 equiv) in acetonitrile (5 mL) and heated at reflux overnight. The reaction mixture was concentrated with silical gel and purified by column chromatography with 15% ethyl acetate in hexanes to afford 4-((4-(5-chloro-2-fluoro-6-((2-methoxyethyl)amino)pyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>19a</b>) (194 mg, 90% yield); mp 141.2–141.6 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.52–8.45 (m, 1H), 7.85–7.77 (m, 2H), 7.66–7.61 (m, 3H), 7.59–7.56 (m, 3H), 5.71 (t, <i>J</i> = 5.4 Hz, 1H), 5.47 (s, 2H), 3.76–3.69 (m, 2H), 3.64–3.62 (m, 2H), 3.44 (s, 3H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 159.53, 159.09, 157.63, 153.64 (d, <i>J</i> = 18.1 Hz), 141.90, 141.61 (d, <i>J</i> = 4.7 Hz), 140.82 (d, <i>J</i> = 5.1 Hz), 133.34, 132.41, 131.92, 129.33, 129.20, 127.87, 127.21, 126.34 (d, <i>J</i> = 2.7 Hz), 118.70, 111.69, 111.00 (d, <i>J</i> = 4.9 Hz), 103.79, 103.53, 70.84, 58.92, 54.62, 41.42. HRMS (ESI): exact mass calcd for C<sub>24</sub>H<sub>20</sub>ClFN<sub>5</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 464.1290; found, 464.1277. HPLC purity 100% (<i>t</i><sub>R</sub> = 17.31 min).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-((4-(5-Chloro-6-((2-(dimethylamino)ethyl)amino)-2-fluoropyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>19b</b>)</h3><div class="NLM_p last">White solid (73% yield); mp 104.1–104.5 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.52–8.48 (m, 1H), 7.84–7.78 (m, 2H), 7.67–7.62 (m, 3H), 7.62–7.57 (m, 3H), 6.04 (brs, 1H), 5.49 (s, 2H), 3.60–3.55 (m, 2H), 2.62 (t, <i>J</i> = 6.0 Hz, 2H), 2.34 (s, 6H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 159.60, 159.10, 157.71, 153.87, 153.73, 141.91, 141.72, 140.60 (d, <i>J</i> = 5.2 Hz), 133.31, 132.41, 131.89, 129.36, 129.20, 127.87, 127.20, 126.39, 118.70, 111.68, 111.01 (d, <i>J</i> = 5.0 Hz), 103.32, 103.06, 57.64, 54.61, 45.20, 39.02. HRMS (ESI): exact mass calcd for C<sub>25</sub>H<sub>23</sub>ClFN<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>, 477.1606; found, 477.1596. HPLC purity 99.5% (<i>t</i><sub>R</sub> = 12.25 min).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Methyl 3-((3-Chloro-5-(3-(4-cyanobenzyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-6-fluoropyridin-2-yl)amino)propanoate (<b>19c</b>)</h3><div class="NLM_p last">White solid (72% yield); mp 157.2–157.7 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.52–8.45 (m, 1H), 7.83–7.77 (m, 2H), 7.66–7.61 (m, 3H), 7.59–7.54 (m, 3H), 5.91 (t, <i>J</i> = 6.2 Hz, 1H), 5.47 (s, 2H), 3.83 (q, <i>J</i> = 6.0 Hz, 2H), 3.75 (s, 3H), 2.73 (<i>t</i>, <i>J</i> = 6.0 Hz, 2H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 172.84, 159.54, 159.07, 157.64, 153.38 (d, <i>J</i> = 18.1 Hz), 141.88, 141.54 (d, <i>J</i> = 4.7 Hz), 140.91 (d, <i>J</i> = 5.0 Hz), 133.35, 132.41, 131.94, 129.30, 129.20, 127.86, 127.22, 126.32 (d, <i>J</i> = 2.7 Hz), 118.69, 111.69, 111.03 (d, <i>J</i> = 4.8 Hz), 104.03, 103.76, 54.62, 51.89, 37.14, 33.62. HRMS (ESI): exact mass calcd for C<sub>25</sub>H<sub>20</sub>ClFN<sub>5</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>, 492.1239; found, 492.1229. HPLC purity 99.4% (<i>t</i><sub>R</sub> = 17.02 min).</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 3-((3-Chloro-5-(3-(4-cyanobenzyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-6-fluoropyridin-2-yl)amino)propanoic Acid (<b>19d</b>)</h3><div class="NLM_p last">White solid (79% yield); mp 128.3–128.8 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.53–8.46 (m, 1H), 7.83–7.77 (m, 2H), 7.68–7.60 (m, 3H), 7.59–7.53 (m, 3H), 5.86 (t, <i>J</i> = 6.4 Hz, 1H), 5.47 (s, 2H), 3.85 (q, <i>J</i> = 6.0 Hz, 2H), 2.80 (t, <i>J</i> = 6.0 Hz, 2H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 177.10, 159.38, 157.64, 153.35 (d, <i>J</i> = 17.9 Hz), 142.00, 141.68, 140.98 (d, <i>J</i> = 5.2 Hz), 133.59, 132.45, 132.16, 129.30, 129.23, 127.68, 127.28, 126.37, 118.62, 111.72, 111.05, 104.10, 103.84, 54.78, 36.93, 33.57. HRMS (ESI): exact mass calcd for C<sub>24</sub>H<sub>18</sub>ClFN<sub>5</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>, 478.1082; found, 478.1070. HPLC purity 99.0% (<i>t</i><sub>R</sub> = 14.91 min).</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-((4-(5-Chloro-2-fluoro-6-((2-hydroxyethyl)amino)pyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>19e</b>)</h3><div class="NLM_p last">White solid (86% yield); mp 201.2–201.4 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.52–8.45 (m, 1H), 7.83–7.77 (m, 2H), 7.68–7.60 (m, 3H), 7.60–7.53 (m, 3H), 5.75 (t, <i>J</i> = 5.8 Hz, 1H), 5.47 (s, 2H), 3.93–3.88 (m, 2H), 3.73 (q, <i>J</i> = 5.3 Hz, 2H), 2.19 (s, 1H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 159.48, 159.10, 157.58, 153.91, 153.77, 141.85, 141.49, 141.02 (d, <i>J</i> = 5.0 Hz), 133.38, 132.43, 131.98, 129.21, 127.87, 127.25, 126.29, 118.69, 111.71, 111.07 (d, <i>J</i> = 5.0 Hz), 104.16, 103.90, 61.94, 54.63, 44.11. HRMS (ESI): exact mass calcd for C<sub>23</sub>H<sub>18</sub>ClFN<sub>5</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>, 450.1133; found, 450.1121. HPLC purity 95.9% (<i>t</i><sub>R</sub> = 14.27 min).</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 4-((4-(5-Chloro-6-((2,3-dihydroxypropyl)amino)-2-fluoropyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>19f</b>)</h3><div class="NLM_p last">White solid (81% yield); mp 108.7–109.3 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.54–8.48 (m, 1H), 7.87–7.79 (m, 2H), 7.72–7.68 (m, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 2H), 7.59 (d, <i>J</i> = 8.0 Hz, 2H), 7.57–7.53(m, 1H), 5.78 (t, <i>J</i> = 6.1 Hz, 1H), 5.49 (s, 2H), 4.00 (s, 1H), 3.82–3.74 (m, 2H), 3.72–3.60 (m, 2H), 2.87 (s, 1H), 2.59 (s, 1H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 159.44, 159.10, 157.53, 154.02, 153.88, 141.83, 141.28, 141.24, 133.44, 132.45, 132.05, 129.20, 127.86, 127.29, 126.23, 118.68, 111.72, 111.16, 104.36, 104.11, 70.97, 64.01, 54.66, 44.19. HRMS (ESI): exact mass calcd for C<sub>24</sub>H<sub>19</sub>ClFN<sub>5</sub>NaO<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>, 502.1058; found, 502.1053. HPLC purity 99.0% (<i>t</i><sub>R</sub> = 13.47 min).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>S</i>)-4-((4-(5-Chloro-6-((2,3-dihydroxypropyl)amino)-2-fluoropyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>19g</b>)</h3><div class="NLM_p last">White solid (83% yield); [α]<sub>D</sub><sup>20</sup> −10.03 (0.108 mg/mL, MeOH); mp 98.8–99.2 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.54–8.47 (m, 1H), 7.86–7.79 (m, 2H), 7.71–7.68 (m, 1H), 7.64 (d, <i>J</i> = 8.0 Hz, 2H), 7.58 (d, <i>J</i> = 8.0 Hz, 2H), 7.57–7.54 (m, 1H), 5.81 (t, <i>J</i> = 6.1 Hz, 1H), 5.49 (s, 2H), 4.05–3.96 (m, 1H), 3.84–3.74 (m, 2H), 3.72–3.59. HRMS (ESI): exact mass calcd for C<sub>24</sub>H<sub>20</sub>ClFN<sub>5</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>, 480.1239; found, 480.1231. HPLC purity 98.9% (<i>t</i><sub>R</sub> = 14.06 min).</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>R</i>)-4-((4-(5-Chloro-6-((2,3-dihydroxypropyl)amino)-2-fluoropyridin-3-yl)-1-oxophthalazin-2(1<i>H</i>)-yl)methyl)benzonitrile (<b>19h</b>)</h3><div class="NLM_p last">White solid (79% yield); [α]<sub>D</sub><sup>20</sup> 11.11 (0.102 mg/mL, MeOH); mp 120.4–120.9 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.53–8.47 (m, 1H), 7.85–7.79 (m, 2H), 7.71–7.68 (m, 1H), 7.64 (d, <i>J</i> = 8.0 Hz, 2H), 7.58 (d, <i>J</i> = 8.0 Hz, 2H), 7.57–7.54 (m, 1H), 5.78 (t, <i>J</i> = 6.0 Hz, 1H), 5.49 (s, 2H), 4.00 (brs, 1H), 3.84–3.73 (m, 2H), 3.70–3.60 (m, 2H), 3.16 (s, 1H), 2.86 (s, 1H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 159.44, 159.09, 157.53, 154.02, 153.88, 141.83, 141.29, 141.25, 133.44, 132.45, 132.04, 129.20, 127.87, 127.29, 126.22, 118.68, 111.73, 111.18 (d, <i>J</i> = 4.8 Hz), 104.39, 104.14, 70.98, 64.00, 54.66, 44.19. HRMS (ESI): exact mass calcd for C<sub>24</sub>H<sub>19</sub>ClFN<sub>5</sub>NaO<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>, 502.1058; found, 502.1054. HPLC purity 98.7% (<i>t</i><sub>R</sub> = 13.46 min).</div></div><div id="sec4_1_26_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Pharmacokinetic (PK) Analysis</h3><div class="NLM_p">All animal studies were performed according to the protocols and guidelines of the institutional care and use committee. All the procedures related to animal handling, care, and treatment in this article were performed in compliance with Agreement of the Ethics Committee on Laboratory Animal Care and the Guidelines for the Care and Use of Laboratory Animals in Shanghai, China. In PK study, 6 male ICR mice (body weight, 18–22g) were assigned randomly into two groups. One group received the test compound orally (po), and the other group was administered intravenous (iv). Test compound was dissolved in Solutol solution (DMSO/Solutol/EtOH/saline, 5/10/10/75, v/v/v/v) for iv dose and in 0.5% CMC-Na for po dose. Test compound was administered at 20 mg/kg and 2 mg/kg for po and iv route, respectively. Blood samples (20 μL) were collected from the femoral vein at 0.25, 0.5, 1, 2, 4, 8, and 24 h into heparin-containing microcentrifuge tubes, and plasma samples were then isolated by centrifugation, followed by collection of 10 μL of plasma and precipitation of protein immediately with ACN/MeOH (1:1, v/v) for analysis. Plasma concentrations of the test compound were analyzed using LC–MS/MS. Individual plasma concentration–time profiles were subjected to a noncompartmental pharmacokinetic analysis (NCA) using WinNonlin Professional, version 5.2.1.</div><div class="NLM_p">In tissue distribution study, 12 male ICR mice (body weight, 18–22g) were randomly assigned into four groups corresponding to the four collection time points (1, 3, 8, and 24 h postdose), and each was orally administered with 20 mg/kg of test compound. After isoflurane inhalation anesthesia, blood samples were collected from heart and liver portal vein, respectively, and centrifuged to obtain plasma samples. After portal vein catheterization and perfusion, livers were removed from mice at designated time points. These tissues were washed with saline and dried with filter paper. For extraction, mice livers were accurately weighed and then homogenized in saline (5 mL/g tissue).</div><div class="NLM_p last">The analysis were performed on an Acquity Ultra liquid chromatography (UPLC) system (Waters Corporation, Milford, MA, USA) coupled to a Xevo TQ-S mass spectrometer (Waters Corporation, Milford, MA, USA). Chromatographic separation was performed using an Acquity UPLC BEH C18 (1.7 μm, 2.1 mm × 50 mm) column supplied by Waters at a flow of 0.5 mL/min. The Xevo TQ-S mass spectrometer was equipped with an electrospray ionization probe and was operated in the positive ion mode.</div></div><div id="sec4_1_26_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Microsomal Stability Assay and Metabolic Identification in Liver Microsomes</h3><div class="NLM_p last">Each incubated mixture contained 0.5 mg/mL liver microsome (human, monkey, dog, rat, or mouse), 3.0 μM test compound, and 100 mM potassium phosphate buffer (pH 7.4) in a total volume of 100 μL. After prewarming at 37 °C for 3 min, 1 mM NADPH was added to initiate the reaction. The reaction was terminated after 60 min by adding 100 μL of ice-cold acetonitrile into the incubation mixture. The sample was then centrifuged at 14 000 rpm for 5 min. The supernatant was then analyzed by UPLC–UV/Q-TOF MS.</div></div><div id="sec4_1_26_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> HBV DNA Quantification and Cytotoxicity Assay<a onclick="showRef(event, 'ref24 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref27">(24,27)</a></h3><div class="NLM_p last">HepG2.2.15 cells (GenBank accession number <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=U95551">U95551</a>) were maintained in minimum essential media (MEM Gibco) supplemented with 10% fetal bovine serum (FBS Hyclone) and 380 μg/mL G418 (Gibco). HepG2.2.15 cells were cultured and treated with different concentrations of agents in 96-well plates at a density of 4 × 10<sup>3</sup> cells for 8 days under standard conditions. HBV DNA from cell culture medium was extracted by QIAsymphony SP (Qiagen) and quantified by real-time PCR and as described previously. After the medium was collected, 100 μL of MTT (final concentration 2.5 mg/mL, Sigma-Aldrich) was added for 1 h at 37 °C. The cells were then lysed with 10% sodium dodecyl sulfate (SDS) and 50% <i>N</i>,<i>N</i>-dimethylformamide, pH 7.2. OD values were read at 570 nm, and the percentage of cell death was calculated.</div></div><div id="sec4_1_26_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Southern Blotting Analysis</h3><div class="NLM_p last">HepG2.2.15 cells were cultured in 12-well plates, and the HBV DNAs from the intracellular HBV capsids were extracted and detected by Southern blotting using a DIG-labeled PCR fragment according to the protocol described previously.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div></div><div id="sec4_1_26_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> In Vivo Efficacy in the AAV/HBV-Infected BALB/c Mice Model</h3><div class="NLM_p last">Balb/c male mice (6–8 weeks) were obtained from Shanghai Lingchang Biotechnology Co, Ltd. and kept under specific pathogen-free (SPF) conditions. Mice were injected intravenously (iv) with a recombinant adeno-associated virus (AAV) carrying the HBV 1.1 genome (10<sup>11</sup> viral genome equivalents) in order to establish an alternative model of chronic HBV infection. Five weeks after injection, mice with stable viremia were selected and treated with antiviral agents for 4 weeks.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Every week, blood was collected and the levels of HBV DNA in plasma were determined by real-time PCR.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00346" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00346?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00346</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Tissue distributions profiles and plasma concentration–time curves in mice of <b>4r</b>, <b>10m</b>, and <b>19f</b>; detailed experimental procedures for the synthesis of analogues <b>10a</b>, <b>10b</b>, <b>10i</b>, <b>10j</b>, <b>10k</b> and intermediates <b>18h</b>–<b>18n</b>; characterization (<sup>1</sup>H NMR spectra and <sup>13</sup>C NMR spectra are attached) and HPLC purity control of the selected final compounds <b>10l</b>, <b>10m</b>, <b>18a</b>, <b>18b</b>, <b>18d</b>, <b>18e</b>, <b>18g</b>, <b>19a</b>–<b>19h</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular-formula strings of the reported compounds and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf">jm0c00346_si_001.pdf (3.66 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_002.csv">jm0c00346_si_002.csv (2.5 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00346" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Yang</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Immunopharmacology, Shanghai Institute
of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f88199969f9491b88b919595d6999bd69b96"><span class="__cf_email__" data-cfemail="384159565f5451784b51555516595b165b56">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianping Zuo</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Immunopharmacology, Shanghai Institute
of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">Laboratory
of Immunology and Virology, Shanghai University
of Traditional Chinese Medicine, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#52382228273d12213b3f3f7c33317c313c"><span class="__cf_email__" data-cfemail="22485258574d62514b4f4f0c43410c414c">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youhong Hu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, Hangzhou 310024, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1770-6272" title="Orcid link">http://orcid.org/0000-0003-1770-6272</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b2cbdadac7f2c1dbdfdf9cd3d19cd1dc"><span class="__cf_email__" data-cfemail="3a4352524f7a49535757145b59145954">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wuhong Chen</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feifei Liu</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Immunopharmacology, Shanghai Institute
of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiliang Zhao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinna Ma</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Immunopharmacology, Shanghai Institute
of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">Laboratory
of Immunology and Virology, Shanghai University
of Traditional Chinese Medicine, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dong Lu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heng Li</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Immunopharmacology, Shanghai Institute
of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanping Zeng</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiankun Tong</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Immunopharmacology, Shanghai Institute
of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Limin Zeng</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>W.C., F.L., and Q.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This project was supported by the National Natural Science Foundation of China (Grant 81872725), Science and Technology Commission of Shanghai Municipality (Grant 18431907100), the National Science Foundation of Shanghai (Grant 17ZR1436400), and National Science and Technology Major Project (Grant 2018ZX09711002-014-004).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">HBV</td><td class="NLM_def"><p class="first last">hepatitis B virus</p></td></tr><tr><td class="NLM_term">ETV</td><td class="NLM_def"><p class="first last">entecavir</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">pgRNA</td><td class="NLM_def"><p class="first last">pregenomic RNA</p></td></tr><tr><td class="NLM_term">NA</td><td class="NLM_def"><p class="first last">not active</p></td></tr><tr><td class="NLM_term">SDPK</td><td class="NLM_def"><p class="first last">single dose pharmacokinetics</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">rcDNA</td><td class="NLM_def"><p class="first last">relaxed circular DNA</p></td></tr><tr><td class="NLM_term">ssDNA</td><td class="NLM_def"><p class="first last">single-stranded DNA</p></td></tr><tr><td class="NLM_term">PCR</td><td class="NLM_def"><p class="first last">polymerase chain reaction</p></td></tr><tr><td class="NLM_term">CMC-Na</td><td class="NLM_def"><p class="first last">sodium carboxymethyl cellulose</p></td></tr><tr><td class="NLM_term">b.i.d.</td><td class="NLM_def"><p class="first last">twice daily</p></td></tr><tr><td class="NLM_term">Cs<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">cesium carbonate</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">X-Phos</td><td class="NLM_def"><p class="first last">dicyclohexyl(2′,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphane</p></td></tr><tr><td class="NLM_term">K<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">potassium carbonate</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DIBAL-H</td><td class="NLM_def"><p class="first last">diisobutylaluminum hydride</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">NCS</td><td class="NLM_def"><p class="first last"><i>N</i>-chlorosuccinimide</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40787" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40787" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span>World Health
Organization Hepatitis B fact sheet. <a href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-B" class="extLink">https://www.who.int/news-room/fact-sheets/detail/hepatitis-B</a> (accessed July 18, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health%0AOrganization+Hepatitis+B+fact+sheet.+https%3A%2F%2Fwww.who.int%2Fnews-room%2Ffact-sheets%2Fdetail%2Fhepatitis-B+%28accessed+July+18%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schweitzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczyk, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, J. J.</span></span> <span> </span><span class="NLM_article-title">Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">1546</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)61412-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2FS0140-6736%2815%2961412-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=26231459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FosV2msw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=1546-1555&author=A.+Schweitzerauthor=J.+Hornauthor=R.+T.+Mikolajczykauthor=G.+Krauseauthor=J.+J.+Ott&title=Estimations+of+worldwide+prevalence+of+chronic+hepatitis+B+virus+infection%3A+a+systematic+review+of+data+published+between+1965+and+2013&doi=10.1016%2FS0140-6736%2815%2961412-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013</span></div><div class="casAuthors">Schweitzer Aparna; Horn Johannes; Mikolajczyk Rafael T; Krause Gerard; Ott Jordis J</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">10003</span>),
    <span class="NLM_cas:pages">1546-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The quantification of the burden of disease attributable to hepatitis B virus (HBV) infection and the adaptation of prevention and control measures requires knowledge on its prevalence in the general population.  For most countries such data are not routinely available.  We estimated the national, regional, and global prevalence of chronic HBV infection.  METHODS:  For this systematic review and pooled analysis, we searched for data on prevalence of chronic HBV infection published between Jan 1, 1965, and Oct 23, 2013, in the databases Medline, Embase, CAB Abstracts (Global health), Popline, and Web of Science.  We included studies reporting the hepatitis B surface antigen (HBsAg) serological marker of chronic HBV infection in non-high-risk groups and extracted data into a customised database.  For each country, we calculated HBsAg prevalence estimates and 95% CIs weighted by study size.  We extrapolated prevalence estimates to population sizes in 2010 to obtain the number of individuals with chronic HBV infection.  FINDINGS:  Of the 17,029 records screened, 1800 report on the prevalence of HBsAg covering 161 countries were included.  HBsAg seroprevalence was 3·61% (95% CI 3·61-3·61) worldwide with highest endemicity in countries of the African region (total 8·83%, 8·82-8·83) and Western Pacific region (total 5·26%, 5·26-5·26).  Within WHO regions, prevalence ranged from 0·20% (0·19-0·21; Mexico) to 13·55% (9·00-19·89; Haiti) in the Americas, to 0·48% (0·12-1·90; the Seychelles) to 22·38% (20·10-24·83; South Sudan) in the African region.  We estimated that in 2010, globally, about 248 million individuals were HBsAg positive.  INTERPRETATION:  This first global assessment of country-level population prevalence of chronic HBV infection found a wide variation between countries and highlights the need for continued prevention and control strategies and the collection of reliable epidemiologic data using standardised methodology.  FUNDING:  World Health Organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqfjRKxbcYNQyMywPm6HgQfW6udTcc2eY6MNa74_W1Zrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FosV2msw%253D%253D&md5=5c7816955fae1c2be9f42428495edcad</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2961412-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252961412-X%26sid%3Dliteratum%253Aachs%26aulast%3DSchweitzer%26aufirst%3DA.%26aulast%3DHorn%26aufirst%3DJ.%26aulast%3DMikolajczyk%26aufirst%3DR.%2BT.%26aulast%3DKrause%26aufirst%3DG.%26aulast%3DOtt%26aufirst%3DJ.%2BJ.%26atitle%3DEstimations%2520of%2520worldwide%2520prevalence%2520of%2520chronic%2520hepatitis%2520B%2520virus%2520infection%253A%2520a%2520systematic%2520review%2520of%2520data%2520published%2520between%25201965%2520and%25202013%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D1546%26epage%3D1555%26doi%3D10.1016%2FS0140-6736%2815%2961412-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span> </span><span class="NLM_article-title">EASL clinical practice guidelines: Management of chronic hepatitis
B virus infection</span>.  <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume">57</span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2012.02.010</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.jhep.2012.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=22436845" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=EASL+clinical+practice+guidelines%3A+Management+of+chronic+hepatitis%0AB+virus+infection.+J.+Hepatol.+2012%2C+57+%281%29%2C+167%E2%80%93185%2C+10.1016%2Fj.jhep.2012.02.010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.02.010%26sid%3Dliteratum%253Aachs%26atitle%3DEASL%2520clinical%2520practice%2520guidelines%253A%2520Management%2520of%2520chronic%2520hepatitis%250AB%2520virus%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D57%26issue%3D1%26spage%3D167%26epage%3D185%26doi%3D10.1016%2Fj.jhep.2012.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span> <span> </span><span class="NLM_article-title">Past, current, and future developments of therapeutic agents for treatment of chronic hepatitis B virus infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6461</span>– <span class="NLM_lpage">6479</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01442</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01442" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslSktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6461-6479&issue=15&author=Y.+Peiauthor=C.+Wangauthor=S.+F.+Yanauthor=G.+Liu&title=Past%2C+current%2C+and+future+developments+of+therapeutic+agents+for+treatment+of+chronic+hepatitis+B+virus+infection&doi=10.1021%2Facs.jmedchem.6b01442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection</span></div><div class="casAuthors">Pei, Yameng; Wang, Chunting; Yan, S. Frank; Liu, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6461-6479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">For decades, treatment of hepatitis B virus (HBV) infection has been relying on interferon (IFN)-based therapies and nucleoside/nucleotide analogs (NAs) that selectively target the viral polymerase reverse transcriptase (RT) domain and thereby disrupt HBV viral DNA synthesis.  We have summarized here the key steps in the HBV viral life cycle, which could potentially be targeted by novel anti-HBV therapeutics.  A wide range of next-generation direct antiviral agents (DAAs) with distinct mechanisms of actions are discussed, including entry inhibitors, transcription inhibitors, nucleoside/nucleotide analogs, inhibitors of viral RNase H (RNase H), modulators of viral capsid assembly, inhibitors of HBV surface antigen (HBsAg) secretion, RNA interference (RNAi) gene silencers, antisense oligonucleotides (ASOs), and natural products.  Compds. that exert their antiviral activities mainly through host factors and immunomodulation, such as host targeting agents (HTAs), programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, and Toll-like receptor (TLR) agonists, are also discussed.  In this Perspective, we hope to provide an overview, albeit by no means being comprehensive, for the recent development of novel therapeutic agents for the treatment of chronic HBV infection, which not only are able to sustainably suppress viral DNA but also aim to achieve functional cure warranted by HBsAg loss and ultimately lead to virus eradication and cure of hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoxbHfWUT-wbVg90H21EOLACvtfcHk0ljl1PtiN6aOcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslSktbw%253D&md5=1a4cde07bc926b2ec7404ab444b66beb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01442%26sid%3Dliteratum%253Aachs%26aulast%3DPei%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DPast%252C%2520current%252C%2520and%2520future%2520developments%2520of%2520therapeutic%2520agents%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D15%26spage%3D6461%26epage%3D6479%26doi%3D10.1021%2Facs.jmedchem.6b01442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banini, B. A.</span></span> <span> </span><span class="NLM_article-title">Updates on chronic HBV: current challenges and future goals</span>. <i>Curr. Treat. Options. Gastro.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1007/s11938-019-00236-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1007%2Fs11938-019-00236-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=31077059" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=271-291&issue=2&author=H.+M.+Leeauthor=B.+A.+Banini&title=Updates+on+chronic+HBV%3A+current+challenges+and+future+goals&doi=10.1007%2Fs11938-019-00236-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs11938-019-00236-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11938-019-00236-3%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BM.%26aulast%3DBanini%26aufirst%3DB.%2BA.%26atitle%3DUpdates%2520on%2520chronic%2520HBV%253A%2520current%2520challenges%2520and%2520future%2520goals%26jtitle%3DCurr.%2520Treat.%2520Options.%2520Gastro.%26date%3D2019%26volume%3D17%26issue%3D2%26spage%3D271%26epage%3D291%26doi%3D10.1007%2Fs11938-019-00236-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.ejmech.2018.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=29438889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1SmtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2018&pages=205-217&author=D.+Sunauthor=L.+Zhuauthor=D.+Yaoauthor=L.+Chenauthor=L.+Fuauthor=L.+Ouyang&title=Recent+progress+in+potential+anti-hepatitis+B+virus+agents%3A+Structural+and+pharmacological+perspectives&doi=10.1016%2Fj.ejmech.2018.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives</span></div><div class="casAuthors">Sun, Dejuan; Zhu, Lingjuan; Yao, Dahong; Chen, Lixia; Fu, Leilei; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205-217</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Hepatitis B virus (HBV) infections affect about 240 million patients worldwide and increase the risk of liver cirrhosis and hepatocellular carcinoma.  It is estd. that about 686 thousand people died annually of liver damage resulted from HBV infections.  At present, two classes of antiviral drugs have been approved by the Food and Drug Administration (FDA) for the treatment of hepatitis B, immunomodulators (interferon [IFN]-a and pegylated-interferon [PEG-IFN]-a) and nucleos(t)ide analogs (lamivudine, telbivudine, adefovir, tenofovir [TDF], and entecavir [ETV]).  However, it still remains a daunting challenge for curing HBV, because of the low sustained response rates (20-30%) and many side effects of IFN and peg-IFN.  Although nucleoside analogs are well tolerated and exhibit an early and potent antiviral effect, the selection of resistant mutants and nephrotoxicity during long-term therapy limit their use.  Here, the authors focus on summarizing the currently approved anti-HBV drugs and characterization of novel HBV inhibitors and analyzing their structures, targets, anti-HBV effects and mechanisms of action, which may shed new light on the discovery of small compds. as potential anti-HBV drugs for treatment of HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqdSeSzutmKLVg90H21EOLACvtfcHk0ljl1PtiN6aOcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1SmtLs%253D&md5=81e2ec7daf64ef5964d33a8737be2376</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DRecent%2520progress%2520in%2520potential%2520anti-hepatitis%2520B%2520virus%2520agents%253A%2520Structural%2520and%2520pharmacological%2520perspectives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D147%26spage%3D205%26epage%3D217%26doi%3D10.1016%2Fj.ejmech.2018.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zlotnick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewellyn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span> <span> </span><span class="NLM_article-title">Core protein: A pleiotropic keystone in the HBV lifecycle</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2015.06.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.antiviral.2015.06.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=26129969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2ltLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=82-93&author=A.+Zlotnickauthor=B.+Venkatakrishnanauthor=Z.+Tanauthor=E.+Lewellynauthor=W.+Turnerauthor=S.+Francis&title=Core+protein%3A+A+pleiotropic+keystone+in+the+HBV+lifecycle&doi=10.1016%2Fj.antiviral.2015.06.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Core protein: A pleiotropic keystone in the HBV lifecycle</span></div><div class="casAuthors">Zlotnick, Adam; Venkatakrishnan, Balasubramanian; Tan, Zhenning; Lewellyn, Eric; Turner, William; Francis, Samson</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-93</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis B Virus (HBV) is a small virus whose genome has only four open reading frames.  We argue that the simplicity of the virion correlates with a complexity of functions for viral proteins.  We focus on the HBV core protein (Cp), a small (183 residue) protein that self-assembles to form the viral capsid.  However, its functions are a little more complicated than that.  In an infected cell Cp modulates almost every step of the viral lifecycle.  Cp is bound to nuclear viral DNA and affects its epigenetics.  Cp correlates with RNA specificity.  Cp assembles specifically on a reverse transcriptase-viral RNA complex or, apparently, nothing at all.  Indeed Cp has been one of the model systems for investigation of virus self-assembly.  Cp participates in regulation of reverse transcription.  Cp signals completion of reverse transcription to support virus secretion.  Cp carries both nuclear localization signals and HBV surface antigen (HBsAg) binding sites; both of these functions appear to be regulated by contents of the capsid.  Cp can be targeted by antivirals - while self-assembly is the most accessible of Cp activities, we argue that it makes sense to engage the broader spectrum of Cp function.  This article forms part of a symposium in Antiviral Research on "From the discovery of the Australia antigen to the development of new curative therapies for hepatitis B: an unfinished story.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyafN5HJZSQLVg90H21EOLACvtfcHk0ljl1PtiN6aOcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2ltLvM&md5=e1bd58b97219cb54136dbb2db2fadb70</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DZlotnick%26aufirst%3DA.%26aulast%3DVenkatakrishnan%26aufirst%3DB.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DLewellyn%26aufirst%3DE.%26aulast%3DTurner%26aufirst%3DW.%26aulast%3DFrancis%26aufirst%3DS.%26atitle%3DCore%2520protein%253A%2520A%2520pleiotropic%2520keystone%2520in%2520the%2520HBV%2520lifecycle%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D121%26spage%3D82%26epage%3D93%26doi%3D10.1016%2Fj.antiviral.2015.06.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijampatnam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of HBV capsid assembly modulators</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2019.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.cbpa.2019.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=30952041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Ohsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=73-79&author=B.+Nijampatnamauthor=D.+C.+Liotta&title=Recent+advances+in+the+development+of+HBV+capsid+assembly+modulators&doi=10.1016%2Fj.cbpa.2019.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of HBV capsid assembly modulators</span></div><div class="casAuthors">Nijampatnam, Bhavitavya; Liotta, Dennis C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73-79</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis B virus (HBV) infections represent a significant burden on global public health.  Current HBV treatments using nucleos(t)ide analogs (NAs) and PEG interferons cannot fully alleviate this burden as they do not affect the transcriptional activity of the tenacious covalently closed circular DNA (cccDNA) responsible for viral persistence.  Capsid assembly modulators (CAMs) disrupt the encapsidation of pre-genomic RNA and can cause nucleocapsid disassembly, thereby affecting multiple steps of HBV replication and redn. of cccDNA pools.  This review provides a concise overview of the development of CAMs and the progress achieved in understanding their interactions with HBV core proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5zQhOPFXEsrVg90H21EOLACvtfcHk0liZokZLd7F-lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Ohsr0%253D&md5=93e42d664e9bbaa38accc6b02080d55a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DNijampatnam%26aufirst%3DB.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520HBV%2520capsid%2520assembly%2520modulators%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D50%26spage%3D73%26epage%3D79%26doi%3D10.1016%2Fj.cbpa.2019.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span> <span> </span><span class="NLM_article-title">Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: recent advances and perspectives</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00337</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00337" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1akt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=713-724&issue=5&author=L.+Yangauthor=F.+Liuauthor=X.+Tongauthor=D.+Hoffmannauthor=J.+Zuoauthor=M.+Lu&title=Treatment+of+chronic+hepatitis+B+virus+infection+using+small+molecule+modulators+of+nucleocapsid+assembly%3A+recent+advances+and+perspectives&doi=10.1021%2Facsinfecdis.8b00337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives</span></div><div class="casAuthors">Yang, Li; Liu, Feifei; Tong, Xiankun; Hoffmann, Daniel; Zuo, Jianping; Lu, Mengji</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">713-724</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  On the basis of the recent advance of basic research on mol. biol. of hepatitis B virus (HBV) infection, novel antiviral drugs targeting various steps of the HBV life cycle have been developed in recent years.  HBV nucleocapsid assembly is now recognized as a hot target for anti-HBV drug development.  Structural and functional anal. of HBV nucleocapsid allowed rational design and improvement of small mols. with the ability to interact with the components of HBV nucleocapsid and modulate the viral nucleocapsid assembly process.  Prototypes of small mol. modulators targeting HBV nucleocapsid assembly are being preclinically tested or have moved forward in clin. trials, with promising results.  This Review summarizes the recent advances in the approach to develop antiviral drugs based on the modulation of HBV nucleocapsid assembly.  The antiviral mechanisms of small mol. modulators beyond the capsid formation and the potential implications will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvT6WVN92udLVg90H21EOLACvtfcHk0liZokZLd7F-lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1akt7o%253D&md5=f602f5c7f6e9af69ac2f777ca82efe28</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00337%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DHoffmann%26aufirst%3DD.%26aulast%3DZuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%26atitle%3DTreatment%2520of%2520chronic%2520hepatitis%2520B%2520virus%2520infection%2520using%2520small%2520molecule%2520modulators%2520of%2520nucleocapsid%2520assembly%253A%2520recent%2520advances%2520and%2520perspectives%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26issue%3D5%26spage%3D713%26epage%3D724%26doi%3D10.1021%2Facsinfecdis.8b00337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stray, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlotnick, A.</span></span> <span> </span><span class="NLM_article-title">BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly</span>. <i>J. Mol. Recognit.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1002/jmr.801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1002%2Fjmr.801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=17006877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVahu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=542-548&issue=6&author=S.+J.+Strayauthor=A.+Zlotnick&title=BAY+41-4109+has+multiple+effects+on+hepatitis+B+virus+capsid+assembly&doi=10.1002%2Fjmr.801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly</span></div><div class="casAuthors">Stray, Stephen J.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Recognition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">542-548</span>CODEN:
                <span class="NLM_cas:coden">JMORE4</span>;
        ISSN:<span class="NLM_cas:issn">0952-3499</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Here we report the effect of a heteroaryldihydropyrimidine (HAP) antiviral compd., BAY 41-4109, on Hepatitis B virus (HBV) capsid assembly and on preformed HBV capsids.  The HBV capsid is an icosahedral complex of 120 capsid protein dimers.  BAY41-4109 inhibits virus prodn. in vivo by a mechanism that targets the viral capsid.  We found that BAY 41-4109 was able to both accelerate and misdirect capsid assembly in vitro.  As little as one HAP mol. for every five HBV dimers was sufficient to induce formation of non-capsid polymers.  Unlike the related mol. HAP-1, no stable assembly intermediates were obsd. in assembly reactions with BAY 41-4109, indicating that accelerated assembly by BAY 41-4109 was still kinetically regulated by the nucleation rate.  Preformed capsids were stabilized by BAY 41-4109, up to a ratio of one inhibitor mol. per two dimers.  However, at BAY 41-4109:dimer ratios of 1:1 and greater, capsids were destabilized to yield very large noncapsid polymers.  These data suggest the existence of two functionally distinguishable classes of drug-binding sites on HBV capsids.  Occupation of the first class of site stabilizes capsid, while binding at the second class requires or induces structural changes that cannot be tolerated without destabilizing the capsid.  Our data suggest that HAP compds. may inhibit virus replication by inducing assembly inappropriately and, when in excess, by misdirecting assembly decreasing the stability of normal capsids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorOaQz7SajJrVg90H21EOLACvtfcHk0liZokZLd7F-lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVahu7s%253D&md5=15c132fcc380b09f691561adf737fbd3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fjmr.801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmr.801%26sid%3Dliteratum%253Aachs%26aulast%3DStray%26aufirst%3DS.%2BJ.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DBAY%252041-4109%2520has%2520multiple%2520effects%2520on%2520hepatitis%2520B%2520virus%2520capsid%2520assembly%26jtitle%3DJ.%2520Mol.%2520Recognit.%26date%3D2006%26volume%3D19%26issue%3D6%26spage%3D542%26epage%3D548%26doi%3D10.1002%2Fjmr.801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B virus (HBV) capsid inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7651</span>– <span class="NLM_lpage">7666</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00879</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00879" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ejt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7651-7666&issue=16&author=Z.+Qiuauthor=X.+Linauthor=M.+Zhouauthor=Y.+Liuauthor=W.+Zhuauthor=W.+Chenauthor=W.+Zhangauthor=L.+Guoauthor=H.+Liuauthor=G.+Wuauthor=M.+Huangauthor=M.+Jiangauthor=Z.+Xuauthor=Z.+Zhouauthor=N.+Qinauthor=S.+Renauthor=H.+Qiuauthor=S.+Zhongauthor=Y.+Zhangauthor=Y.+Zhangauthor=X.+Wuauthor=L.+Shiauthor=F.+Shenauthor=Y.+Maoauthor=X.+Zhouauthor=W.+Yangauthor=J.+Z.+Wuauthor=G.+Yangauthor=A.+V.+Maywegauthor=H.+C.+Shenauthor=G.+Tang&title=Design+and+synthesis+of+orally+bioavailable+4-methyl+heteroaryldihydropyrimidine+based+hepatitis+B+virus+%28HBV%29+capsid+inhibitors&doi=10.1021%2Facs.jmedchem.6b00879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors</span></div><div class="casAuthors">Qiu, Zongxing; Lin, Xianfeng; Zhou, Mingwei; Liu, Yongfu; Zhu, Wei; Chen, Wenming; Zhang, Weixing; Guo, Lei; Liu, Haixia; Wu, Guolong; Huang, Mengwei; Jiang, Min; Xu, Zhiheng; Zhou, Zheng; Qin, Ning; Ren, Shuang; Qiu, Hongxia; Zhong, Sheng; Zhang, Yuxia; Zhang, Yi; Wu, Xiaoyue; Shi, Liping; Shen, Fang; Mao, Yi; Zhou, Xue; Yang, Wengang; Wu, Jim Z.; Yang, Guang; Mayweg, Alexander V.; Shen, Hong C.; Tang, Guozhi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7651-7666</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting the capsid protein of hepatitis B virus (HBV) and thus interrupting normal capsid formation have been an attractive approach to block the replication of HBV viruses.  We carried out multidimensional structural optimizations based on the heteroaryldihydropyrimidine (HAP) analog Bay41-4109 and identified a novel series of HBV capsid inhibitors that demonstrated promising cellular selectivity indexes, metabolic stabilities, and in vitro safety profiles.  Herein we disclose the design, synthesis, structure-activity relationship (SAR), cocrystal structure in complex with HBV capsid proteins and in vivo pharmacol. study of the 4-Me HAP analogs.  In particular, the (2S,4S)-4,4-difluoroproline substituted analog demonstrated high oral bioavailability and liver exposure and achieved over 2 log viral load redn. in a hydrodynamic injected (HDI) HBV mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjzkw8e0cupLVg90H21EOLACvtfcHk0liFpWYDQrkNWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ejt7%252FM&md5=68a71ce041575861d257c42b6922f8b1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00879%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DTang%26aufirst%3DG.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520orally%2520bioavailable%25204-methyl%2520heteroaryldihydropyrimidine%2520based%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520capsid%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D16%26spage%3D7651%26epage%3D7666%26doi%3D10.1021%2Facs.jmedchem.6b00879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boucle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassit, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozturk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amblard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">904</span>– <span class="NLM_lpage">910</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.bmcl.2017.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=28094179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=904-910&issue=4&author=S.+Boucleauthor=X.+Luauthor=L.+Bassitauthor=T.+Ozturkauthor=O.+O.+Russellauthor=F.+Amblardauthor=S.+J.+Coatsauthor=R.+F.+Schinazi&title=Synthesis+and+antiviral+evaluation+of+novel+heteroarylpyrimidines+analogs+as+HBV+capsid+effectors&doi=10.1016%2Fj.bmcl.2017.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors</span></div><div class="casAuthors">Boucle, Sebastien; Lu, Xiao; Bassit, Leda; Ozturk, Tugba; Russell, Olivia Ollinger; Amblard, Franck; Coats, Steven J.; Schinazi, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">904-910</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ne120w modifications to the scaffold of previously reported HBV capsid assembly effectors such as BAY 41-4109, HAP-12 and GLS4 were explored.  The anti-HBV activity in the HepAD38 system, and cytotoxicity profiles of each of the new compds. has been assessed.  Among them, five new iodo- and bromo-heteroarylpyrimidines analogs displayed anti-HBV activity in the low micromolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvFdqr3-w22rVg90H21EOLACvtfcHk0liFpWYDQrkNWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wlsro%253D&md5=5bdb4f7106b993f816b8dde56b242465</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DBoucle%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DBassit%26aufirst%3DL.%26aulast%3DOzturk%26aufirst%3DT.%26aulast%3DRussell%26aufirst%3DO.%2BO.%26aulast%3DAmblard%26aufirst%3DF.%26aulast%3DCoats%26aufirst%3DS.%2BJ.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520and%2520antiviral%2520evaluation%2520of%2520novel%2520heteroarylpyrimidines%2520analogs%2520as%2520HBV%2520capsid%2520effectors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D904%26epage%3D910%26doi%3D10.1016%2Fj.bmcl.2017.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of tetrahydropyrrolo[1,2-c]pyrimidines as capsid assembly inhibitors for HBV treatment</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">969</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00288</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00288" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlygtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=969-974&issue=9&author=X.+Liauthor=K.+Zhouauthor=H.+Heauthor=Q.+Zhouauthor=Y.+Sunauthor=L.+Houauthor=L.+Shenauthor=X.+Wangauthor=Y.+Zhouauthor=Z.+Gongauthor=S.+Heauthor=H.+Jinauthor=Z.+Guauthor=S.+Zhaoauthor=L.+Zhangauthor=C.+Sunauthor=S.+Zhengauthor=Z.+Chengauthor=Y.+Zhuauthor=M.+Zhangauthor=J.+Liauthor=S.+Chen&title=Design%2C+synthesis%2C+and+evaluation+of+tetrahydropyrrolo%5B1%2C2-c%5Dpyrimidines+as+capsid+assembly+inhibitors+for+HBV+treatment&doi=10.1021%2Facsmedchemlett.7b00288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Tetrahydropyrrolo[1,2-c]pyrimidines as Capsid Assembly Inhibitors for HBV Treatment</span></div><div class="casAuthors">Li, Xiaolin; Zhou, Kai; He, Haiying; Zhou, Qiong; Sun, Ya; Hou, Lijuan; Shen, Liang; Wang, Xiaofei; Zhou, Yuedong; Gong, Zhen; He, Shibo; Jin, Huangtao; Gu, Zhengxian; Zhao, Shuyong; Zhang, Long; Sun, Chunyan; Zheng, Shansong; Cheng, Zhe; Zhu, Yidong; Zhang, Minghui; Li, Jian; Chen, Shuhui</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">969-974</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of novel tetrahydropyrrolo[1,2-c]pyrimidines derivs. from Bay41_4109 as hepatitis B virus (HBV) inhibitors is herein reported.  The structure-activity relation optimization led to one highly efficacious compd. (IC50 = 10 nM) with good PK profiles and the favorite L/P ratio.  The hydrodynamic injection model in mice clearly demonstrated the efficacy of this compd. against HBV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9SjwozsLNxbVg90H21EOLACvtfcHk0liFpWYDQrkNWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlygtb7O&md5=635d05b364961eff3d79ba663fcbd005</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00288%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520tetrahydropyrrolo%255B1%252C2-c%255Dpyrimidines%2520as%2520capsid%2520assembly%2520inhibitors%2520for%2520HBV%2520treatment%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D9%26spage%3D969%26epage%3D974%26doi%3D10.1021%2Facsmedchemlett.7b00288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span> <span> </span><span class="NLM_article-title">Discovery and pre-clinical characterization of third-generation 4-H heteroaryldihydropyrimidine (HAP) analogues as hepatitis B virus (HBV) capsid inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3352</span>– <span class="NLM_lpage">3371</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3352-3371&issue=8&author=Z.+Qiuauthor=X.+Linauthor=W.+Zhangauthor=M.+Zhouauthor=L.+Guoauthor=B.+Kocerauthor=G.+Wuauthor=Z.+Zhangauthor=H.+Liuauthor=H.+Shiauthor=B.+Kouauthor=T.+Huauthor=Y.+Huauthor=M.+Huangauthor=S.+F.+Yanauthor=Z.+Xuauthor=Z.+Zhouauthor=N.+Qinauthor=Y.+F.+Wangauthor=S.+Renauthor=H.+Qiuauthor=Y.+Zhangauthor=Y.+Zhangauthor=X.+Wuauthor=K.+Sunauthor=S.+Zhongauthor=J.+Xieauthor=G.+Ottavianiauthor=Y.+Zhouauthor=L.+Zhuauthor=X.+Tianauthor=L.+Shiauthor=F.+Shenauthor=Y.+Maoauthor=X.+Zhouauthor=L.+Gaoauthor=J.+A.+T.+Youngauthor=J.+Z.+Wuauthor=G.+Yangauthor=A.+V.+Maywegauthor=H.+C.+Shenauthor=G.+Tangauthor=W.+Zhu&title=Discovery+and+pre-clinical+characterization+of+third-generation+4-H+heteroaryldihydropyrimidine+%28HAP%29+analogues+as+hepatitis+B+virus+%28HBV%29+capsid+inhibitors&doi=10.1021%2Facs.jmedchem.7b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors</span></div><div class="casAuthors">Qiu, Zongxing; Lin, Xianfeng; Zhang, Weixing; Zhou, Mingwei; Guo, Lei; Kocer, Buelent; Wu, Guolong; Zhang, Zhisen; Liu, Haixia; Shi, Houguang; Kou, Buyu; Hu, Taishan; Hu, Yimin; Huang, Mengwei; Yan, S. Frank; Xu, Zhiheng; Zhou, Zheng; Qin, Ning; Wang, Yue Fen; Ren, Shuang; Qiu, Hongxia; Zhang, Yuxia; Zhang, Yi; Wu, Xiaoyue; Sun, Kai; Zhong, Sheng; Xie, Jianxun; Ottaviani, Giorgio; Zhou, Yuan; Zhu, Lina; Tian, Xiaojun; Shi, Liping; Shen, Fang; Mao, Yi; Zhou, Xue; Gao, Lu; Young, John A. T.; Wu, Jim Zhen; Yang, Guang; Mayweg, Alexander V.; Shen, Hong C.; Tang, Guozhi; Zhu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3352-3371</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) (I) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors.  This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs.  X-ray crystallog. study of analog 12 (HAP_R01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen bonding interactions with capsid protein and coordinated waters.  The representative analog 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further development as oral anti-HBV infection agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolNkEF9n_vqrVg90H21EOLACvtfcHk0liZMWYyf9H8hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWjtbw%253D&md5=6c2a89c594f2c735855f64aca2240837</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00083%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DKou%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DOttaviani%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DJ.%2BA.%2BT.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DW.%26atitle%3DDiscovery%2520and%2520pre-clinical%2520characterization%2520of%2520third-generation%25204-H%2520heteroaryldihydropyrimidine%2520%2528HAP%2529%2520analogues%2520as%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520capsid%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D8%26spage%3D3352%26epage%3D3371%26doi%3D10.1021%2Facs.jmedchem.7b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6 -dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic acid (HEC72702), a novel hepatitis B virus capsid inhibitor based on clinical candidate GLS4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1374</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01914</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01914" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1355-1374&issue=3&author=Q.+Renauthor=X.+Liuauthor=G.+Yanauthor=B.+Nieauthor=Z.+Zouauthor=J.+Liauthor=Y.+Chenauthor=Y.+Weiauthor=J.+Huangauthor=Z.+Luoauthor=B.+Guauthor=S.+Goldmannauthor=J.+Zhangauthor=Y.+Zhang&title=3-%28%28R%29-4-%28%28%28R%29-6-%282-Bromo-4-fluorophenyl%29-5-%28ethoxycarbonyl%29-2-%28thiazol-2-yl%29-3%2C6+-dihydropyrimidin-4-yl%29methyl%29morpholin-2-yl%29propanoic+acid+%28HEC72702%29%2C+a+novel+hepatitis+B+virus+capsid+inhibitor+based+on+clinical+candidate+GLS4&doi=10.1021%2Facs.jmedchem.7b01914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4</span></div><div class="casAuthors">Ren, Qingyun; Liu, Xinchang; Yan, Guanghua; Nie, Biao; Zou, Zhifu; Li, Jing; Chen, Yunfu; Wei, Yu; Huang, Jianzhou; Luo, Zhonghua; Gu, Baohua; Goldmann, Siegfried; Zhang, Jiancun; Zhang, Yingjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1355-1374</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics.  On the basis of the preclin. properties and clin. results of GLS4, we carried out further investigation to seek a better candidate compd. with appropriate anti-HBV potency, reduced hERG activity, decreased CYP enzyme induction, and improved pharmacokinetic (PK) properties.  To this end, we have successfully found that morpholine carboxyl analogs with comparable anti-HBV activities to that of GLS4 showed decreased hERG activities, but they displayed strong CYP3A4 induction in a concn.-dependent manner, except for morpholine propionic acid analogs.  After several rounds of modification, compd. 58 (HEC72702), which had an (R)-morpholine-2-propionic acid at the C6 position of its dihydropyrimidine core ring, was found to display no induction of the CYP1A2, CYP3A4, or CYP2B6 enzyme at the high concn. of 10 μM.  In particular, it demonstrated a good systemic exposure and high oral bioavailability and achieved a viral-load redn. greater than 2 log in a hydrodynamic-injected (HDI) HBV mouse model and has now been selected for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg4uSQeAhrXbVg90H21EOLACvtfcHk0liZMWYyf9H8hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWksLc%253D&md5=f4abf118fdddb8c09f9e9fb290b850ea</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01914%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DG.%26aulast%3DNie%26aufirst%3DB.%26aulast%3DZou%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DGu%26aufirst%3DB.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3D3-%2528%2528R%2529-4-%2528%2528%2528R%2529-6-%25282-Bromo-4-fluorophenyl%2529-5-%2528ethoxycarbonyl%2529-2-%2528thiazol-2-yl%2529-3%252C6%2520-dihydropyrimidin-4-yl%2529methyl%2529morpholin-2-yl%2529propanoic%2520acid%2520%2528HEC72702%2529%252C%2520a%2520novel%2520hepatitis%2520B%2520virus%2520capsid%2520inhibitor%2520based%2520on%2520clinical%2520candidate%2520GLS4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D3%26spage%3D1355%26epage%3D1374%26doi%3D10.1021%2Facs.jmedchem.7b01914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.ejmech.2017.12.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=29288943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Kksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=424-434&author=J.+Qiuauthor=Q.+Gongauthor=J.+Gaoauthor=W.+Chenauthor=Y.+Zhangauthor=X.+Guauthor=D.+Tang&title=Design%2C+synthesis+and+evaluation+of+novel+phenyl+propionamide+derivatives+as+non-nucleoside+hepatitis+B+virus+inhibitors&doi=10.1016%2Fj.ejmech.2017.12.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors</span></div><div class="casAuthors">Qiu, Jingying; Gong, Qineng; Gao, Jian; Chen, Wang; Zhang, Yinpeng; Gu, Xiaoke; Tang, Daoquan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">424-434</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As an ongoing search for potent non-nucleoside anti-HBV agents with novel structures, the authors described a series of Ph propionamide derivs. (3a-b, 4a-e, 7a-g, 8a-h and 9a-b) by pharmacophore fusion strategy in the present work.  All the compds. exhibited an anti-HBV activity to some extent.  Among them, compds. 8d ((S,Z)-N-(1-bromo-3-((1-hydroxy-3-phenylpropan-2-yl)amino)-3-oxo-1-(m-tolyl)prop-1-en-2-yl)benzamide) and 9b ((S,Z)-N-(1-bromo-1-(4-(2-(dimethylamino)ethoxy)phenyl)-3-((1-hydroxy-3-phenylpropan-2-yl)amino)-3-oxoprop-1-en-2-yl)benzamide) displayed most potent anti-HBV activity with IC50 values on HBV DNA replication of 0.46 and 0.14 μM, resp.  And the selective index values of 8d and 9b were more than 217.39 and 153.14, suggesting that 8d and 9b exhibited favorable safety profiles.  Interestingly, 8d and 9b possessed significantly antiviral activities against lamivudine and entecavir resistant HBV mutants with IC50 values of 0.77 and 0.32 μM.  Notably, preliminary anti-HBV action mechanism studies showed that 8d could inhibit intracellular HBV pgRNA and RT activity of the HBV polymerase.  Mol. docking studies suggested that compd. 8d could fit into the dimer-dimer interface of HBV core protein by hydrophobic interaction.  In addn., in silico prediction of physicochem. properties showed that 8d conformed well to the Lipinski's rule of five, suggesting its potential for use as a drug like mol.  Taken together, 8d possessed significantly anti-HBV activity, low toxicity, diverse anti-HBV mechanism and favorable physicochem. properties, and warranted further investigation as a promising non-nucleoside anti-HBV candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofINd0i0cF7bVg90H21EOLACvtfcHk0lgg0xXpiim1aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Kksw%253D%253D&md5=991c10a5e00f117441437c189182ba82</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.042%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DJ.%26aulast%3DGong%26aufirst%3DQ.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DD.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520novel%2520phenyl%2520propionamide%2520derivatives%2520as%2520non-nucleoside%2520hepatitis%2520B%2520virus%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D424%26epage%3D434%26doi%3D10.1016%2Fj.ejmech.2017.12.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondylis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlicksup, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katen, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlotnick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, S. C.</span></span> <span> </span><span class="NLM_article-title">Evolution of intermediates during capsid assembly of hepatitis B virus with phenylpropenamide-based antivirals</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">777</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00290</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00290" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktlGhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=769-777&issue=5&author=P.+Kondylisauthor=C.+J.+Schlicksupauthor=S.+P.+Katenauthor=L.+S.+Leeauthor=A.+Zlotnickauthor=S.+C.+Jacobson&title=Evolution+of+intermediates+during+capsid+assembly+of+hepatitis+B+virus+with+phenylpropenamide-based+antivirals&doi=10.1021%2Facsinfecdis.8b00290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Intermediates during Capsid Assembly of Hepatitis B Virus with Phenylpropenamide-Based Antivirals</span></div><div class="casAuthors">Kondylis, Panagiotis; Schlicksup, Christopher J.; Katen, Sarah P.; Lee, Lye Siang; Zlotnick, Adam; Jacobson, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">769-777</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Self-assembly of virus capsids is a potential target for antivirals due to its importance in the virus lifecycle.  Here, we investigate the effect of phenylpropenamide derivs. B-21 and AT-130 on the assembly of hepatitis B virus (HBV) core protein.  Phenylpropenamides are widely believed to yield assembly of spherical particles resembling native, empty HBV capsids.  Because the details of assembly can be overlooked with ensemble measurements, we performed resistive-pulse sensing on nanofluidic devices with four pores in series to characterize the size distributions of the products in real time.  With its single particle sensitivity and compatibility with typical assembly buffers, resistive-pulse sensing is well-suited for analyzing virus assembly in vitro.  We obsd. that assembly with B-21 and AT-130 produced a large fraction of partially complete virus particles that may be on-path, off-path, or trapped.  For both B-21 and AT-130, capsid assembly was more sensitive to disruption under conditions where the interprotein assocn. energy was low at lower salt concns.  Diln. of the reaction solns. led to the rearrangement of the incomplete particles and demonstrated that these large intermediates may be on-path, but are labile, and exist in a frustrated dynamic equil.  During capsid assembly, phenylpropenamide mols. modestly increase the assocn. energy of dimers, prevent intermediates from dissocg., and lead to kinetic trapping where the formation of too many capsids has been initiated, which results in both empty and incomplete particles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYUJqkh83pVrVg90H21EOLACvtfcHk0lgg0xXpiim1aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktlGhsw%253D%253D&md5=89dec0d941b97b0d067af0d5ae3e2ac2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00290%26sid%3Dliteratum%253Aachs%26aulast%3DKondylis%26aufirst%3DP.%26aulast%3DSchlicksup%26aufirst%3DC.%2BJ.%26aulast%3DKaten%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DL.%2BS.%26aulast%3DZlotnick%26aufirst%3DA.%26aulast%3DJacobson%26aufirst%3DS.%2BC.%26atitle%3DEvolution%2520of%2520intermediates%2520during%2520capsid%2520assembly%2520of%2520hepatitis%2520B%2520virus%2520with%2520phenylpropenamide-based%2520antivirals%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26issue%3D5%26spage%3D769%26epage%3D777%26doi%3D10.1021%2Facsinfecdis.8b00290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozturk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassit, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amblard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.ejmech.2017.06.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=28688280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFChurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=407-421&author=O.+Sariauthor=S.+Boucleauthor=B.+D.+Coxauthor=T.+Ozturkauthor=O.+O.+Russellauthor=L.+Bassitauthor=F.+Amblardauthor=R.+F.+Schinazi&title=Synthesis+of+sulfamoylbenzamide+derivatives+as+HBV+capsid+assembly+effector&doi=10.1016%2Fj.ejmech.2017.06.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effectors</span></div><div class="casAuthors">Sari, Ozkan; Boucle, Sebastien; Cox, Bryan D.; Ozturk, Tugba; Russell, Olivia Ollinger; Bassit, Leda; Amblard, Franck; Schinazi, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">407-421</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The synthesis of novel series of sulfamoylbenzamides, e.g. I [R1 = F, R2 = H; R1R2 = (CH2)2, (CH2)3; X = R3R4NSO2, R5SO2NH; R3 = cyclopentyl, cyclopentyloxy, MeSO2, PhCHMe, etc., R4 = H; R3R4 = CH2CF2CH2CH2, C(O)(CH2)3, etc.; R5 = cyclopropyl, cyclopentyl, cyclohexyl] as HBV capsid assembly effector is reported.  The structure was divided into five parts which were independently modified as part of the lead optimization.  All the synthesized compds. were evaluated for their anti-HBV activity and toxicity in human hepatocytes, lymphocytes and other cells.  Addnl., their effect on HBV cccDNA formation in an HBeAg reporter cell-based assay was assessed.  Among the 27 compds. reported, several analogs exhibited submicromolar activities and significant redn. of HBeAg secretion.  Selected compds. were studied under neg.-stain electron microscopy for their ability to disrupt the HBV capsid formation.  Structures were modeled into a binding site recently identified in the HBV capsid protein for similar mols. to rationalize the structure-activity relationships for this family of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUa_fzgDe9WrVg90H21EOLACvtfcHk0lgg0xXpiim1aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFChurvI&md5=cc0de429427455fac4cebd76c51119ed</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.062%26sid%3Dliteratum%253Aachs%26aulast%3DSari%26aufirst%3DO.%26aulast%3DBoucle%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DB.%2BD.%26aulast%3DOzturk%26aufirst%3DT.%26aulast%3DRussell%26aufirst%3DO.%2BO.%26aulast%3DBassit%26aufirst%3DL.%26aulast%3DAmblard%26aufirst%3DF.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520of%2520sulfamoylbenzamide%2520derivatives%2520as%2520HBV%2520capsid%2520assembly%2520effector%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D407%26epage%3D421%26doi%3D10.1016%2Fj.ejmech.2017.06.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vandyck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoops, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschueren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehertogh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of N-phenyl-3-sulfamoyl-benzamide derivatives as capsid assembly modulators inhibiting hepatitis B virus (HBV)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6247</span>– <span class="NLM_lpage">6260</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00654</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00654" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6247-6260&issue=14&author=K.+Vandyckauthor=G.+Romboutsauthor=B.+Stoopsauthor=A.+Tahriauthor=A.+Vosauthor=W.+Verschuerenauthor=Y.+Wuauthor=J.+Yangauthor=F.+Houauthor=B.+Huangauthor=K.+Vergauwenauthor=P.+Dehertoghauthor=J.+M.+Berkeauthor=P.+Raboisson&title=Synthesis+and+evaluation+of+N-phenyl-3-sulfamoyl-benzamide+derivatives+as+capsid+assembly+modulators+inhibiting+hepatitis+B+virus+%28HBV%29&doi=10.1021%2Facs.jmedchem.8b00654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)</span></div><div class="casAuthors">Vandyck, Koen; Rombouts, Geert; Stoops, Bart; Tahri, Abdellah; Vos, Ann; Verschueren, Wim; Wu, Yiming; Yang, Jingmei; Hou, Fuliang; Huang, Bing; Vergauwen, Karen; Dehertogh, Pascale; Berke, Jan Martin; Raboisson, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6247-6260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. induced hepatitis B virus (HBV) capsid assembly modulation is considered an attractive approach for new antiviral therapies against HBV.  Here we describe efforts toward the discovery of a HBV capsid assembly modulator in a hit-to-lead optimization, resulting in JNJ-632, a tool compd. used to further profile the mode of action.  Administration of JNJ-632 (54) in HBV genotype D infected chimeric mice resulted in a 2.77 log redn. of the HBV DNA viral load.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKzPnHUf4R5LVg90H21EOLACvtfcHk0lhUsU5Phuljvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsrfF&md5=b877a4732f8dc2141c60fba79f27aa52</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00654%26sid%3Dliteratum%253Aachs%26aulast%3DVandyck%26aufirst%3DK.%26aulast%3DRombouts%26aufirst%3DG.%26aulast%3DStoops%26aufirst%3DB.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DVos%26aufirst%3DA.%26aulast%3DVerschueren%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DVergauwen%26aufirst%3DK.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520N-phenyl-3-sulfamoyl-benzamide%2520derivatives%2520as%2520capsid%2520assembly%2520modulators%2520inhibiting%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D14%26spage%3D6247%26epage%3D6260%26doi%3D10.1021%2Facs.jmedchem.8b00654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuduk, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator against hepatitis B virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e01734-18</span> <span class="refDoi"> DOI: 10.1128/AAC.01734-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1128%2FAAC.01734-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=30373799" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&issue=1&author=A.+M.+Lamauthor=C.+Espirituauthor=R.+Vogelauthor=S.+Renauthor=V.+Lauauthor=M.+Kellyauthor=S.+D.+Kudukauthor=G.+D.+Hartmanauthor=O.+A.+Floresauthor=K.+Klumpp&title=Preclinical+characterization+of+NVR+3-778%2C+a+first-in-class+capsid+assembly+modulator+against+hepatitis+B+virus&doi=10.1128%2FAAC.01734-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FAAC.01734-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01734-18%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DVogel%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DLau%26aufirst%3DV.%26aulast%3DKelly%26aufirst%3DM.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DFlores%26aufirst%3DO.%2BA.%26aulast%3DKlumpp%26aufirst%3DK.%26atitle%3DPreclinical%2520characterization%2520of%2520NVR%25203-778%252C%2520a%2520first-in-class%2520capsid%2520assembly%2520modulator%2520against%2520hepatitis%2520B%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26issue%3D1%26doi%3D10.1128%2FAAC.01734-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weilert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen Chan, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaw, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuda, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talloen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>156</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1403</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2018.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1053%2Fj.gastro.2018.12.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=30625297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVykurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2019&pages=1392-1403&issue=5&author=M.+F.+Yuenauthor=E.+J.+Ganeauthor=D.+J.+Kimauthor=F.+Weilertauthor=H.+L.+Yuen+Chanauthor=J.+Lalezariauthor=S.+G.+Hwangauthor=T.+Nguyenauthor=O.+Floresauthor=G.+Hartmanauthor=S.+Liawauthor=O.+Lenzauthor=T.+N.+Kakudaauthor=W.+Talloenauthor=C.+Schwabeauthor=K.+Klumppauthor=N.+Brown&title=Antiviral+activity%2C+safety%2C+and+pharmacokinetics+of+capsid+assembly+modulator+NVR+3-778+in+patients+with+chronic+HBV+infection&doi=10.1053%2Fj.gastro.2018.12.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection</span></div><div class="casAuthors">Yuen, Man Fung; Gane, Edward J.; Kim, Dong Joon; Weilert, Frank; Yuen Chan, Henry Lik; Lalezari, Jacob; Hwang, Seong Gyu; Nguyen, Tuan; Flores, Osvaldo; Hartman, George; Liaw, Sandy; Lenz, Oliver; Kakuda, Thomas N.; Talloen, Willem; Schwabe, Christian; Klumpp, Klaus; Brown, Nathaniel</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1392-1403.e7</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NVR 3-778 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator that can inhibit HBV replication.  We performed a proof-of-concept study to examine the safety, pharmacokinetics, and antiviral activity of NVR 3-778 in patients with chronic HBV infection.  We performed a phase 1 study in 73 hepatitis B envelope antigen (HBeAg)-pos. patients with chronic HBV infection without cirrhosis.  In a 2-part study (part 1 in New Zealand and part 2 in Hong Kong, Singapore, Taiwan, Korea, and the United States), patients were randomly assigned to groups that were given oral NVR 3-778 (100 mg, 200 mg, or 400 mg daily or 600 mg or 1000 mg twice daily) or placebo for 4 wk.  Addnl. groups received combination treatment with pegylated interferon (pegIFN) and NVR 3-778 (600 mg twice daily) or pegIFN with placebo.  Redns. in serum levels of HBV DNA and HBV RNA were obsd. in patients receiving ≥1200 mg/d NVR 3-778.  The largest mean redn. in HBV DNA was obsd. in the group given NVR 3-778 plus pegIFN (1.97 log10 IU/mL), compared with the groups given NVR 3-778 or pegIFN alone (1.43 log10 IU/mL and 1.06 log10 IU/mL, resp.).  The mean redn. in HBV RNA was also greatest in the group given NVR 3-778 plus pegIFN (2.09 log10 copies/mL), compared with the groups given NVR 3-778 or pegIFN alone (1.42 log10 copies/mL and 0.89 log10 copies/mL, resp.).  There was no significant mean redn. in HBsAg during the 4-wk treatment period.  There were no discontinuations and no pattern of dose-related adverse effects with NVR 3-778.  In a phase 1 study of HBeAg-pos. patients with chronic HBV infection without cirrhosis, NVR 3-778 was well tolerated and demonstrated antiviral activity.  The agent reduced serum levels of HBV DNA and HBV RNA, to the greatest extent in combination with pegIFN.  The obsd. redns. in HBV RNA confirmed the novel mechanism of NVR 3-778.  Clinicaltrials.gov no.  NCT02112799 (single-center) and NCT02401737 (multicenter).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJKwCp-m7BoLVg90H21EOLACvtfcHk0lhUsU5Phuljvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVykurY%253D&md5=b4a4af2356d344f8e3848b5f55d3887a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2018.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2018.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DM.%2BF.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BJ.%26aulast%3DWeilert%26aufirst%3DF.%26aulast%3DYuen%2BChan%26aufirst%3DH.%2BL.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DHwang%26aufirst%3DS.%2BG.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DFlores%26aufirst%3DO.%26aulast%3DHartman%26aufirst%3DG.%26aulast%3DLiaw%26aufirst%3DS.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DKakuda%26aufirst%3DT.%2BN.%26aulast%3DTalloen%26aufirst%3DW.%26aulast%3DSchwabe%26aufirst%3DC.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DN.%26atitle%3DAntiviral%2520activity%252C%2520safety%252C%2520and%2520pharmacokinetics%2520of%2520capsid%2520assembly%2520modulator%2520NVR%25203-778%2520in%2520patients%2520with%2520chronic%2520HBV%2520infection%26jtitle%3DGastroenterology%26date%3D2019%26volume%3D156%26issue%3D5%26spage%3D1392%26epage%3D1403%26doi%3D10.1053%2Fj.gastro.2018.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trépo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, A.</span></span> <span> </span><span class="NLM_article-title">Hepatitis B virus infection</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>384</i></span>,  <span class="NLM_fpage">2053</span>– <span class="NLM_lpage">2063</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)60220-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2FS0140-6736%2814%2960220-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=24954675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVanu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=2053-2063&author=C.+Tr%C3%A9poauthor=H.+L.+Y.+Chanauthor=A.+Lok&title=Hepatitis+B+virus+infection&doi=10.1016%2FS0140-6736%2814%2960220-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus infection</span></div><div class="casAuthors">Trepo, Christian; Chan, Henry L. Y.; Lok, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">9959</span>),
    <span class="NLM_cas:pages">2053-2063</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the world's population show serol. evidence of current or past infection.  Hepatitis B virus is a partly double-stranded DNA virus with several serol. markers: HBsAg and anti-HBs, HBeAg and anti-HBe, and anti-HBc IgM and IgG.  It is transmitted through contact with infected blood and semen.  A safe and effective vaccine has been available since 1981, and, although variable, the implementation of universal vaccination in infants has resulted in a sharp decline in prevalence.  Hepatitis B virus is not cytopathic; both liver damage and viral control-and therefore clin. outcome-depend on the complex interplay between virus replication and host immune response.  Overall, as much as 40% of men and 15% of women with perinatally acquired hepatitis B virus infection will die of liver cirrhosis or hepatocellular carcinoma.  In addn. to decreasing hepatic inflammation, long-term antiviral treatment can reverse cirrhosis and reduce hepatocellular carcinoma.  Development of new therapies that can improve HBsAg clearance and virol. cure is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRAto9E_Y-YLVg90H21EOLACvtfcHk0lgQtcA0YAjZhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVanu7nM&md5=b7192bf0aa7f91bb430c61e344aaaa26</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2960220-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252960220-8%26sid%3Dliteratum%253Aachs%26aulast%3DTr%25C3%25A9po%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26aulast%3DLok%26aufirst%3DA.%26atitle%3DHepatitis%2520B%2520virus%2520infection%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D2053%26epage%3D2063%26doi%3D10.1016%2FS0140-6736%2814%2960220-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Alcalde, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najera, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, N.</span></span> <span> </span><span class="NLM_article-title">Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">42374</span>, <span class="refDoi"> DOI: 10.1038/srep42374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1038%2Fsrep42374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=28205569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislOiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42374&author=Z.+Zhouauthor=T.+Huauthor=X.+Zhouauthor=S.+Wildumauthor=F.+Garcia-Alcaldeauthor=Z.+Xuauthor=D.+Wuauthor=Y.+Maoauthor=X.+Tianauthor=Y.+Zhouauthor=F.+Shenauthor=Z.+Zhangauthor=G.+Tangauthor=I.+Najeraauthor=G.+Yangauthor=H.+C.+Shenauthor=J.+A.+Youngauthor=N.+Qin&title=Heteroaryldihydropyrimidine+%28HAP%29+and+sulfamoylbenzamide+%28SBA%29+inhibit+hepatitis+B+virus+replication+by+different+molecular+mechanisms&doi=10.1038%2Fsrep42374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms</span></div><div class="casAuthors">Zhou, Zheng; Hu, Taishan; Zhou, Xue; Wildum, Steffen; Garcia-Alcalde, Fernando; Xu, Zhiheng; Wu, Daitze; Mao, Yi; Tian, Xiaojun; Zhou, Yuan; Shen, Fang; Zhang, Zhisen; Tang, Guozhi; Najera, Isabel; Yang, Guang; Shen, Hong C.; Young, John A. T.; Qin, Ning</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42374</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) are promising non-nucleos(t)ide HBV replication inhibitors.  HAPs are known to promote core protein mis-assembly, but the mol. mechanism of abnormal assembly is still elusive.  Likewise, the assembly status of core protein induced by SBA remains unknown.  Here we show that SBA, unlike HAP, does not promote core protein mis-assembly.  Interestingly, two ref. compds. HAP_R01 and SBA_R01 bind to the same pocket at the dimer-dimer interface in the crystal structures of core protein Y132A hexamer.  The striking difference lies in a unique hydrophobic subpocket that is occupied by the thiazole group of HAP_R01, but is unperturbed by SBA_R01.  Photoaffinity labeling confirms the HAP_R01 binding pose at the dimer-dimer interface on capsid and suggests a new mechanism of HAP-induced mis-assembly.  Based on the common features in crystal structures we predict that T33 mutations generate similar susceptibility changes to both compds.  In contrast, mutations at positions in close contact with HAP-specific groups (P25A, P25S, or V124F) only reduce susceptibility to HAP_R01, but not to SBA_R01.  Thus, HAP and SBA are likely to have distinctive resistance profiles.  Notably, P25S and V124F substitutions exist in low-abundance quasispecies in treatment-naive patients, suggesting potential clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw-qU6eO7rCrVg90H21EOLACvtfcHk0lgQtcA0YAjZhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislOiurs%253D&md5=1e401e3133194ae374435df0d0cfa637</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fsrep42374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42374%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DWildum%26aufirst%3DS.%26aulast%3DGarcia-Alcalde%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DNajera%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DYoung%26aufirst%3DJ.%2BA.%26aulast%3DQin%26aufirst%3DN.%26atitle%3DHeteroaryldihydropyrimidine%2520%2528HAP%2529%2520and%2520sulfamoylbenzamide%2520%2528SBA%2529%2520inhibit%2520hepatitis%2520B%2520virus%2520replication%2520by%2520different%2520molecular%2520mechanisms%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42374%26doi%3D10.1038%2Fsrep42374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Optimization and synthesis of pyridazinone derivatives as novel inhibitors of hepatitis B virus by inducing genome-free capsid formation</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.6b00159</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.6b00159" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2ksLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=199-205&issue=3&author=D.+Luauthor=F.+Liuauthor=W.+Xingauthor=X.+Tongauthor=L.+Wangauthor=Y.+Wangauthor=L.+Zengauthor=C.+Fengauthor=L.+Yangauthor=J.+Zuoauthor=Y.+Hu&title=Optimization+and+synthesis+of+pyridazinone+derivatives+as+novel+inhibitors+of+hepatitis+B+virus+by+inducing+genome-free+capsid+formation&doi=10.1021%2Facsinfecdis.6b00159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and Synthesis of Pyridazinone Derivatives as Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation</span></div><div class="casAuthors">Lu, Dong; Liu, Feifei; Xing, Weiqiang; Tong, Xiankun; Wang, Lang; Wang, Yajuan; Zeng, Limin; Feng, Chunlan; Yang, Li; Zuo, Jianping; Hu, Youhong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">199-205</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The capsid of Hepatitis B virus (HBV) plays a vital role in the virus DNA replication.  Targeting nucleocapsid function has been demonstrated as an effective approach for anti-HBV drugs development.  The high-throughput screening and mechanism study revealed the hit compd. as an HBV assembly effectors (AEfs), which could inhibit HBV replication by inducing the formation of HBV DNA-free capsids.  The subsequent SARs study and drug-like optimization resulted in the discovery of the lead candidate (I), with potent antiviral activity (IC50 = 0.087±0.002 μM) and, low cytotoxicity (CC50 = 90.6±2.06 μM), sensitivity to nucleoside-analog resistant HBV mutants and synergistic effect with nucleoside-analogs in HepG2.2.15 cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYYefy7nCJKLVg90H21EOLACvtfcHk0lgQtcA0YAjZhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2ksLzP&md5=493eb7d5c9839e77bf36cfa342891bfa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.6b00159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.6b00159%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZuo%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DOptimization%2520and%2520synthesis%2520of%2520pyridazinone%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520by%2520inducing%2520genome-free%2520capsid%2520formation%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2017%26volume%3D3%26issue%3D3%26spage%3D199%26epage%3D205%26doi%3D10.1021%2Facsinfecdis.6b00159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delaney
IV, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colledge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locarnini, S.</span></span> <span> </span><span class="NLM_article-title">Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3057</span>– <span class="NLM_lpage">3060</span>, <span class="refDoi"> DOI: 10.1128/AAC.46.9.3057-3060.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1128%2FAAC.46.9.3057-3060.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=12183271" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=3057-3060&issue=9&author=W.+E.+Delaney%0AIVauthor=R.+Edwardsauthor=D.+Colledgeauthor=T.+Shawauthor=P.+Furmanauthor=G.+Painterauthor=S.+Locarnini&title=Phenylpropenamide+derivatives+AT-61+and+AT-130+inhibit+replication+of+wild-type+and+lamivudine-resistant+strains+of+hepatitis+B+virus+in+vitro&doi=10.1128%2FAAC.46.9.3057-3060.2002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.9.3057-3060.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.9.3057-3060.2002%26sid%3Dliteratum%253Aachs%26aulast%3DDelaney%2BIV%26aufirst%3DW.%2BE.%26aulast%3DEdwards%26aufirst%3DR.%26aulast%3DColledge%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DT.%26aulast%3DFurman%26aufirst%3DP.%26aulast%3DPainter%26aufirst%3DG.%26aulast%3DLocarnini%26aufirst%3DS.%26atitle%3DPhenylpropenamide%2520derivatives%2520AT-61%2520and%2520AT-130%2520inhibit%2520replication%2520of%2520wild-type%2520and%2520lamivudine-resistant%2520strains%2520of%2520hepatitis%2520B%2520virus%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26issue%3D9%26spage%3D3057%26epage%3D3060%26doi%3D10.1128%2FAAC.46.9.3057-3060.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brezillon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunelle, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massinet, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berissi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belghiti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannoun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puerstinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wimmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hantz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morosan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsdorf, D.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e25096</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0025096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1371%2Fjournal.pone.0025096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=22162746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Kht7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&issue=12&author=N.+Brezillonauthor=M.+N.+Brunelleauthor=H.+Massinetauthor=E.+Giangauthor=C.+Lamantauthor=L.+DaSilvaauthor=S.+Berissiauthor=J.+Belghitiauthor=L.+Hannounauthor=G.+Puerstingerauthor=E.+Wimmerauthor=J.+Neytsauthor=O.+Hantzauthor=P.+Soussanauthor=S.+Morosanauthor=D.+Kremsdorf&title=Antiviral+activity+of+Bay+41-4109+on+hepatitis+B+virus+in+humanized+Alb-uPA%2FSCID+mice&doi=10.1371%2Fjournal.pone.0025096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice</span></div><div class="casAuthors">Brezillon, Nicolas; Brunelle, Marie-Noelle; Massinet, Helene; Giang, Eric; Lamant, Celine; DaSilva, Lucie; Berissi, Sophie; Belghiti, Jacques; Hannoun, Laurent; Puerstinger, Gherard; Wimmer, Eva; Neyts, Johan; Hantz, Olivier; Soussan, Patrick; Morosan, Serban; Kremsdorf, Dina</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e25096</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Current treatments for HBV chronic carriers using interferon alpha or nucleoside analogs are not effective in all patients and may induce the emergence of HBV resistant strains.  Bay 41-4109, a member of the heteroaryldihydropyrimidine family, inhibits HBV replication by destabilizing capsid assembly.  The aim of this study was to det. the antiviral effect of Bay 41-4109 in a mouse model with humanized liver and the spread of active HBV.  Antiviral assays of Bay 41-4109 on HepG2.2.15 cells constitutively expressing HBV, displayed an IC50 of about 202 nM with no cell toxicity.  Alb-uPA/SCID mice were transplanted with human hepatocytes and infected with HBV.  Ten days post-infection, the mice were treated with Bay 41-4109 for five days.  During the 30 days of follow-up, the HBV load was evaluated by quant. PCR.  At the end of treatment, decreased HBV viremia of about 1 log(10) copies/mL was obsd.  By contrast, increased HBV viremia of about 0.5 log(10) copies/mL was measured in the control group.  Five days after the end of treatment, a rebound of HBV viremia occurred in the treated group.  Furthermore, 15 days after treatment discontinuation, a similar expression of the viral capsid was evidenced in liver biopsies.  Our findings demonstrate that Bay 41-4109 displayed antiviral properties against HBV in humanized Alb-uPA/SCID mice and confirm the usefulness of Alb-uPA/SCID mice for the evaluation of pharmaceutical compds.  The administration of Bay 41-4109 may constitute a new strategy for the treatment of patients in escape from std. antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiN9ZgdNSCebVg90H21EOLACvtfcHk0lhQkYEnxjnj6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Kht7fE&md5=bdbc5dacf4457b3c90121e28b6edb73d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0025096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0025096%26sid%3Dliteratum%253Aachs%26aulast%3DBrezillon%26aufirst%3DN.%26aulast%3DBrunelle%26aufirst%3DM.%2BN.%26aulast%3DMassinet%26aufirst%3DH.%26aulast%3DGiang%26aufirst%3DE.%26aulast%3DLamant%26aufirst%3DC.%26aulast%3DDaSilva%26aufirst%3DL.%26aulast%3DBerissi%26aufirst%3DS.%26aulast%3DBelghiti%26aufirst%3DJ.%26aulast%3DHannoun%26aufirst%3DL.%26aulast%3DPuerstinger%26aufirst%3DG.%26aulast%3DWimmer%26aufirst%3DE.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DHantz%26aufirst%3DO.%26aulast%3DSoussan%26aufirst%3DP.%26aulast%3DMorosan%26aufirst%3DS.%26aulast%3DKremsdorf%26aufirst%3DD.%26atitle%3DAntiviral%2520activity%2520of%2520Bay%252041-4109%2520on%2520hepatitis%2520B%2520virus%2520in%2520humanized%2520Alb-uPA%252FSCID%2520mice%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26issue%3D12%26doi%3D10.1371%2Fjournal.pone.0025096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span> <span> </span><span class="NLM_article-title">A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7061</span>– <span class="NLM_lpage">7072</span>, <span class="refDoi"> DOI: 10.1128/AAC.01558-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1128%2FAAC.01558-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=26349829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVymu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=7061-7072&issue=1&author=Y.+Wangauthor=D.+Luauthor=Y.+Xuauthor=W.+Xingauthor=X.+Tongauthor=G.+Wangauthor=C.+Fengauthor=P.+Heauthor=L.+Yangauthor=W.+Tangauthor=Y.+Huauthor=J.+Zuo&title=A+novel+pyridazinone+derivative+inhibits+hepatitis+B+virus+replication+by+inducing+genome-free+capsid+formation&doi=10.1128%2FAAC.01558-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation</span></div><div class="casAuthors">Wang, Ya-Juan; Lu, Dong; Xu, Yi-Bin; Xing, Wei-Qiang; Tong, Xian-Kun; Wang, Gui-Feng; Feng, Chun-Lan; He, Pei-Lan; Yang, Li; Tang, Wei; Hu, You-Hong; Zuo, Jian-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7061-7072</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Here we first identified a novel pyridazinone deriv., compd. 3711, as a nonnucleosidic hepatitis B virus (HBV) inhibitor in a cell model system. 3711 decreased extracellular HBV DNA levels by 50% (50% inhibitory concn. [IC50]) at 1.5 ± 0.2 μM and intracellular DNA levels at 1.9 ± 0.1 μM, which demonstrated antiviral activity at levels far below those assocd. with toxicity.  Both the 3TC/ETV dually resistant L180M/M204I mutant and the adefovir (ADV)-resistant A181T/N236T mutant were as susceptible to 3711 as wild-type HBV. 3711 treatment induced the formation of genome-free capsids, a portion of which migrated faster on 1.8% native agarose gel.  The induced genome-free capsids sedimented more slowly in isopycnic CsCl gradient centrifugation without significant morphol. changes.  3711 Treatment decreased levels of HBV DNA contained in both secreted enveloped virion and naked virus particles in supernatant.  3711 Could interfere with capsid formation of the core protein (Cp) assembly domain.  A Cp V124W mutant, which strengthens capsid interdimer interactions, recapitulated the effect of 3711 on capsid assembly.  Pyridazinone deriv. 3711, a novel chem. entity and HBV inhibitor, may provide a new opportunity to combat chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyJKHo9W8Xt7Vg90H21EOLACvtfcHk0ljzfG38PjQ5Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVymu70%253D&md5=8aa8af6163ee6395b2b634f654125a8b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1128%2FAAC.01558-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01558-15%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZuo%26aufirst%3DJ.%26atitle%3DA%2520novel%2520pyridazinone%2520derivative%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520by%2520inducing%2520genome-free%2520capsid%2520formation%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26issue%3D1%26spage%3D7061%26epage%3D7072%26doi%3D10.1128%2FAAC.01558-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span> <span> </span><span class="NLM_article-title">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1038/aps.2013.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1038%2Faps.2013.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=24487969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=410-418&author=L.+Yangauthor=L.+Shiauthor=H.+Chenauthor=X.+Tongauthor=G.+Wangauthor=Y.+Zhangauthor=W.+Wangauthor=C.+Fengauthor=P.+Heauthor=F.+Zhuauthor=Y.+Haoauthor=B.+Wangauthor=D.+Yangauthor=W.+Tangauthor=F.+Nanauthor=J.+Zuo&title=Isothiafludine%2C+a+novel+non-nucleoside+compound%2C+inhibits+hepatitis+B+virus+replication+through+blocking+pregenomic+RNA+encapsidation&doi=10.1038%2Faps.2013.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span></div><div class="casAuthors">Yang, Li; Shi, Li-ping; Chen, Hai-jun; Tong, Xian-Kun; Wang, Gui-feng; Zhang, Yang-ming; Wang, Wen-long; Feng, Chun-lan; He, Pei-lan; Zhu, Feng-hua; Hao, You-hua; Wang, Bao-ju; Yang, Dong-liang; Tang, Wei; Nan, Fa-jun; Zuo, Jian-ping</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">410-418</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: To investigate the action of isothiafludine (NZ-4), a deriv. of bis-heterocycle tandem pairs from the natural product leucamide A, on the replication cycle of hepatitis B virus (HBV) in vitro and in vivo.  Methods: HBV replication cycle was monitored in HepG2.2.15 cells using qPCR, qRT-PCR, and Southern and Northern blotting.  HBV protein expression and capsid assembly were detected using Western blotting and native agarose gel electrophoresis anal.  The interaction of pregenomic RNA (pgRNA) and the core protein was investigated by RNA immunopptn.  To evaluate the anti-HBV effect of NZ-4 in vivo, DHBV-infected ducks were orally administered NZ-4 (25, 50 or 100 mg·kg-1·d-1) for 15 d.  Results: NZ-4 suppressed intracellular HBV replication in HepG2.2.15 cells with an IC50 value of 1.33 μmol/L, whereas the compd. inhibited the cell viability with an IC50 value of 50.4 μmol/L.  Furthermore, NZ-4 was active against the replication of various drug-resistant HBV mutants, including 3TC/ETV-dual-resistant and ADV-resistant HBV mutants.  NZ-4 (5, 10, 20 μmol/L) concn.-dependently reduced the encapsidated HBV pgRNA, resulting in the assembly of replication-deficient capsids in HepG2.2.15 cells.  Oral administration of NZ-4 dose-dependently inhibited DHBV DNA replication in the DHBV-infected ducks.  Conclusion: NZ-4 inhibits HBV replication by interfering with the interaction between pgRNA and HBcAg in the capsid assembly process, thus increasing the replication-deficient HBV capsids.  Such mechanism of action might provide a new therapeutic strategy to combat HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfXI1ksk5-erVg90H21EOLACvtfcHk0ljzfG38PjQ5Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D&md5=7a046b35ab2f26aa43cf52fa76f85dea</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Faps.2013.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2013.175%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DNan%26aufirst%3DF.%26aulast%3DZuo%26aufirst%3DJ.%26atitle%3DIsothiafludine%252C%2520a%2520novel%2520non-nucleoside%2520compound%252C%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520through%2520blocking%2520pregenomic%2520RNA%2520encapsidation%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2014%26volume%3D35%26spage%3D410%26epage%3D418%26doi%3D10.1038%2Faps.2013.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Scala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Farina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanrell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olagüe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galarraga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guembe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz de
Solorzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maini, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Aseguinolaza, G.</span></span> <span> </span><span class="NLM_article-title">Complementary effects of interleukin-15 and alpha interferon induce immunity in hepatitis B virus transgenic mice</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">8563</span>– <span class="NLM_lpage">8574</span>, <span class="refDoi"> DOI: 10.1128/JVI.01030-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1128%2FJVI.01030-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=27440883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVCnu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=8563-8574&issue=19&author=M.+Di%0AScalaauthor=I.+Otanoauthor=I.+Gil-Farinaauthor=L.+Vanrellauthor=M.+Hommelauthor=C.+Olag%C3%BCeauthor=A.+Valesauthor=M.+Galarragaauthor=L.+Guembeauthor=C.+Ortiz+de%0ASolorzanoauthor=I.+Ghoshauthor=M.+K.+Mainiauthor=J.+Prietoauthor=G.+Gonz%C3%A1lez-Aseguinolaza&title=Complementary+effects+of+interleukin-15+and+alpha+interferon+induce+immunity+in+hepatitis+B+virus+transgenic+mice&doi=10.1128%2FJVI.01030-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Complementary effects of interleukin-15 and alpha interferon induce immunity in hepatitis B virus transgenic mice</span></div><div class="casAuthors">Di Scala, Marianna; Otano, Itziar; Gil-Farina, Irene; Vanrell, Lucia; Hommel, Mirja; Olague, Cristina; Vales, Africa; Galarraga, Miguel; Guembe, Laura; de Solorzano, Carlos Ortiz; Ghosh, Indrajit; Maini, Mala K.; Prieto, Jesus; Gonzalez-Aseguinolaza, Gloria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8563-8574</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In chronic hepatitis B (CHB), failure to control hepatitis B virus (HBV) is assocd. with T cell dysfunction.  HBV transgenic mice mirror many features of the human disease, including T cell unresponsiveness, and thus represent an appropriate model in which to test novel therapeutic strategies.  To date, the tolerant state of CD8+ T cells in these animals could be altered only by strong immunogens or by immunization with HBV antigen-pulsed dendritic cells; however, the effectors induced were unable to suppress viral gene expression or replication.  Because of the known stimulatory properties of alpha interferon (IFN-α) and interleukin- 15 (IL-15), this study explored the therapeutic potential of liver-directed gene transfer of these cytokines in a murine model of CHB using adeno-assocd. virus (AAV) delivery.  This combination not only resulted in a redn. in the viral load in the liver and the induction of an antibody response but also gave rise to functional and specific CD8+ immunity.  Furthermore, when splenic and intrahepatic lymphocytes from IFN-α- and IL-15-treated animals were transferred to new HBV carriers, partial antiviral immunity was achieved.  In contrast to previous observations made using either cytokine alone, markedly attenuated PD-L1 induction in hepatic tissue was obsd. upon coadministration.  An initial study with CHB patient samples also gave promising results.  Hence, we demonstrated synergy between two stimulating cytokines, IL-15 and IFN-α, which, given together, constitute a potent approach to significantly enhance the CD8+ T cell response in a state of immune hyporesponsiveness.  Such an approach may be useful for treating chronic viral infections and neoplastic conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQqxfnBus2P7Vg90H21EOLACvtfcHk0ljzfG38PjQ5Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVCnu73J&md5=e767be4e23738e4428cde3bc29d58098</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FJVI.01030-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01030-16%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BScala%26aufirst%3DM.%26aulast%3DOtano%26aufirst%3DI.%26aulast%3DGil-Farina%26aufirst%3DI.%26aulast%3DVanrell%26aufirst%3DL.%26aulast%3DHommel%26aufirst%3DM.%26aulast%3DOlag%25C3%25BCe%26aufirst%3DC.%26aulast%3DVales%26aufirst%3DA.%26aulast%3DGalarraga%26aufirst%3DM.%26aulast%3DGuembe%26aufirst%3DL.%26aulast%3DOrtiz%2Bde%2BSolorzano%26aufirst%3DC.%26aulast%3DGhosh%26aufirst%3DI.%26aulast%3DMaini%26aufirst%3DM.%2BK.%26aulast%3DPrieto%26aufirst%3DJ.%26aulast%3DGonz%25C3%25A1lez-Aseguinolaza%26aufirst%3DG.%26atitle%3DComplementary%2520effects%2520of%2520interleukin-15%2520and%2520alpha%2520interferon%2520induce%2520immunity%2520in%2520hepatitis%2520B%2520virus%2520transgenic%2520mice%26jtitle%3DJ.%2520Virol.%26date%3D2016%26volume%3D90%26issue%3D19%26spage%3D8563%26epage%3D8574%26doi%3D10.1128%2FJVI.01030-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Efthymios P  Tsounis</span>, <span class="hlFld-ContribAuthor ">Evanthia  Tourkochristou</span>, <span class="hlFld-ContribAuthor ">Athanasia  Mouzaki</span>, <span class="hlFld-ContribAuthor ">Christos  Triantos</span>. </span><span class="cited-content_cbyCitation_article-title">Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Gastroenterology</span><span> <strong>2021,</strong> <em>27 </em>
                                    (21)
                                     , 2727-2757. <a href="https://doi.org/10.3748/wjg.v27.i21.2727" title="DOI URL">https://doi.org/10.3748/wjg.v27.i21.2727</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3748/wjg.v27.i21.2727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3748%2Fwjg.v27.i21.2727%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Gastroenterology%26atitle%3DToward%252Ba%252Bnew%252Bera%252Bof%252Bhepatitis%252BB%252Bvirus%252Btherapeutics%25253A%252BThe%252Bpursuit%252Bof%252Ba%252Bfunctional%252Bcure%26aulast%3DTsounis%26aufirst%3DEfthymios%2BP%26date%3D2021%26volume%3D27%26issue%3D21%26spage%3D2727%26epage%3D2757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roshan I.  Patel</span>, <span class="hlFld-ContribAuthor ">Shivani  Sharma</span>, <span class="hlFld-ContribAuthor ">Anuj  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Cyanation: a photochemical approach and applications in organic synthesis. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>53 </em><a href="https://doi.org/10.1039/D1QO00162K" title="DOI URL">https://doi.org/10.1039/D1QO00162K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1QO00162K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1QO00162K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DCyanation%25253A%252Ba%252Bphotochemical%252Bapproach%252Band%252Bapplications%252Bin%252Borganic%252Bsynthesis%26aulast%3DPatel%26aufirst%3DRoshan%2BI.%26date%3D2021%26date%3D2021%26volume%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative HBV capsid assembly modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed metabolic pathway of <b>4r</b> in liver microsomes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <b>10m</b>, <b>19a</b>, and <b>19f</b> inhibited HBV DNA replication <i>in vitro</i>. HepG2.2.15 cells were treated with <b>10m</b>, <b>19a</b>, or <b>19f</b> at the indicated concentrations for 8 days. HBV replication intermediates were detected by Southern blotting hybridization using a DIG-labeled HBV genomic fragment as a probe. All three compounds inhibited the various forms in a dose-dependent manner, and <b>19f</b> specifically decreased the amount of intracellular HBV DNA with lower concentrations. rcDNA is relaxed circular HBV DNA. ssDNA is single-stranded HBV DNA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <b>19f</b> induced the formation of HBV DNA-free capsids. HepG2.2.15 cells were treated with <b>19f</b> at the indicated concentrations for 8 days. Capsids were analyzed on 1.8% agarose gel (top panel). Capsid-associated HBV DNA was detected by the transfer of HBV capsids on a nylon sheet, followed by Southern blotting hybridization upon disruption of capsids in situ (bottom panel). Compound <b>19f</b> treatment led to an accumulation of faster-migrating capsid. The levels of HBV DNA packaged in capsid with the same electrophoresis mobility as the control were decreased by <b>19f</b> treatment in a dose-dependent manner.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Levels of HBV DNA in the plasma of AAV/HBV-infected mice by treatment of <b>19f</b> with 50 mg/kg and 150 mg/kg, b.i.d. After 4 weeks treatment, oral administration of <b>19f</b> (b.i.d.) demonstrates a statistically significant reduction of the HBV DNA level of up to 2.67 log at 150 mg/kg in mice transduced with a recombinant AAV-HBV virus compared to that in the vehicle-treated control mice (Dunnett’s multiple comparisons test, <i>P</i> < 0.0001). The treatment regimen with 50 mg/kg <b>19f</b> resulted in a 1.08 log reduction of the HBV DNA viral load (<i>P</i> < 0.01). Data were shown as the mean ± SD. The number of animals per group for data analysis was 5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>10a</b>–<b>10m</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AcOH, reflux; (b) 1-chloro-4-(chloromethyl)benzene/4-(chloromethyl)benzonitrile, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C; (c) boronic acids, Pd(OAc)<sub>2</sub>, X-Phos, K<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, 60 °C; (d) DIBAL-H, toluene, −10 °C; (e) LiOH, THF/H<sub>2</sub>O, rt; (f) tetramethyltin, Pd(PdPh<sub>3</sub>)<sub>4</sub>, toluene, reflux; (g) 1-chloro-4-(chloromethyl)benzene, Bu<sub>3</sub>SnSnBu<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, microwave, 170 °C.</p></p></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/medium/jm0c00346_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>18f</b>–<b>18n</b> and <b>19a</b>–<b>19h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00346/20200806/images/large/jm0c00346_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00346&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (h) CH<sub>3</sub>CH<sub>2</sub>OH, NaH, THF, 0 °C or RNH<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMSO, 70 °C, 3 h; (i) NCS, CH<sub>3</sub>CN/THF, reflux 3 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span>World Health
Organization Hepatitis B fact sheet. <a href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-B" class="extLink">https://www.who.int/news-room/fact-sheets/detail/hepatitis-B</a> (accessed July 18, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health%0AOrganization+Hepatitis+B+fact+sheet.+https%3A%2F%2Fwww.who.int%2Fnews-room%2Ffact-sheets%2Fdetail%2Fhepatitis-B+%28accessed+July+18%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schweitzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczyk, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, J. J.</span></span> <span> </span><span class="NLM_article-title">Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">1546</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)61412-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2FS0140-6736%2815%2961412-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=26231459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FosV2msw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=1546-1555&author=A.+Schweitzerauthor=J.+Hornauthor=R.+T.+Mikolajczykauthor=G.+Krauseauthor=J.+J.+Ott&title=Estimations+of+worldwide+prevalence+of+chronic+hepatitis+B+virus+infection%3A+a+systematic+review+of+data+published+between+1965+and+2013&doi=10.1016%2FS0140-6736%2815%2961412-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013</span></div><div class="casAuthors">Schweitzer Aparna; Horn Johannes; Mikolajczyk Rafael T; Krause Gerard; Ott Jordis J</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">10003</span>),
    <span class="NLM_cas:pages">1546-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The quantification of the burden of disease attributable to hepatitis B virus (HBV) infection and the adaptation of prevention and control measures requires knowledge on its prevalence in the general population.  For most countries such data are not routinely available.  We estimated the national, regional, and global prevalence of chronic HBV infection.  METHODS:  For this systematic review and pooled analysis, we searched for data on prevalence of chronic HBV infection published between Jan 1, 1965, and Oct 23, 2013, in the databases Medline, Embase, CAB Abstracts (Global health), Popline, and Web of Science.  We included studies reporting the hepatitis B surface antigen (HBsAg) serological marker of chronic HBV infection in non-high-risk groups and extracted data into a customised database.  For each country, we calculated HBsAg prevalence estimates and 95% CIs weighted by study size.  We extrapolated prevalence estimates to population sizes in 2010 to obtain the number of individuals with chronic HBV infection.  FINDINGS:  Of the 17,029 records screened, 1800 report on the prevalence of HBsAg covering 161 countries were included.  HBsAg seroprevalence was 3·61% (95% CI 3·61-3·61) worldwide with highest endemicity in countries of the African region (total 8·83%, 8·82-8·83) and Western Pacific region (total 5·26%, 5·26-5·26).  Within WHO regions, prevalence ranged from 0·20% (0·19-0·21; Mexico) to 13·55% (9·00-19·89; Haiti) in the Americas, to 0·48% (0·12-1·90; the Seychelles) to 22·38% (20·10-24·83; South Sudan) in the African region.  We estimated that in 2010, globally, about 248 million individuals were HBsAg positive.  INTERPRETATION:  This first global assessment of country-level population prevalence of chronic HBV infection found a wide variation between countries and highlights the need for continued prevention and control strategies and the collection of reliable epidemiologic data using standardised methodology.  FUNDING:  World Health Organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqfjRKxbcYNQyMywPm6HgQfW6udTcc2eayP8pn0MDtxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FosV2msw%253D%253D&md5=5c7816955fae1c2be9f42428495edcad</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2961412-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252961412-X%26sid%3Dliteratum%253Aachs%26aulast%3DSchweitzer%26aufirst%3DA.%26aulast%3DHorn%26aufirst%3DJ.%26aulast%3DMikolajczyk%26aufirst%3DR.%2BT.%26aulast%3DKrause%26aufirst%3DG.%26aulast%3DOtt%26aufirst%3DJ.%2BJ.%26atitle%3DEstimations%2520of%2520worldwide%2520prevalence%2520of%2520chronic%2520hepatitis%2520B%2520virus%2520infection%253A%2520a%2520systematic%2520review%2520of%2520data%2520published%2520between%25201965%2520and%25202013%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D1546%26epage%3D1555%26doi%3D10.1016%2FS0140-6736%2815%2961412-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span> </span><span class="NLM_article-title">EASL clinical practice guidelines: Management of chronic hepatitis
B virus infection</span>.  <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume">57</span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2012.02.010</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.jhep.2012.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=22436845" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=EASL+clinical+practice+guidelines%3A+Management+of+chronic+hepatitis%0AB+virus+infection.+J.+Hepatol.+2012%2C+57+%281%29%2C+167%E2%80%93185%2C+10.1016%2Fj.jhep.2012.02.010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.02.010%26sid%3Dliteratum%253Aachs%26atitle%3DEASL%2520clinical%2520practice%2520guidelines%253A%2520Management%2520of%2520chronic%2520hepatitis%250AB%2520virus%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D57%26issue%3D1%26spage%3D167%26epage%3D185%26doi%3D10.1016%2Fj.jhep.2012.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span> <span> </span><span class="NLM_article-title">Past, current, and future developments of therapeutic agents for treatment of chronic hepatitis B virus infection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6461</span>– <span class="NLM_lpage">6479</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01442</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01442" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslSktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6461-6479&issue=15&author=Y.+Peiauthor=C.+Wangauthor=S.+F.+Yanauthor=G.+Liu&title=Past%2C+current%2C+and+future+developments+of+therapeutic+agents+for+treatment+of+chronic+hepatitis+B+virus+infection&doi=10.1021%2Facs.jmedchem.6b01442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection</span></div><div class="casAuthors">Pei, Yameng; Wang, Chunting; Yan, S. Frank; Liu, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6461-6479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">For decades, treatment of hepatitis B virus (HBV) infection has been relying on interferon (IFN)-based therapies and nucleoside/nucleotide analogs (NAs) that selectively target the viral polymerase reverse transcriptase (RT) domain and thereby disrupt HBV viral DNA synthesis.  We have summarized here the key steps in the HBV viral life cycle, which could potentially be targeted by novel anti-HBV therapeutics.  A wide range of next-generation direct antiviral agents (DAAs) with distinct mechanisms of actions are discussed, including entry inhibitors, transcription inhibitors, nucleoside/nucleotide analogs, inhibitors of viral RNase H (RNase H), modulators of viral capsid assembly, inhibitors of HBV surface antigen (HBsAg) secretion, RNA interference (RNAi) gene silencers, antisense oligonucleotides (ASOs), and natural products.  Compds. that exert their antiviral activities mainly through host factors and immunomodulation, such as host targeting agents (HTAs), programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, and Toll-like receptor (TLR) agonists, are also discussed.  In this Perspective, we hope to provide an overview, albeit by no means being comprehensive, for the recent development of novel therapeutic agents for the treatment of chronic HBV infection, which not only are able to sustainably suppress viral DNA but also aim to achieve functional cure warranted by HBsAg loss and ultimately lead to virus eradication and cure of hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoxbHfWUT-wbVg90H21EOLACvtfcHk0lj_XQexheqFhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslSktbw%253D&md5=1a4cde07bc926b2ec7404ab444b66beb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01442%26sid%3Dliteratum%253Aachs%26aulast%3DPei%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DPast%252C%2520current%252C%2520and%2520future%2520developments%2520of%2520therapeutic%2520agents%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D15%26spage%3D6461%26epage%3D6479%26doi%3D10.1021%2Facs.jmedchem.6b01442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banini, B. A.</span></span> <span> </span><span class="NLM_article-title">Updates on chronic HBV: current challenges and future goals</span>. <i>Curr. Treat. Options. Gastro.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1007/s11938-019-00236-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1007%2Fs11938-019-00236-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=31077059" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=271-291&issue=2&author=H.+M.+Leeauthor=B.+A.+Banini&title=Updates+on+chronic+HBV%3A+current+challenges+and+future+goals&doi=10.1007%2Fs11938-019-00236-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs11938-019-00236-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11938-019-00236-3%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BM.%26aulast%3DBanini%26aufirst%3DB.%2BA.%26atitle%3DUpdates%2520on%2520chronic%2520HBV%253A%2520current%2520challenges%2520and%2520future%2520goals%26jtitle%3DCurr.%2520Treat.%2520Options.%2520Gastro.%26date%3D2019%26volume%3D17%26issue%3D2%26spage%3D271%26epage%3D291%26doi%3D10.1007%2Fs11938-019-00236-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.ejmech.2018.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=29438889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1SmtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2018&pages=205-217&author=D.+Sunauthor=L.+Zhuauthor=D.+Yaoauthor=L.+Chenauthor=L.+Fuauthor=L.+Ouyang&title=Recent+progress+in+potential+anti-hepatitis+B+virus+agents%3A+Structural+and+pharmacological+perspectives&doi=10.1016%2Fj.ejmech.2018.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives</span></div><div class="casAuthors">Sun, Dejuan; Zhu, Lingjuan; Yao, Dahong; Chen, Lixia; Fu, Leilei; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205-217</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Hepatitis B virus (HBV) infections affect about 240 million patients worldwide and increase the risk of liver cirrhosis and hepatocellular carcinoma.  It is estd. that about 686 thousand people died annually of liver damage resulted from HBV infections.  At present, two classes of antiviral drugs have been approved by the Food and Drug Administration (FDA) for the treatment of hepatitis B, immunomodulators (interferon [IFN]-a and pegylated-interferon [PEG-IFN]-a) and nucleos(t)ide analogs (lamivudine, telbivudine, adefovir, tenofovir [TDF], and entecavir [ETV]).  However, it still remains a daunting challenge for curing HBV, because of the low sustained response rates (20-30%) and many side effects of IFN and peg-IFN.  Although nucleoside analogs are well tolerated and exhibit an early and potent antiviral effect, the selection of resistant mutants and nephrotoxicity during long-term therapy limit their use.  Here, the authors focus on summarizing the currently approved anti-HBV drugs and characterization of novel HBV inhibitors and analyzing their structures, targets, anti-HBV effects and mechanisms of action, which may shed new light on the discovery of small compds. as potential anti-HBV drugs for treatment of HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqdSeSzutmKLVg90H21EOLACvtfcHk0ljIqmofNAMZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1SmtLs%253D&md5=81e2ec7daf64ef5964d33a8737be2376</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DRecent%2520progress%2520in%2520potential%2520anti-hepatitis%2520B%2520virus%2520agents%253A%2520Structural%2520and%2520pharmacological%2520perspectives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D147%26spage%3D205%26epage%3D217%26doi%3D10.1016%2Fj.ejmech.2018.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zlotnick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewellyn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span> <span> </span><span class="NLM_article-title">Core protein: A pleiotropic keystone in the HBV lifecycle</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2015.06.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.antiviral.2015.06.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=26129969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2ltLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=82-93&author=A.+Zlotnickauthor=B.+Venkatakrishnanauthor=Z.+Tanauthor=E.+Lewellynauthor=W.+Turnerauthor=S.+Francis&title=Core+protein%3A+A+pleiotropic+keystone+in+the+HBV+lifecycle&doi=10.1016%2Fj.antiviral.2015.06.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Core protein: A pleiotropic keystone in the HBV lifecycle</span></div><div class="casAuthors">Zlotnick, Adam; Venkatakrishnan, Balasubramanian; Tan, Zhenning; Lewellyn, Eric; Turner, William; Francis, Samson</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-93</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis B Virus (HBV) is a small virus whose genome has only four open reading frames.  We argue that the simplicity of the virion correlates with a complexity of functions for viral proteins.  We focus on the HBV core protein (Cp), a small (183 residue) protein that self-assembles to form the viral capsid.  However, its functions are a little more complicated than that.  In an infected cell Cp modulates almost every step of the viral lifecycle.  Cp is bound to nuclear viral DNA and affects its epigenetics.  Cp correlates with RNA specificity.  Cp assembles specifically on a reverse transcriptase-viral RNA complex or, apparently, nothing at all.  Indeed Cp has been one of the model systems for investigation of virus self-assembly.  Cp participates in regulation of reverse transcription.  Cp signals completion of reverse transcription to support virus secretion.  Cp carries both nuclear localization signals and HBV surface antigen (HBsAg) binding sites; both of these functions appear to be regulated by contents of the capsid.  Cp can be targeted by antivirals - while self-assembly is the most accessible of Cp activities, we argue that it makes sense to engage the broader spectrum of Cp function.  This article forms part of a symposium in Antiviral Research on "From the discovery of the Australia antigen to the development of new curative therapies for hepatitis B: an unfinished story.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyafN5HJZSQLVg90H21EOLACvtfcHk0ljIqmofNAMZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2ltLvM&md5=e1bd58b97219cb54136dbb2db2fadb70</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DZlotnick%26aufirst%3DA.%26aulast%3DVenkatakrishnan%26aufirst%3DB.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DLewellyn%26aufirst%3DE.%26aulast%3DTurner%26aufirst%3DW.%26aulast%3DFrancis%26aufirst%3DS.%26atitle%3DCore%2520protein%253A%2520A%2520pleiotropic%2520keystone%2520in%2520the%2520HBV%2520lifecycle%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D121%26spage%3D82%26epage%3D93%26doi%3D10.1016%2Fj.antiviral.2015.06.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijampatnam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of HBV capsid assembly modulators</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2019.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.cbpa.2019.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=30952041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Ohsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=73-79&author=B.+Nijampatnamauthor=D.+C.+Liotta&title=Recent+advances+in+the+development+of+HBV+capsid+assembly+modulators&doi=10.1016%2Fj.cbpa.2019.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of HBV capsid assembly modulators</span></div><div class="casAuthors">Nijampatnam, Bhavitavya; Liotta, Dennis C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73-79</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hepatitis B virus (HBV) infections represent a significant burden on global public health.  Current HBV treatments using nucleos(t)ide analogs (NAs) and PEG interferons cannot fully alleviate this burden as they do not affect the transcriptional activity of the tenacious covalently closed circular DNA (cccDNA) responsible for viral persistence.  Capsid assembly modulators (CAMs) disrupt the encapsidation of pre-genomic RNA and can cause nucleocapsid disassembly, thereby affecting multiple steps of HBV replication and redn. of cccDNA pools.  This review provides a concise overview of the development of CAMs and the progress achieved in understanding their interactions with HBV core proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5zQhOPFXEsrVg90H21EOLACvtfcHk0lghAJlrGMX6Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Ohsr0%253D&md5=93e42d664e9bbaa38accc6b02080d55a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DNijampatnam%26aufirst%3DB.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520HBV%2520capsid%2520assembly%2520modulators%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D50%26spage%3D73%26epage%3D79%26doi%3D10.1016%2Fj.cbpa.2019.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span> <span> </span><span class="NLM_article-title">Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: recent advances and perspectives</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00337</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00337" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1akt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=713-724&issue=5&author=L.+Yangauthor=F.+Liuauthor=X.+Tongauthor=D.+Hoffmannauthor=J.+Zuoauthor=M.+Lu&title=Treatment+of+chronic+hepatitis+B+virus+infection+using+small+molecule+modulators+of+nucleocapsid+assembly%3A+recent+advances+and+perspectives&doi=10.1021%2Facsinfecdis.8b00337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives</span></div><div class="casAuthors">Yang, Li; Liu, Feifei; Tong, Xiankun; Hoffmann, Daniel; Zuo, Jianping; Lu, Mengji</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">713-724</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  On the basis of the recent advance of basic research on mol. biol. of hepatitis B virus (HBV) infection, novel antiviral drugs targeting various steps of the HBV life cycle have been developed in recent years.  HBV nucleocapsid assembly is now recognized as a hot target for anti-HBV drug development.  Structural and functional anal. of HBV nucleocapsid allowed rational design and improvement of small mols. with the ability to interact with the components of HBV nucleocapsid and modulate the viral nucleocapsid assembly process.  Prototypes of small mol. modulators targeting HBV nucleocapsid assembly are being preclinically tested or have moved forward in clin. trials, with promising results.  This Review summarizes the recent advances in the approach to develop antiviral drugs based on the modulation of HBV nucleocapsid assembly.  The antiviral mechanisms of small mol. modulators beyond the capsid formation and the potential implications will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvT6WVN92udLVg90H21EOLACvtfcHk0lghAJlrGMX6Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1akt7o%253D&md5=f602f5c7f6e9af69ac2f777ca82efe28</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00337%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DHoffmann%26aufirst%3DD.%26aulast%3DZuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%26atitle%3DTreatment%2520of%2520chronic%2520hepatitis%2520B%2520virus%2520infection%2520using%2520small%2520molecule%2520modulators%2520of%2520nucleocapsid%2520assembly%253A%2520recent%2520advances%2520and%2520perspectives%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26issue%3D5%26spage%3D713%26epage%3D724%26doi%3D10.1021%2Facsinfecdis.8b00337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stray, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlotnick, A.</span></span> <span> </span><span class="NLM_article-title">BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly</span>. <i>J. Mol. Recognit.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1002/jmr.801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1002%2Fjmr.801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=17006877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVahu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=542-548&issue=6&author=S.+J.+Strayauthor=A.+Zlotnick&title=BAY+41-4109+has+multiple+effects+on+hepatitis+B+virus+capsid+assembly&doi=10.1002%2Fjmr.801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly</span></div><div class="casAuthors">Stray, Stephen J.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Recognition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">542-548</span>CODEN:
                <span class="NLM_cas:coden">JMORE4</span>;
        ISSN:<span class="NLM_cas:issn">0952-3499</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Here we report the effect of a heteroaryldihydropyrimidine (HAP) antiviral compd., BAY 41-4109, on Hepatitis B virus (HBV) capsid assembly and on preformed HBV capsids.  The HBV capsid is an icosahedral complex of 120 capsid protein dimers.  BAY41-4109 inhibits virus prodn. in vivo by a mechanism that targets the viral capsid.  We found that BAY 41-4109 was able to both accelerate and misdirect capsid assembly in vitro.  As little as one HAP mol. for every five HBV dimers was sufficient to induce formation of non-capsid polymers.  Unlike the related mol. HAP-1, no stable assembly intermediates were obsd. in assembly reactions with BAY 41-4109, indicating that accelerated assembly by BAY 41-4109 was still kinetically regulated by the nucleation rate.  Preformed capsids were stabilized by BAY 41-4109, up to a ratio of one inhibitor mol. per two dimers.  However, at BAY 41-4109:dimer ratios of 1:1 and greater, capsids were destabilized to yield very large noncapsid polymers.  These data suggest the existence of two functionally distinguishable classes of drug-binding sites on HBV capsids.  Occupation of the first class of site stabilizes capsid, while binding at the second class requires or induces structural changes that cannot be tolerated without destabilizing the capsid.  Our data suggest that HAP compds. may inhibit virus replication by inducing assembly inappropriately and, when in excess, by misdirecting assembly decreasing the stability of normal capsids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorOaQz7SajJrVg90H21EOLACvtfcHk0lhXLSdMCN7wEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVahu7s%253D&md5=15c132fcc380b09f691561adf737fbd3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fjmr.801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmr.801%26sid%3Dliteratum%253Aachs%26aulast%3DStray%26aufirst%3DS.%2BJ.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DBAY%252041-4109%2520has%2520multiple%2520effects%2520on%2520hepatitis%2520B%2520virus%2520capsid%2520assembly%26jtitle%3DJ.%2520Mol.%2520Recognit.%26date%3D2006%26volume%3D19%26issue%3D6%26spage%3D542%26epage%3D548%26doi%3D10.1002%2Fjmr.801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B virus (HBV) capsid inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7651</span>– <span class="NLM_lpage">7666</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00879</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00879" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ejt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7651-7666&issue=16&author=Z.+Qiuauthor=X.+Linauthor=M.+Zhouauthor=Y.+Liuauthor=W.+Zhuauthor=W.+Chenauthor=W.+Zhangauthor=L.+Guoauthor=H.+Liuauthor=G.+Wuauthor=M.+Huangauthor=M.+Jiangauthor=Z.+Xuauthor=Z.+Zhouauthor=N.+Qinauthor=S.+Renauthor=H.+Qiuauthor=S.+Zhongauthor=Y.+Zhangauthor=Y.+Zhangauthor=X.+Wuauthor=L.+Shiauthor=F.+Shenauthor=Y.+Maoauthor=X.+Zhouauthor=W.+Yangauthor=J.+Z.+Wuauthor=G.+Yangauthor=A.+V.+Maywegauthor=H.+C.+Shenauthor=G.+Tang&title=Design+and+synthesis+of+orally+bioavailable+4-methyl+heteroaryldihydropyrimidine+based+hepatitis+B+virus+%28HBV%29+capsid+inhibitors&doi=10.1021%2Facs.jmedchem.6b00879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors</span></div><div class="casAuthors">Qiu, Zongxing; Lin, Xianfeng; Zhou, Mingwei; Liu, Yongfu; Zhu, Wei; Chen, Wenming; Zhang, Weixing; Guo, Lei; Liu, Haixia; Wu, Guolong; Huang, Mengwei; Jiang, Min; Xu, Zhiheng; Zhou, Zheng; Qin, Ning; Ren, Shuang; Qiu, Hongxia; Zhong, Sheng; Zhang, Yuxia; Zhang, Yi; Wu, Xiaoyue; Shi, Liping; Shen, Fang; Mao, Yi; Zhou, Xue; Yang, Wengang; Wu, Jim Z.; Yang, Guang; Mayweg, Alexander V.; Shen, Hong C.; Tang, Guozhi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7651-7666</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting the capsid protein of hepatitis B virus (HBV) and thus interrupting normal capsid formation have been an attractive approach to block the replication of HBV viruses.  We carried out multidimensional structural optimizations based on the heteroaryldihydropyrimidine (HAP) analog Bay41-4109 and identified a novel series of HBV capsid inhibitors that demonstrated promising cellular selectivity indexes, metabolic stabilities, and in vitro safety profiles.  Herein we disclose the design, synthesis, structure-activity relationship (SAR), cocrystal structure in complex with HBV capsid proteins and in vivo pharmacol. study of the 4-Me HAP analogs.  In particular, the (2S,4S)-4,4-difluoroproline substituted analog demonstrated high oral bioavailability and liver exposure and achieved over 2 log viral load redn. in a hydrodynamic injected (HDI) HBV mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjzkw8e0cupLVg90H21EOLACvtfcHk0lhXLSdMCN7wEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ejt7%252FM&md5=68a71ce041575861d257c42b6922f8b1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00879%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DTang%26aufirst%3DG.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520orally%2520bioavailable%25204-methyl%2520heteroaryldihydropyrimidine%2520based%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520capsid%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D16%26spage%3D7651%26epage%3D7666%26doi%3D10.1021%2Facs.jmedchem.6b00879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boucle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassit, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozturk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amblard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">904</span>– <span class="NLM_lpage">910</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.bmcl.2017.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=28094179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=904-910&issue=4&author=S.+Boucleauthor=X.+Luauthor=L.+Bassitauthor=T.+Ozturkauthor=O.+O.+Russellauthor=F.+Amblardauthor=S.+J.+Coatsauthor=R.+F.+Schinazi&title=Synthesis+and+antiviral+evaluation+of+novel+heteroarylpyrimidines+analogs+as+HBV+capsid+effectors&doi=10.1016%2Fj.bmcl.2017.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors</span></div><div class="casAuthors">Boucle, Sebastien; Lu, Xiao; Bassit, Leda; Ozturk, Tugba; Russell, Olivia Ollinger; Amblard, Franck; Coats, Steven J.; Schinazi, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">904-910</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ne120w modifications to the scaffold of previously reported HBV capsid assembly effectors such as BAY 41-4109, HAP-12 and GLS4 were explored.  The anti-HBV activity in the HepAD38 system, and cytotoxicity profiles of each of the new compds. has been assessed.  Among them, five new iodo- and bromo-heteroarylpyrimidines analogs displayed anti-HBV activity in the low micromolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvFdqr3-w22rVg90H21EOLACvtfcHk0lhV9YrO9jeHqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wlsro%253D&md5=5bdb4f7106b993f816b8dde56b242465</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DBoucle%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DBassit%26aufirst%3DL.%26aulast%3DOzturk%26aufirst%3DT.%26aulast%3DRussell%26aufirst%3DO.%2BO.%26aulast%3DAmblard%26aufirst%3DF.%26aulast%3DCoats%26aufirst%3DS.%2BJ.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520and%2520antiviral%2520evaluation%2520of%2520novel%2520heteroarylpyrimidines%2520analogs%2520as%2520HBV%2520capsid%2520effectors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D904%26epage%3D910%26doi%3D10.1016%2Fj.bmcl.2017.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of tetrahydropyrrolo[1,2-c]pyrimidines as capsid assembly inhibitors for HBV treatment</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">969</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00288</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00288" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlygtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=969-974&issue=9&author=X.+Liauthor=K.+Zhouauthor=H.+Heauthor=Q.+Zhouauthor=Y.+Sunauthor=L.+Houauthor=L.+Shenauthor=X.+Wangauthor=Y.+Zhouauthor=Z.+Gongauthor=S.+Heauthor=H.+Jinauthor=Z.+Guauthor=S.+Zhaoauthor=L.+Zhangauthor=C.+Sunauthor=S.+Zhengauthor=Z.+Chengauthor=Y.+Zhuauthor=M.+Zhangauthor=J.+Liauthor=S.+Chen&title=Design%2C+synthesis%2C+and+evaluation+of+tetrahydropyrrolo%5B1%2C2-c%5Dpyrimidines+as+capsid+assembly+inhibitors+for+HBV+treatment&doi=10.1021%2Facsmedchemlett.7b00288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Tetrahydropyrrolo[1,2-c]pyrimidines as Capsid Assembly Inhibitors for HBV Treatment</span></div><div class="casAuthors">Li, Xiaolin; Zhou, Kai; He, Haiying; Zhou, Qiong; Sun, Ya; Hou, Lijuan; Shen, Liang; Wang, Xiaofei; Zhou, Yuedong; Gong, Zhen; He, Shibo; Jin, Huangtao; Gu, Zhengxian; Zhao, Shuyong; Zhang, Long; Sun, Chunyan; Zheng, Shansong; Cheng, Zhe; Zhu, Yidong; Zhang, Minghui; Li, Jian; Chen, Shuhui</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">969-974</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of novel tetrahydropyrrolo[1,2-c]pyrimidines derivs. from Bay41_4109 as hepatitis B virus (HBV) inhibitors is herein reported.  The structure-activity relation optimization led to one highly efficacious compd. (IC50 = 10 nM) with good PK profiles and the favorite L/P ratio.  The hydrodynamic injection model in mice clearly demonstrated the efficacy of this compd. against HBV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9SjwozsLNxbVg90H21EOLACvtfcHk0lhV9YrO9jeHqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlygtb7O&md5=635d05b364961eff3d79ba663fcbd005</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00288%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520tetrahydropyrrolo%255B1%252C2-c%255Dpyrimidines%2520as%2520capsid%2520assembly%2520inhibitors%2520for%2520HBV%2520treatment%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D9%26spage%3D969%26epage%3D974%26doi%3D10.1021%2Facsmedchemlett.7b00288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span> <span> </span><span class="NLM_article-title">Discovery and pre-clinical characterization of third-generation 4-H heteroaryldihydropyrimidine (HAP) analogues as hepatitis B virus (HBV) capsid inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3352</span>– <span class="NLM_lpage">3371</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3352-3371&issue=8&author=Z.+Qiuauthor=X.+Linauthor=W.+Zhangauthor=M.+Zhouauthor=L.+Guoauthor=B.+Kocerauthor=G.+Wuauthor=Z.+Zhangauthor=H.+Liuauthor=H.+Shiauthor=B.+Kouauthor=T.+Huauthor=Y.+Huauthor=M.+Huangauthor=S.+F.+Yanauthor=Z.+Xuauthor=Z.+Zhouauthor=N.+Qinauthor=Y.+F.+Wangauthor=S.+Renauthor=H.+Qiuauthor=Y.+Zhangauthor=Y.+Zhangauthor=X.+Wuauthor=K.+Sunauthor=S.+Zhongauthor=J.+Xieauthor=G.+Ottavianiauthor=Y.+Zhouauthor=L.+Zhuauthor=X.+Tianauthor=L.+Shiauthor=F.+Shenauthor=Y.+Maoauthor=X.+Zhouauthor=L.+Gaoauthor=J.+A.+T.+Youngauthor=J.+Z.+Wuauthor=G.+Yangauthor=A.+V.+Maywegauthor=H.+C.+Shenauthor=G.+Tangauthor=W.+Zhu&title=Discovery+and+pre-clinical+characterization+of+third-generation+4-H+heteroaryldihydropyrimidine+%28HAP%29+analogues+as+hepatitis+B+virus+%28HBV%29+capsid+inhibitors&doi=10.1021%2Facs.jmedchem.7b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors</span></div><div class="casAuthors">Qiu, Zongxing; Lin, Xianfeng; Zhang, Weixing; Zhou, Mingwei; Guo, Lei; Kocer, Buelent; Wu, Guolong; Zhang, Zhisen; Liu, Haixia; Shi, Houguang; Kou, Buyu; Hu, Taishan; Hu, Yimin; Huang, Mengwei; Yan, S. Frank; Xu, Zhiheng; Zhou, Zheng; Qin, Ning; Wang, Yue Fen; Ren, Shuang; Qiu, Hongxia; Zhang, Yuxia; Zhang, Yi; Wu, Xiaoyue; Sun, Kai; Zhong, Sheng; Xie, Jianxun; Ottaviani, Giorgio; Zhou, Yuan; Zhu, Lina; Tian, Xiaojun; Shi, Liping; Shen, Fang; Mao, Yi; Zhou, Xue; Gao, Lu; Young, John A. T.; Wu, Jim Zhen; Yang, Guang; Mayweg, Alexander V.; Shen, Hong C.; Tang, Guozhi; Zhu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3352-3371</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) (I) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors.  This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs.  X-ray crystallog. study of analog 12 (HAP_R01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen bonding interactions with capsid protein and coordinated waters.  The representative analog 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further development as oral anti-HBV infection agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolNkEF9n_vqrVg90H21EOLACvtfcHk0ljvF63NrTLKew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWjtbw%253D&md5=6c2a89c594f2c735855f64aca2240837</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00083%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DKou%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DOttaviani%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DJ.%2BA.%2BT.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DW.%26atitle%3DDiscovery%2520and%2520pre-clinical%2520characterization%2520of%2520third-generation%25204-H%2520heteroaryldihydropyrimidine%2520%2528HAP%2529%2520analogues%2520as%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520capsid%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D8%26spage%3D3352%26epage%3D3371%26doi%3D10.1021%2Facs.jmedchem.7b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6 -dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic acid (HEC72702), a novel hepatitis B virus capsid inhibitor based on clinical candidate GLS4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1374</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01914</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01914" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1355-1374&issue=3&author=Q.+Renauthor=X.+Liuauthor=G.+Yanauthor=B.+Nieauthor=Z.+Zouauthor=J.+Liauthor=Y.+Chenauthor=Y.+Weiauthor=J.+Huangauthor=Z.+Luoauthor=B.+Guauthor=S.+Goldmannauthor=J.+Zhangauthor=Y.+Zhang&title=3-%28%28R%29-4-%28%28%28R%29-6-%282-Bromo-4-fluorophenyl%29-5-%28ethoxycarbonyl%29-2-%28thiazol-2-yl%29-3%2C6+-dihydropyrimidin-4-yl%29methyl%29morpholin-2-yl%29propanoic+acid+%28HEC72702%29%2C+a+novel+hepatitis+B+virus+capsid+inhibitor+based+on+clinical+candidate+GLS4&doi=10.1021%2Facs.jmedchem.7b01914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4</span></div><div class="casAuthors">Ren, Qingyun; Liu, Xinchang; Yan, Guanghua; Nie, Biao; Zou, Zhifu; Li, Jing; Chen, Yunfu; Wei, Yu; Huang, Jianzhou; Luo, Zhonghua; Gu, Baohua; Goldmann, Siegfried; Zhang, Jiancun; Zhang, Yingjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1355-1374</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics.  On the basis of the preclin. properties and clin. results of GLS4, we carried out further investigation to seek a better candidate compd. with appropriate anti-HBV potency, reduced hERG activity, decreased CYP enzyme induction, and improved pharmacokinetic (PK) properties.  To this end, we have successfully found that morpholine carboxyl analogs with comparable anti-HBV activities to that of GLS4 showed decreased hERG activities, but they displayed strong CYP3A4 induction in a concn.-dependent manner, except for morpholine propionic acid analogs.  After several rounds of modification, compd. 58 (HEC72702), which had an (R)-morpholine-2-propionic acid at the C6 position of its dihydropyrimidine core ring, was found to display no induction of the CYP1A2, CYP3A4, or CYP2B6 enzyme at the high concn. of 10 μM.  In particular, it demonstrated a good systemic exposure and high oral bioavailability and achieved a viral-load redn. greater than 2 log in a hydrodynamic-injected (HDI) HBV mouse model and has now been selected for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg4uSQeAhrXbVg90H21EOLACvtfcHk0ljvF63NrTLKew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWksLc%253D&md5=f4abf118fdddb8c09f9e9fb290b850ea</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01914%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DG.%26aulast%3DNie%26aufirst%3DB.%26aulast%3DZou%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DGu%26aufirst%3DB.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3D3-%2528%2528R%2529-4-%2528%2528%2528R%2529-6-%25282-Bromo-4-fluorophenyl%2529-5-%2528ethoxycarbonyl%2529-2-%2528thiazol-2-yl%2529-3%252C6%2520-dihydropyrimidin-4-yl%2529methyl%2529morpholin-2-yl%2529propanoic%2520acid%2520%2528HEC72702%2529%252C%2520a%2520novel%2520hepatitis%2520B%2520virus%2520capsid%2520inhibitor%2520based%2520on%2520clinical%2520candidate%2520GLS4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D3%26spage%3D1355%26epage%3D1374%26doi%3D10.1021%2Facs.jmedchem.7b01914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.ejmech.2017.12.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=29288943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Kksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=424-434&author=J.+Qiuauthor=Q.+Gongauthor=J.+Gaoauthor=W.+Chenauthor=Y.+Zhangauthor=X.+Guauthor=D.+Tang&title=Design%2C+synthesis+and+evaluation+of+novel+phenyl+propionamide+derivatives+as+non-nucleoside+hepatitis+B+virus+inhibitors&doi=10.1016%2Fj.ejmech.2017.12.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors</span></div><div class="casAuthors">Qiu, Jingying; Gong, Qineng; Gao, Jian; Chen, Wang; Zhang, Yinpeng; Gu, Xiaoke; Tang, Daoquan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">424-434</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As an ongoing search for potent non-nucleoside anti-HBV agents with novel structures, the authors described a series of Ph propionamide derivs. (3a-b, 4a-e, 7a-g, 8a-h and 9a-b) by pharmacophore fusion strategy in the present work.  All the compds. exhibited an anti-HBV activity to some extent.  Among them, compds. 8d ((S,Z)-N-(1-bromo-3-((1-hydroxy-3-phenylpropan-2-yl)amino)-3-oxo-1-(m-tolyl)prop-1-en-2-yl)benzamide) and 9b ((S,Z)-N-(1-bromo-1-(4-(2-(dimethylamino)ethoxy)phenyl)-3-((1-hydroxy-3-phenylpropan-2-yl)amino)-3-oxoprop-1-en-2-yl)benzamide) displayed most potent anti-HBV activity with IC50 values on HBV DNA replication of 0.46 and 0.14 μM, resp.  And the selective index values of 8d and 9b were more than 217.39 and 153.14, suggesting that 8d and 9b exhibited favorable safety profiles.  Interestingly, 8d and 9b possessed significantly antiviral activities against lamivudine and entecavir resistant HBV mutants with IC50 values of 0.77 and 0.32 μM.  Notably, preliminary anti-HBV action mechanism studies showed that 8d could inhibit intracellular HBV pgRNA and RT activity of the HBV polymerase.  Mol. docking studies suggested that compd. 8d could fit into the dimer-dimer interface of HBV core protein by hydrophobic interaction.  In addn., in silico prediction of physicochem. properties showed that 8d conformed well to the Lipinski's rule of five, suggesting its potential for use as a drug like mol.  Taken together, 8d possessed significantly anti-HBV activity, low toxicity, diverse anti-HBV mechanism and favorable physicochem. properties, and warranted further investigation as a promising non-nucleoside anti-HBV candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofINd0i0cF7bVg90H21EOLACvtfcHk0lhjo-FknBvpvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Kksw%253D%253D&md5=991c10a5e00f117441437c189182ba82</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.042%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DJ.%26aulast%3DGong%26aufirst%3DQ.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DD.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520novel%2520phenyl%2520propionamide%2520derivatives%2520as%2520non-nucleoside%2520hepatitis%2520B%2520virus%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D424%26epage%3D434%26doi%3D10.1016%2Fj.ejmech.2017.12.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondylis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlicksup, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katen, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlotnick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, S. C.</span></span> <span> </span><span class="NLM_article-title">Evolution of intermediates during capsid assembly of hepatitis B virus with phenylpropenamide-based antivirals</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">777</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00290</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00290" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktlGhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=769-777&issue=5&author=P.+Kondylisauthor=C.+J.+Schlicksupauthor=S.+P.+Katenauthor=L.+S.+Leeauthor=A.+Zlotnickauthor=S.+C.+Jacobson&title=Evolution+of+intermediates+during+capsid+assembly+of+hepatitis+B+virus+with+phenylpropenamide-based+antivirals&doi=10.1021%2Facsinfecdis.8b00290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Intermediates during Capsid Assembly of Hepatitis B Virus with Phenylpropenamide-Based Antivirals</span></div><div class="casAuthors">Kondylis, Panagiotis; Schlicksup, Christopher J.; Katen, Sarah P.; Lee, Lye Siang; Zlotnick, Adam; Jacobson, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">769-777</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Self-assembly of virus capsids is a potential target for antivirals due to its importance in the virus lifecycle.  Here, we investigate the effect of phenylpropenamide derivs. B-21 and AT-130 on the assembly of hepatitis B virus (HBV) core protein.  Phenylpropenamides are widely believed to yield assembly of spherical particles resembling native, empty HBV capsids.  Because the details of assembly can be overlooked with ensemble measurements, we performed resistive-pulse sensing on nanofluidic devices with four pores in series to characterize the size distributions of the products in real time.  With its single particle sensitivity and compatibility with typical assembly buffers, resistive-pulse sensing is well-suited for analyzing virus assembly in vitro.  We obsd. that assembly with B-21 and AT-130 produced a large fraction of partially complete virus particles that may be on-path, off-path, or trapped.  For both B-21 and AT-130, capsid assembly was more sensitive to disruption under conditions where the interprotein assocn. energy was low at lower salt concns.  Diln. of the reaction solns. led to the rearrangement of the incomplete particles and demonstrated that these large intermediates may be on-path, but are labile, and exist in a frustrated dynamic equil.  During capsid assembly, phenylpropenamide mols. modestly increase the assocn. energy of dimers, prevent intermediates from dissocg., and lead to kinetic trapping where the formation of too many capsids has been initiated, which results in both empty and incomplete particles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYUJqkh83pVrVg90H21EOLACvtfcHk0lhjo-FknBvpvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktlGhsw%253D%253D&md5=89dec0d941b97b0d067af0d5ae3e2ac2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00290%26sid%3Dliteratum%253Aachs%26aulast%3DKondylis%26aufirst%3DP.%26aulast%3DSchlicksup%26aufirst%3DC.%2BJ.%26aulast%3DKaten%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DL.%2BS.%26aulast%3DZlotnick%26aufirst%3DA.%26aulast%3DJacobson%26aufirst%3DS.%2BC.%26atitle%3DEvolution%2520of%2520intermediates%2520during%2520capsid%2520assembly%2520of%2520hepatitis%2520B%2520virus%2520with%2520phenylpropenamide-based%2520antivirals%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26issue%3D5%26spage%3D769%26epage%3D777%26doi%3D10.1021%2Facsinfecdis.8b00290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozturk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassit, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amblard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2Fj.ejmech.2017.06.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=28688280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFChurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=407-421&author=O.+Sariauthor=S.+Boucleauthor=B.+D.+Coxauthor=T.+Ozturkauthor=O.+O.+Russellauthor=L.+Bassitauthor=F.+Amblardauthor=R.+F.+Schinazi&title=Synthesis+of+sulfamoylbenzamide+derivatives+as+HBV+capsid+assembly+effector&doi=10.1016%2Fj.ejmech.2017.06.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effectors</span></div><div class="casAuthors">Sari, Ozkan; Boucle, Sebastien; Cox, Bryan D.; Ozturk, Tugba; Russell, Olivia Ollinger; Bassit, Leda; Amblard, Franck; Schinazi, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">407-421</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The synthesis of novel series of sulfamoylbenzamides, e.g. I [R1 = F, R2 = H; R1R2 = (CH2)2, (CH2)3; X = R3R4NSO2, R5SO2NH; R3 = cyclopentyl, cyclopentyloxy, MeSO2, PhCHMe, etc., R4 = H; R3R4 = CH2CF2CH2CH2, C(O)(CH2)3, etc.; R5 = cyclopropyl, cyclopentyl, cyclohexyl] as HBV capsid assembly effector is reported.  The structure was divided into five parts which were independently modified as part of the lead optimization.  All the synthesized compds. were evaluated for their anti-HBV activity and toxicity in human hepatocytes, lymphocytes and other cells.  Addnl., their effect on HBV cccDNA formation in an HBeAg reporter cell-based assay was assessed.  Among the 27 compds. reported, several analogs exhibited submicromolar activities and significant redn. of HBeAg secretion.  Selected compds. were studied under neg.-stain electron microscopy for their ability to disrupt the HBV capsid formation.  Structures were modeled into a binding site recently identified in the HBV capsid protein for similar mols. to rationalize the structure-activity relationships for this family of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUa_fzgDe9WrVg90H21EOLACvtfcHk0licynQPtn0ujQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFChurvI&md5=cc0de429427455fac4cebd76c51119ed</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.062%26sid%3Dliteratum%253Aachs%26aulast%3DSari%26aufirst%3DO.%26aulast%3DBoucle%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DB.%2BD.%26aulast%3DOzturk%26aufirst%3DT.%26aulast%3DRussell%26aufirst%3DO.%2BO.%26aulast%3DBassit%26aufirst%3DL.%26aulast%3DAmblard%26aufirst%3DF.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520of%2520sulfamoylbenzamide%2520derivatives%2520as%2520HBV%2520capsid%2520assembly%2520effector%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D407%26epage%3D421%26doi%3D10.1016%2Fj.ejmech.2017.06.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vandyck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rombouts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoops, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschueren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergauwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehertogh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of N-phenyl-3-sulfamoyl-benzamide derivatives as capsid assembly modulators inhibiting hepatitis B virus (HBV)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6247</span>– <span class="NLM_lpage">6260</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00654</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00654" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6247-6260&issue=14&author=K.+Vandyckauthor=G.+Romboutsauthor=B.+Stoopsauthor=A.+Tahriauthor=A.+Vosauthor=W.+Verschuerenauthor=Y.+Wuauthor=J.+Yangauthor=F.+Houauthor=B.+Huangauthor=K.+Vergauwenauthor=P.+Dehertoghauthor=J.+M.+Berkeauthor=P.+Raboisson&title=Synthesis+and+evaluation+of+N-phenyl-3-sulfamoyl-benzamide+derivatives+as+capsid+assembly+modulators+inhibiting+hepatitis+B+virus+%28HBV%29&doi=10.1021%2Facs.jmedchem.8b00654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)</span></div><div class="casAuthors">Vandyck, Koen; Rombouts, Geert; Stoops, Bart; Tahri, Abdellah; Vos, Ann; Verschueren, Wim; Wu, Yiming; Yang, Jingmei; Hou, Fuliang; Huang, Bing; Vergauwen, Karen; Dehertogh, Pascale; Berke, Jan Martin; Raboisson, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6247-6260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. induced hepatitis B virus (HBV) capsid assembly modulation is considered an attractive approach for new antiviral therapies against HBV.  Here we describe efforts toward the discovery of a HBV capsid assembly modulator in a hit-to-lead optimization, resulting in JNJ-632, a tool compd. used to further profile the mode of action.  Administration of JNJ-632 (54) in HBV genotype D infected chimeric mice resulted in a 2.77 log redn. of the HBV DNA viral load.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKzPnHUf4R5LVg90H21EOLACvtfcHk0licynQPtn0ujQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsrfF&md5=b877a4732f8dc2141c60fba79f27aa52</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00654%26sid%3Dliteratum%253Aachs%26aulast%3DVandyck%26aufirst%3DK.%26aulast%3DRombouts%26aufirst%3DG.%26aulast%3DStoops%26aufirst%3DB.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DVos%26aufirst%3DA.%26aulast%3DVerschueren%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DVergauwen%26aufirst%3DK.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520N-phenyl-3-sulfamoyl-benzamide%2520derivatives%2520as%2520capsid%2520assembly%2520modulators%2520inhibiting%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D14%26spage%3D6247%26epage%3D6260%26doi%3D10.1021%2Facs.jmedchem.8b00654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuduk, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator against hepatitis B virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e01734-18</span> <span class="refDoi"> DOI: 10.1128/AAC.01734-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1128%2FAAC.01734-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=30373799" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&issue=1&author=A.+M.+Lamauthor=C.+Espirituauthor=R.+Vogelauthor=S.+Renauthor=V.+Lauauthor=M.+Kellyauthor=S.+D.+Kudukauthor=G.+D.+Hartmanauthor=O.+A.+Floresauthor=K.+Klumpp&title=Preclinical+characterization+of+NVR+3-778%2C+a+first-in-class+capsid+assembly+modulator+against+hepatitis+B+virus&doi=10.1128%2FAAC.01734-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FAAC.01734-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01734-18%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DVogel%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DLau%26aufirst%3DV.%26aulast%3DKelly%26aufirst%3DM.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DFlores%26aufirst%3DO.%2BA.%26aulast%3DKlumpp%26aufirst%3DK.%26atitle%3DPreclinical%2520characterization%2520of%2520NVR%25203-778%252C%2520a%2520first-in-class%2520capsid%2520assembly%2520modulator%2520against%2520hepatitis%2520B%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26issue%3D1%26doi%3D10.1128%2FAAC.01734-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weilert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen Chan, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liaw, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuda, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talloen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>156</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1403</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2018.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1053%2Fj.gastro.2018.12.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=30625297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVykurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2019&pages=1392-1403&issue=5&author=M.+F.+Yuenauthor=E.+J.+Ganeauthor=D.+J.+Kimauthor=F.+Weilertauthor=H.+L.+Yuen+Chanauthor=J.+Lalezariauthor=S.+G.+Hwangauthor=T.+Nguyenauthor=O.+Floresauthor=G.+Hartmanauthor=S.+Liawauthor=O.+Lenzauthor=T.+N.+Kakudaauthor=W.+Talloenauthor=C.+Schwabeauthor=K.+Klumppauthor=N.+Brown&title=Antiviral+activity%2C+safety%2C+and+pharmacokinetics+of+capsid+assembly+modulator+NVR+3-778+in+patients+with+chronic+HBV+infection&doi=10.1053%2Fj.gastro.2018.12.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection</span></div><div class="casAuthors">Yuen, Man Fung; Gane, Edward J.; Kim, Dong Joon; Weilert, Frank; Yuen Chan, Henry Lik; Lalezari, Jacob; Hwang, Seong Gyu; Nguyen, Tuan; Flores, Osvaldo; Hartman, George; Liaw, Sandy; Lenz, Oliver; Kakuda, Thomas N.; Talloen, Willem; Schwabe, Christian; Klumpp, Klaus; Brown, Nathaniel</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1392-1403.e7</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NVR 3-778 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator that can inhibit HBV replication.  We performed a proof-of-concept study to examine the safety, pharmacokinetics, and antiviral activity of NVR 3-778 in patients with chronic HBV infection.  We performed a phase 1 study in 73 hepatitis B envelope antigen (HBeAg)-pos. patients with chronic HBV infection without cirrhosis.  In a 2-part study (part 1 in New Zealand and part 2 in Hong Kong, Singapore, Taiwan, Korea, and the United States), patients were randomly assigned to groups that were given oral NVR 3-778 (100 mg, 200 mg, or 400 mg daily or 600 mg or 1000 mg twice daily) or placebo for 4 wk.  Addnl. groups received combination treatment with pegylated interferon (pegIFN) and NVR 3-778 (600 mg twice daily) or pegIFN with placebo.  Redns. in serum levels of HBV DNA and HBV RNA were obsd. in patients receiving ≥1200 mg/d NVR 3-778.  The largest mean redn. in HBV DNA was obsd. in the group given NVR 3-778 plus pegIFN (1.97 log10 IU/mL), compared with the groups given NVR 3-778 or pegIFN alone (1.43 log10 IU/mL and 1.06 log10 IU/mL, resp.).  The mean redn. in HBV RNA was also greatest in the group given NVR 3-778 plus pegIFN (2.09 log10 copies/mL), compared with the groups given NVR 3-778 or pegIFN alone (1.42 log10 copies/mL and 0.89 log10 copies/mL, resp.).  There was no significant mean redn. in HBsAg during the 4-wk treatment period.  There were no discontinuations and no pattern of dose-related adverse effects with NVR 3-778.  In a phase 1 study of HBeAg-pos. patients with chronic HBV infection without cirrhosis, NVR 3-778 was well tolerated and demonstrated antiviral activity.  The agent reduced serum levels of HBV DNA and HBV RNA, to the greatest extent in combination with pegIFN.  The obsd. redns. in HBV RNA confirmed the novel mechanism of NVR 3-778.  Clinicaltrials.gov no.  NCT02112799 (single-center) and NCT02401737 (multicenter).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJKwCp-m7BoLVg90H21EOLACvtfcHk0lifT6buLv8c_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVykurY%253D&md5=b4a4af2356d344f8e3848b5f55d3887a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2018.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2018.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DM.%2BF.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BJ.%26aulast%3DWeilert%26aufirst%3DF.%26aulast%3DYuen%2BChan%26aufirst%3DH.%2BL.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DHwang%26aufirst%3DS.%2BG.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DFlores%26aufirst%3DO.%26aulast%3DHartman%26aufirst%3DG.%26aulast%3DLiaw%26aufirst%3DS.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DKakuda%26aufirst%3DT.%2BN.%26aulast%3DTalloen%26aufirst%3DW.%26aulast%3DSchwabe%26aufirst%3DC.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DN.%26atitle%3DAntiviral%2520activity%252C%2520safety%252C%2520and%2520pharmacokinetics%2520of%2520capsid%2520assembly%2520modulator%2520NVR%25203-778%2520in%2520patients%2520with%2520chronic%2520HBV%2520infection%26jtitle%3DGastroenterology%26date%3D2019%26volume%3D156%26issue%3D5%26spage%3D1392%26epage%3D1403%26doi%3D10.1053%2Fj.gastro.2018.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trépo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, A.</span></span> <span> </span><span class="NLM_article-title">Hepatitis B virus infection</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>384</i></span>,  <span class="NLM_fpage">2053</span>– <span class="NLM_lpage">2063</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)60220-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1016%2FS0140-6736%2814%2960220-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=24954675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVanu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=2053-2063&author=C.+Tr%C3%A9poauthor=H.+L.+Y.+Chanauthor=A.+Lok&title=Hepatitis+B+virus+infection&doi=10.1016%2FS0140-6736%2814%2960220-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus infection</span></div><div class="casAuthors">Trepo, Christian; Chan, Henry L. Y.; Lok, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">9959</span>),
    <span class="NLM_cas:pages">2053-2063</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the world's population show serol. evidence of current or past infection.  Hepatitis B virus is a partly double-stranded DNA virus with several serol. markers: HBsAg and anti-HBs, HBeAg and anti-HBe, and anti-HBc IgM and IgG.  It is transmitted through contact with infected blood and semen.  A safe and effective vaccine has been available since 1981, and, although variable, the implementation of universal vaccination in infants has resulted in a sharp decline in prevalence.  Hepatitis B virus is not cytopathic; both liver damage and viral control-and therefore clin. outcome-depend on the complex interplay between virus replication and host immune response.  Overall, as much as 40% of men and 15% of women with perinatally acquired hepatitis B virus infection will die of liver cirrhosis or hepatocellular carcinoma.  In addn. to decreasing hepatic inflammation, long-term antiviral treatment can reverse cirrhosis and reduce hepatocellular carcinoma.  Development of new therapies that can improve HBsAg clearance and virol. cure is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRAto9E_Y-YLVg90H21EOLACvtfcHk0lifT6buLv8c_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVanu7nM&md5=b7192bf0aa7f91bb430c61e344aaaa26</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2960220-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252960220-8%26sid%3Dliteratum%253Aachs%26aulast%3DTr%25C3%25A9po%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DH.%2BL.%2BY.%26aulast%3DLok%26aufirst%3DA.%26atitle%3DHepatitis%2520B%2520virus%2520infection%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D2053%26epage%3D2063%26doi%3D10.1016%2FS0140-6736%2814%2960220-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Alcalde, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najera, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, N.</span></span> <span> </span><span class="NLM_article-title">Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">42374</span>, <span class="refDoi"> DOI: 10.1038/srep42374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1038%2Fsrep42374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=28205569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislOiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42374&author=Z.+Zhouauthor=T.+Huauthor=X.+Zhouauthor=S.+Wildumauthor=F.+Garcia-Alcaldeauthor=Z.+Xuauthor=D.+Wuauthor=Y.+Maoauthor=X.+Tianauthor=Y.+Zhouauthor=F.+Shenauthor=Z.+Zhangauthor=G.+Tangauthor=I.+Najeraauthor=G.+Yangauthor=H.+C.+Shenauthor=J.+A.+Youngauthor=N.+Qin&title=Heteroaryldihydropyrimidine+%28HAP%29+and+sulfamoylbenzamide+%28SBA%29+inhibit+hepatitis+B+virus+replication+by+different+molecular+mechanisms&doi=10.1038%2Fsrep42374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms</span></div><div class="casAuthors">Zhou, Zheng; Hu, Taishan; Zhou, Xue; Wildum, Steffen; Garcia-Alcalde, Fernando; Xu, Zhiheng; Wu, Daitze; Mao, Yi; Tian, Xiaojun; Zhou, Yuan; Shen, Fang; Zhang, Zhisen; Tang, Guozhi; Najera, Isabel; Yang, Guang; Shen, Hong C.; Young, John A. T.; Qin, Ning</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42374</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) are promising non-nucleos(t)ide HBV replication inhibitors.  HAPs are known to promote core protein mis-assembly, but the mol. mechanism of abnormal assembly is still elusive.  Likewise, the assembly status of core protein induced by SBA remains unknown.  Here we show that SBA, unlike HAP, does not promote core protein mis-assembly.  Interestingly, two ref. compds. HAP_R01 and SBA_R01 bind to the same pocket at the dimer-dimer interface in the crystal structures of core protein Y132A hexamer.  The striking difference lies in a unique hydrophobic subpocket that is occupied by the thiazole group of HAP_R01, but is unperturbed by SBA_R01.  Photoaffinity labeling confirms the HAP_R01 binding pose at the dimer-dimer interface on capsid and suggests a new mechanism of HAP-induced mis-assembly.  Based on the common features in crystal structures we predict that T33 mutations generate similar susceptibility changes to both compds.  In contrast, mutations at positions in close contact with HAP-specific groups (P25A, P25S, or V124F) only reduce susceptibility to HAP_R01, but not to SBA_R01.  Thus, HAP and SBA are likely to have distinctive resistance profiles.  Notably, P25S and V124F substitutions exist in low-abundance quasispecies in treatment-naive patients, suggesting potential clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw-qU6eO7rCrVg90H21EOLACvtfcHk0lhzHUlmUXDiow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislOiurs%253D&md5=1e401e3133194ae374435df0d0cfa637</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fsrep42374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42374%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DWildum%26aufirst%3DS.%26aulast%3DGarcia-Alcalde%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DNajera%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DYoung%26aufirst%3DJ.%2BA.%26aulast%3DQin%26aufirst%3DN.%26atitle%3DHeteroaryldihydropyrimidine%2520%2528HAP%2529%2520and%2520sulfamoylbenzamide%2520%2528SBA%2529%2520inhibit%2520hepatitis%2520B%2520virus%2520replication%2520by%2520different%2520molecular%2520mechanisms%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42374%26doi%3D10.1038%2Fsrep42374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Optimization and synthesis of pyridazinone derivatives as novel inhibitors of hepatitis B virus by inducing genome-free capsid formation</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.6b00159</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.6b00159" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2ksLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=199-205&issue=3&author=D.+Luauthor=F.+Liuauthor=W.+Xingauthor=X.+Tongauthor=L.+Wangauthor=Y.+Wangauthor=L.+Zengauthor=C.+Fengauthor=L.+Yangauthor=J.+Zuoauthor=Y.+Hu&title=Optimization+and+synthesis+of+pyridazinone+derivatives+as+novel+inhibitors+of+hepatitis+B+virus+by+inducing+genome-free+capsid+formation&doi=10.1021%2Facsinfecdis.6b00159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and Synthesis of Pyridazinone Derivatives as Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation</span></div><div class="casAuthors">Lu, Dong; Liu, Feifei; Xing, Weiqiang; Tong, Xiankun; Wang, Lang; Wang, Yajuan; Zeng, Limin; Feng, Chunlan; Yang, Li; Zuo, Jianping; Hu, Youhong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">199-205</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The capsid of Hepatitis B virus (HBV) plays a vital role in the virus DNA replication.  Targeting nucleocapsid function has been demonstrated as an effective approach for anti-HBV drugs development.  The high-throughput screening and mechanism study revealed the hit compd. as an HBV assembly effectors (AEfs), which could inhibit HBV replication by inducing the formation of HBV DNA-free capsids.  The subsequent SARs study and drug-like optimization resulted in the discovery of the lead candidate (I), with potent antiviral activity (IC50 = 0.087±0.002 μM) and, low cytotoxicity (CC50 = 90.6±2.06 μM), sensitivity to nucleoside-analog resistant HBV mutants and synergistic effect with nucleoside-analogs in HepG2.2.15 cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYYefy7nCJKLVg90H21EOLACvtfcHk0lhzHUlmUXDiow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2ksLzP&md5=493eb7d5c9839e77bf36cfa342891bfa</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.6b00159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.6b00159%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZuo%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DOptimization%2520and%2520synthesis%2520of%2520pyridazinone%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520by%2520inducing%2520genome-free%2520capsid%2520formation%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2017%26volume%3D3%26issue%3D3%26spage%3D199%26epage%3D205%26doi%3D10.1021%2Facsinfecdis.6b00159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delaney
IV, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colledge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locarnini, S.</span></span> <span> </span><span class="NLM_article-title">Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3057</span>– <span class="NLM_lpage">3060</span>, <span class="refDoi"> DOI: 10.1128/AAC.46.9.3057-3060.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1128%2FAAC.46.9.3057-3060.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=12183271" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=3057-3060&issue=9&author=W.+E.+Delaney%0AIVauthor=R.+Edwardsauthor=D.+Colledgeauthor=T.+Shawauthor=P.+Furmanauthor=G.+Painterauthor=S.+Locarnini&title=Phenylpropenamide+derivatives+AT-61+and+AT-130+inhibit+replication+of+wild-type+and+lamivudine-resistant+strains+of+hepatitis+B+virus+in+vitro&doi=10.1128%2FAAC.46.9.3057-3060.2002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.9.3057-3060.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.9.3057-3060.2002%26sid%3Dliteratum%253Aachs%26aulast%3DDelaney%2BIV%26aufirst%3DW.%2BE.%26aulast%3DEdwards%26aufirst%3DR.%26aulast%3DColledge%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DT.%26aulast%3DFurman%26aufirst%3DP.%26aulast%3DPainter%26aufirst%3DG.%26aulast%3DLocarnini%26aufirst%3DS.%26atitle%3DPhenylpropenamide%2520derivatives%2520AT-61%2520and%2520AT-130%2520inhibit%2520replication%2520of%2520wild-type%2520and%2520lamivudine-resistant%2520strains%2520of%2520hepatitis%2520B%2520virus%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26issue%3D9%26spage%3D3057%26epage%3D3060%26doi%3D10.1128%2FAAC.46.9.3057-3060.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brezillon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunelle, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massinet, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berissi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belghiti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannoun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puerstinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wimmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hantz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morosan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsdorf, D.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">12</span>), <span class="NLM_elocation-id">e25096</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0025096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1371%2Fjournal.pone.0025096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=22162746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Kht7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&issue=12&author=N.+Brezillonauthor=M.+N.+Brunelleauthor=H.+Massinetauthor=E.+Giangauthor=C.+Lamantauthor=L.+DaSilvaauthor=S.+Berissiauthor=J.+Belghitiauthor=L.+Hannounauthor=G.+Puerstingerauthor=E.+Wimmerauthor=J.+Neytsauthor=O.+Hantzauthor=P.+Soussanauthor=S.+Morosanauthor=D.+Kremsdorf&title=Antiviral+activity+of+Bay+41-4109+on+hepatitis+B+virus+in+humanized+Alb-uPA%2FSCID+mice&doi=10.1371%2Fjournal.pone.0025096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice</span></div><div class="casAuthors">Brezillon, Nicolas; Brunelle, Marie-Noelle; Massinet, Helene; Giang, Eric; Lamant, Celine; DaSilva, Lucie; Berissi, Sophie; Belghiti, Jacques; Hannoun, Laurent; Puerstinger, Gherard; Wimmer, Eva; Neyts, Johan; Hantz, Olivier; Soussan, Patrick; Morosan, Serban; Kremsdorf, Dina</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e25096</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Current treatments for HBV chronic carriers using interferon alpha or nucleoside analogs are not effective in all patients and may induce the emergence of HBV resistant strains.  Bay 41-4109, a member of the heteroaryldihydropyrimidine family, inhibits HBV replication by destabilizing capsid assembly.  The aim of this study was to det. the antiviral effect of Bay 41-4109 in a mouse model with humanized liver and the spread of active HBV.  Antiviral assays of Bay 41-4109 on HepG2.2.15 cells constitutively expressing HBV, displayed an IC50 of about 202 nM with no cell toxicity.  Alb-uPA/SCID mice were transplanted with human hepatocytes and infected with HBV.  Ten days post-infection, the mice were treated with Bay 41-4109 for five days.  During the 30 days of follow-up, the HBV load was evaluated by quant. PCR.  At the end of treatment, decreased HBV viremia of about 1 log(10) copies/mL was obsd.  By contrast, increased HBV viremia of about 0.5 log(10) copies/mL was measured in the control group.  Five days after the end of treatment, a rebound of HBV viremia occurred in the treated group.  Furthermore, 15 days after treatment discontinuation, a similar expression of the viral capsid was evidenced in liver biopsies.  Our findings demonstrate that Bay 41-4109 displayed antiviral properties against HBV in humanized Alb-uPA/SCID mice and confirm the usefulness of Alb-uPA/SCID mice for the evaluation of pharmaceutical compds.  The administration of Bay 41-4109 may constitute a new strategy for the treatment of patients in escape from std. antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiN9ZgdNSCebVg90H21EOLACvtfcHk0lgfYwVamIHNsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Kht7fE&md5=bdbc5dacf4457b3c90121e28b6edb73d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0025096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0025096%26sid%3Dliteratum%253Aachs%26aulast%3DBrezillon%26aufirst%3DN.%26aulast%3DBrunelle%26aufirst%3DM.%2BN.%26aulast%3DMassinet%26aufirst%3DH.%26aulast%3DGiang%26aufirst%3DE.%26aulast%3DLamant%26aufirst%3DC.%26aulast%3DDaSilva%26aufirst%3DL.%26aulast%3DBerissi%26aufirst%3DS.%26aulast%3DBelghiti%26aufirst%3DJ.%26aulast%3DHannoun%26aufirst%3DL.%26aulast%3DPuerstinger%26aufirst%3DG.%26aulast%3DWimmer%26aufirst%3DE.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DHantz%26aufirst%3DO.%26aulast%3DSoussan%26aufirst%3DP.%26aulast%3DMorosan%26aufirst%3DS.%26aulast%3DKremsdorf%26aufirst%3DD.%26atitle%3DAntiviral%2520activity%2520of%2520Bay%252041-4109%2520on%2520hepatitis%2520B%2520virus%2520in%2520humanized%2520Alb-uPA%252FSCID%2520mice%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26issue%3D12%26doi%3D10.1371%2Fjournal.pone.0025096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span> <span> </span><span class="NLM_article-title">A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7061</span>– <span class="NLM_lpage">7072</span>, <span class="refDoi"> DOI: 10.1128/AAC.01558-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1128%2FAAC.01558-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=26349829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVymu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=7061-7072&issue=1&author=Y.+Wangauthor=D.+Luauthor=Y.+Xuauthor=W.+Xingauthor=X.+Tongauthor=G.+Wangauthor=C.+Fengauthor=P.+Heauthor=L.+Yangauthor=W.+Tangauthor=Y.+Huauthor=J.+Zuo&title=A+novel+pyridazinone+derivative+inhibits+hepatitis+B+virus+replication+by+inducing+genome-free+capsid+formation&doi=10.1128%2FAAC.01558-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation</span></div><div class="casAuthors">Wang, Ya-Juan; Lu, Dong; Xu, Yi-Bin; Xing, Wei-Qiang; Tong, Xian-Kun; Wang, Gui-Feng; Feng, Chun-Lan; He, Pei-Lan; Yang, Li; Tang, Wei; Hu, You-Hong; Zuo, Jian-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7061-7072</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Here we first identified a novel pyridazinone deriv., compd. 3711, as a nonnucleosidic hepatitis B virus (HBV) inhibitor in a cell model system. 3711 decreased extracellular HBV DNA levels by 50% (50% inhibitory concn. [IC50]) at 1.5 ± 0.2 μM and intracellular DNA levels at 1.9 ± 0.1 μM, which demonstrated antiviral activity at levels far below those assocd. with toxicity.  Both the 3TC/ETV dually resistant L180M/M204I mutant and the adefovir (ADV)-resistant A181T/N236T mutant were as susceptible to 3711 as wild-type HBV. 3711 treatment induced the formation of genome-free capsids, a portion of which migrated faster on 1.8% native agarose gel.  The induced genome-free capsids sedimented more slowly in isopycnic CsCl gradient centrifugation without significant morphol. changes.  3711 Treatment decreased levels of HBV DNA contained in both secreted enveloped virion and naked virus particles in supernatant.  3711 Could interfere with capsid formation of the core protein (Cp) assembly domain.  A Cp V124W mutant, which strengthens capsid interdimer interactions, recapitulated the effect of 3711 on capsid assembly.  Pyridazinone deriv. 3711, a novel chem. entity and HBV inhibitor, may provide a new opportunity to combat chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyJKHo9W8Xt7Vg90H21EOLACvtfcHk0lhj0ZF-GUhSEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVymu70%253D&md5=8aa8af6163ee6395b2b634f654125a8b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1128%2FAAC.01558-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01558-15%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZuo%26aufirst%3DJ.%26atitle%3DA%2520novel%2520pyridazinone%2520derivative%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520by%2520inducing%2520genome-free%2520capsid%2520formation%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26issue%3D1%26spage%3D7061%26epage%3D7072%26doi%3D10.1128%2FAAC.01558-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span> <span> </span><span class="NLM_article-title">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1038/aps.2013.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1038%2Faps.2013.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=24487969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=410-418&author=L.+Yangauthor=L.+Shiauthor=H.+Chenauthor=X.+Tongauthor=G.+Wangauthor=Y.+Zhangauthor=W.+Wangauthor=C.+Fengauthor=P.+Heauthor=F.+Zhuauthor=Y.+Haoauthor=B.+Wangauthor=D.+Yangauthor=W.+Tangauthor=F.+Nanauthor=J.+Zuo&title=Isothiafludine%2C+a+novel+non-nucleoside+compound%2C+inhibits+hepatitis+B+virus+replication+through+blocking+pregenomic+RNA+encapsidation&doi=10.1038%2Faps.2013.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span></div><div class="casAuthors">Yang, Li; Shi, Li-ping; Chen, Hai-jun; Tong, Xian-Kun; Wang, Gui-feng; Zhang, Yang-ming; Wang, Wen-long; Feng, Chun-lan; He, Pei-lan; Zhu, Feng-hua; Hao, You-hua; Wang, Bao-ju; Yang, Dong-liang; Tang, Wei; Nan, Fa-jun; Zuo, Jian-ping</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">410-418</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: To investigate the action of isothiafludine (NZ-4), a deriv. of bis-heterocycle tandem pairs from the natural product leucamide A, on the replication cycle of hepatitis B virus (HBV) in vitro and in vivo.  Methods: HBV replication cycle was monitored in HepG2.2.15 cells using qPCR, qRT-PCR, and Southern and Northern blotting.  HBV protein expression and capsid assembly were detected using Western blotting and native agarose gel electrophoresis anal.  The interaction of pregenomic RNA (pgRNA) and the core protein was investigated by RNA immunopptn.  To evaluate the anti-HBV effect of NZ-4 in vivo, DHBV-infected ducks were orally administered NZ-4 (25, 50 or 100 mg·kg-1·d-1) for 15 d.  Results: NZ-4 suppressed intracellular HBV replication in HepG2.2.15 cells with an IC50 value of 1.33 μmol/L, whereas the compd. inhibited the cell viability with an IC50 value of 50.4 μmol/L.  Furthermore, NZ-4 was active against the replication of various drug-resistant HBV mutants, including 3TC/ETV-dual-resistant and ADV-resistant HBV mutants.  NZ-4 (5, 10, 20 μmol/L) concn.-dependently reduced the encapsidated HBV pgRNA, resulting in the assembly of replication-deficient capsids in HepG2.2.15 cells.  Oral administration of NZ-4 dose-dependently inhibited DHBV DNA replication in the DHBV-infected ducks.  Conclusion: NZ-4 inhibits HBV replication by interfering with the interaction between pgRNA and HBcAg in the capsid assembly process, thus increasing the replication-deficient HBV capsids.  Such mechanism of action might provide a new therapeutic strategy to combat HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfXI1ksk5-erVg90H21EOLACvtfcHk0lhj0ZF-GUhSEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D&md5=7a046b35ab2f26aa43cf52fa76f85dea</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Faps.2013.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2013.175%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DNan%26aufirst%3DF.%26aulast%3DZuo%26aufirst%3DJ.%26atitle%3DIsothiafludine%252C%2520a%2520novel%2520non-nucleoside%2520compound%252C%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520through%2520blocking%2520pregenomic%2520RNA%2520encapsidation%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2014%26volume%3D35%26spage%3D410%26epage%3D418%26doi%3D10.1038%2Faps.2013.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Scala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Farina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanrell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olagüe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galarraga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guembe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz de
Solorzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maini, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Aseguinolaza, G.</span></span> <span> </span><span class="NLM_article-title">Complementary effects of interleukin-15 and alpha interferon induce immunity in hepatitis B virus transgenic mice</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">8563</span>– <span class="NLM_lpage">8574</span>, <span class="refDoi"> DOI: 10.1128/JVI.01030-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=10.1128%2FJVI.01030-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=27440883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVCnu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=8563-8574&issue=19&author=M.+Di%0AScalaauthor=I.+Otanoauthor=I.+Gil-Farinaauthor=L.+Vanrellauthor=M.+Hommelauthor=C.+Olag%C3%BCeauthor=A.+Valesauthor=M.+Galarragaauthor=L.+Guembeauthor=C.+Ortiz+de%0ASolorzanoauthor=I.+Ghoshauthor=M.+K.+Mainiauthor=J.+Prietoauthor=G.+Gonz%C3%A1lez-Aseguinolaza&title=Complementary+effects+of+interleukin-15+and+alpha+interferon+induce+immunity+in+hepatitis+B+virus+transgenic+mice&doi=10.1128%2FJVI.01030-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Complementary effects of interleukin-15 and alpha interferon induce immunity in hepatitis B virus transgenic mice</span></div><div class="casAuthors">Di Scala, Marianna; Otano, Itziar; Gil-Farina, Irene; Vanrell, Lucia; Hommel, Mirja; Olague, Cristina; Vales, Africa; Galarraga, Miguel; Guembe, Laura; de Solorzano, Carlos Ortiz; Ghosh, Indrajit; Maini, Mala K.; Prieto, Jesus; Gonzalez-Aseguinolaza, Gloria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8563-8574</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In chronic hepatitis B (CHB), failure to control hepatitis B virus (HBV) is assocd. with T cell dysfunction.  HBV transgenic mice mirror many features of the human disease, including T cell unresponsiveness, and thus represent an appropriate model in which to test novel therapeutic strategies.  To date, the tolerant state of CD8+ T cells in these animals could be altered only by strong immunogens or by immunization with HBV antigen-pulsed dendritic cells; however, the effectors induced were unable to suppress viral gene expression or replication.  Because of the known stimulatory properties of alpha interferon (IFN-α) and interleukin- 15 (IL-15), this study explored the therapeutic potential of liver-directed gene transfer of these cytokines in a murine model of CHB using adeno-assocd. virus (AAV) delivery.  This combination not only resulted in a redn. in the viral load in the liver and the induction of an antibody response but also gave rise to functional and specific CD8+ immunity.  Furthermore, when splenic and intrahepatic lymphocytes from IFN-α- and IL-15-treated animals were transferred to new HBV carriers, partial antiviral immunity was achieved.  In contrast to previous observations made using either cytokine alone, markedly attenuated PD-L1 induction in hepatic tissue was obsd. upon coadministration.  An initial study with CHB patient samples also gave promising results.  Hence, we demonstrated synergy between two stimulating cytokines, IL-15 and IFN-α, which, given together, constitute a potent approach to significantly enhance the CD8+ T cell response in a state of immune hyporesponsiveness.  Such an approach may be useful for treating chronic viral infections and neoplastic conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQqxfnBus2P7Vg90H21EOLACvtfcHk0lglwu-k_gLiUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVCnu73J&md5=e767be4e23738e4428cde3bc29d58098</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FJVI.01030-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01030-16%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BScala%26aufirst%3DM.%26aulast%3DOtano%26aufirst%3DI.%26aulast%3DGil-Farina%26aufirst%3DI.%26aulast%3DVanrell%26aufirst%3DL.%26aulast%3DHommel%26aufirst%3DM.%26aulast%3DOlag%25C3%25BCe%26aufirst%3DC.%26aulast%3DVales%26aufirst%3DA.%26aulast%3DGalarraga%26aufirst%3DM.%26aulast%3DGuembe%26aufirst%3DL.%26aulast%3DOrtiz%2Bde%2BSolorzano%26aufirst%3DC.%26aulast%3DGhosh%26aufirst%3DI.%26aulast%3DMaini%26aufirst%3DM.%2BK.%26aulast%3DPrieto%26aufirst%3DJ.%26aulast%3DGonz%25C3%25A1lez-Aseguinolaza%26aufirst%3DG.%26atitle%3DComplementary%2520effects%2520of%2520interleukin-15%2520and%2520alpha%2520interferon%2520induce%2520immunity%2520in%2520hepatitis%2520B%2520virus%2520transgenic%2520mice%26jtitle%3DJ.%2520Virol.%26date%3D2016%26volume%3D90%26issue%3D19%26spage%3D8563%26epage%3D8574%26doi%3D10.1128%2FJVI.01030-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=U95551" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=U95551','Genbank','U95551'); return false;">Genbank: U95551</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i50"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00346">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_21820"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00346?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00346</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Tissue distributions profiles and plasma concentration–time curves in mice of <b>4r</b>, <b>10m</b>, and <b>19f</b>; detailed experimental procedures for the synthesis of analogues <b>10a</b>, <b>10b</b>, <b>10i</b>, <b>10j</b>, <b>10k</b> and intermediates <b>18h</b>–<b>18n</b>; characterization (<sup>1</sup>H NMR spectra and <sup>13</sup>C NMR spectra are attached) and HPLC purity control of the selected final compounds <b>10l</b>, <b>10m</b>, <b>18a</b>, <b>18b</b>, <b>18d</b>, <b>18e</b>, <b>18g</b>, <b>19a</b>–<b>19h</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular-formula strings of the reported compounds and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf">jm0c00346_si_001.pdf (3.66 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_002.csv">jm0c00346_si_002.csv (2.5 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00346&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-15%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00346" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00346" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996e6509953291","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
